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1 ABSTRACT 
Inhibitor of apoptosis proteins (IAPs) constitute a conserved family of molecules, 
which regulate both apoptosis and receptor signalling. They are often deregulated in cancer 
cells and represent potential targets for therapy. In my work, I investigated the effect of IAP 
inhibition in vivo to identify novel down-stream genes expressed in an IAP-dependent 
manner that could contribute to cancer aggressiveness. To this end, immunocompromised 
mice engrafted subcutaneously with the triple negative breast cancer (TNBC) cell line MDA-
MB231 were treated with SM83, a Smac mimetic developed in our laboratory that acts as a 
pan-IAP inhibitor, and tumour nodules were profiled for gene expression. The analysis 
revealed that the inhibition of IAPs significantly reduces the expression of SNAI2, a zinc finger 
transcriptional repressor often associated with cancer aggressiveness, resistance to therapy 
and metastatic potential, especially in breast cancer. By testing several TNBC cell lines, I 
found that SNAI2 levels is promoted specifically by cellular IAP1 (cIAP1), and not by other 
IAPs, and that SM83-dependent down-regulation of SNAI2 reduces cancer cell motility. 
Accordingly, cIAP1 depletion blocks epidermal growth factor receptor (EGFR)-dependent 
activation of the mitogen-activated protein kinase (MAPK) pathway causing the reduction of 
SNAI2 transcription levels. The inhibition of EGFR signalling stems from the block of receptor 
signalling and from the down-regulation of its levels, but paradoxically the silencing of cIAP1 
promotes EGFR stability rather than its degradation. Nonetheless, EGFR levels decrease upon 
cIAP1 silencing due to reduced NF-kB-dependent gene expression supporting the notion that 
cIAP1 controls EGFR in an opposite fashion, promoting its gene expression while causing its 
degradation. In conclusion, my work indicates that IAP-targeted therapy could contribute to 
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EGFR inhibition and to the reduction of its down-stream mediators. This approach could be 
particularly effective in tumours characterized by high levels of EGFR and SNAI2, such as 
TNBCs.  
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2 INTRODUCTION  
2.1 Apoptosis: a process of programmed cell death 
 Apoptosis is the most studied type of programmed cell death; it is regulated by 
molecular pathways, which are evolutionarily conserved among the species (Degterev and 
Yuan, 2008). Apoptosis is crucial during embryonic development of multicellular organisms 
and, therefore, its deregulation is responsible for several diseases (Favaloro et al., 2012). For 
instance, excessive apoptosis leads to neurodegeneration (Mattson, 2000), while insufficient 
activation of the apoptotic machinery results in autoimmune disorders (Nagata, 2010) and 
many cancer types. Accordingly, pathological inhibition of apoptosis has been shown to 
favour cancer development. Therefore, several approaches have been designed to induce 
apoptosis or prevent its inhibition in tumours in order to eradicate them.  
 Resistance to apoptosis is one of the hallmarks of cancer, which were proposed by 
Hannah and Weinberg (Hanahan and Weinberg, 2011; Figure 2.1). In fact, aggressive 
tumours develop various strategies to escape the apoptotic process, and there is therefore 
the need to target the apoptotic blocks in order to promote the activity of therapeutic 
treatments, which usually rely on apoptotic activation to be effective (Gimenez-Bonafe et al., 
2009).  
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Figure 2.1 - Hallmarks of cancer (Hanahan and Weinberg, 2011). The figure shows the hallmarks of cancer that 
characterize neoplastic cells compared to normal cells. 
2.1.1 Mechanisms of apoptosis  
Two main pathways constitute the apoptotic machinery: the extrinsic and the 
intrinsic apoptotic programs, which both depend on the balance between pro- and anti-
apoptotic effectors. The extrinsic pathway senses and propagates death-inducing signals and 
soluble factors originated from the microenvironment outside the cells, while the intrinsic 
circuit is triggered by a variety of intra-cellular signals (Fulda and Debatin, 2006; Galluzzi et 
al., 2012). Importantly, these two pathways are tightly linked and culminate in the activation 
of normally inactive proteases (caspases-8 and -9, respectively), which, in turn, trigger the 
effector caspases (caspases-3, -6 and -7). The final step is then the execution phase of 
apoptosis, thus leading to the cell disruption. 
Although different mechanisms regulate programmed cell death, all the apoptosis 
pathways converge in the activation of caspases, which are therefore executioners of 
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apoptosis (Figure 2.2). Caspases are conserved cysteine proteases that, in the absence of 
apoptosis signals, are expressed as inactive zymogens (pro-caspases) and, upon strictly 
controlled activation, acquire the capability to cleave their substrates after an aspartate 
residue (Thornberry and Lazebnik, 1998). Caspases are classified in initiator and effector 
depending whether they are apical activators of the apoptotic pathway or if they amplify an 
up-stream stimulus received by another caspase. Of note, initiator and effector caspases are 
characterized by a different structure. Initiator caspases display a long pro-domain that 
interacts with the up-stream adapter molecules through two different motifs: the caspase 
recruitment domain (CARD; caspase-2, -9) and the death effector domain (DED; caspase-8 
and -10). On the contrary, a short pro-domain defines effector caspases (caspase-3, -6 and -
7) and allows the cleavage of diverse substrates, which have already been processed by up-
stream caspases, leading to the apoptosis demolition phase. A vast number of substrates can 
be cleaved by caspases (Fischer et al., 2003), such as nuclear lamin, inhibitor of caspase 
activated DNase (ICAD) and especially cleaved poly(adenosine diphosphate– 
ribose)polymerase (PARP), which, upon cleavage, is universally exploited as a marker for 
apoptotic cells (Nosseri et al., 1994).  
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Figure 2.2 - Human caspase-mediated apoptosis (Lamkanfi, 2011). Based on their mechanism of action, 
caspases are distinguished in initiator caspases and effector caspases. Initiator caspase-8 and -10 comprise a 
DED motif in their long pro-domain, while the other initiator caspases show the CARD motif. 
 
Importantly, the caspase-mediated proteolytic process is accompanied by discrete 
morphological changes resulting from various events, including DNA fragmentation, 
chromatin condensation and nuclear remodelling (Figure 2.3). Interestingly, apoptotic cells, 
on the basis of morphological alterations, can be distinguished from cells dying by diverse 
types of death, such as necrosis, necroptosis and autophagy (Degterev and Yuan, 2008; 
Galluzzi et al., 2015). 
 
Figure 2.3 - Morphological changes in apoptotic cells. Adapted from (Lamkanfi, 2011). Apoptosis is 
accompanied by a variety of biochemical and morphological features, including nuclear condensation and 
oligo-nucleosomal DNA fragmentation, shrinkage of the cell, cytoplasmic packing in apoptotic bodies and rapid 
phagocytosis by neighbouring cells. Cleaved PARP is commonly used as marker of apoptosis. All these features 
uniquely identify the apoptosis process. 
2.1.2 The intrinsic apoptotic pathway 
The activation of the intrinsic apoptosis pathway is mediated by diverse non-
receptor-induced stimuli that produce intracellular signals leading to mitochondrial-
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dependent death. In response to the mitochondrial outer membrane permeabilization 
(MOMP), cytochrome c is released from the inter-mitochondrial membrane space to the 
cytosol, where forms the apoptosome by interacting with the initiator caspase-9 and 
apoptotic protease activating factor 1 (APAF-1; Reubold and Eschenburg, 2012). This event is 
tightly controlled by the B-cell lymphoma-2 (BCL-2) family members (Figure 2.4), and, in 
particular, it is inhibited by the anti-apoptotic (BCL-2, BCL-XL and myeloid cell leukaemia 1-
MCL-1) proteins, whereas it is promoted by the pro-apoptotic (BCL-2 antagonist killer 1 –BAK, 
BCL-2-associated X protein –BAX and BH3-only protein -BID) ones. Following apoptosome 
formation, caspase-9 is cleaved and activates the effector caspases-3, -6 and -7. These 
caspases, in turn, cleave diverse cellular substrates hence causing the biochemical and 
morphological changes, which are classically associated with the apoptotic phenotype 
(Danial and Korsmeyer, 2004). 
 
Figure 2.4 - The intrinsic apoptosis signalling pathway (Ashkenazi et al., 2017). Cellular stress, either DNA 
damage or endoplasmic reticulum (ER) stress, induces the intrinsic apoptosis pathway with consequent 
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inhibition of the anti-apoptotic proteins, BCL-2, BCL-XL, BCL-W and MCL-1, and subsequent activation of the 
pro-apoptotic ones, BAK and BAX. This event results in MOMP, which allows the release of cytochrome c from 
the mitochondria. Once in the cytosol, cytochrome c forms a complex with pro-caspase-9 and APAF-1, thus 
activating the caspase-9. The latter promotes the induction of pro-caspase-3 and -7, and consequently cell 
death. 
2.1.3 The extrinsic apoptotic pathway 
The extrinsic apoptotic program, also named death receptor-dependent pathway, is 
activated by the binding of death ligands belonging to the tumour necrosis factor (TNF) 
superfamily to its cognate receptors, the TNF-Receptors (TNF-Rs), which are localized in the 
cell surface (Walczak, 2013). The stimulation of the TNF-Rs leads to rapid activation of the 
initiator caspase-8 and -10 (Barnhart et al., 2003; Dickens et al., 2012; Ganten et al., 2004), 
which are critically involved in the activation of apoptosis signalling. In details, upon binding 
to its ligand, the adaptor proteins Fas-associated protein with death domain (FADD) and TNF 
receptor-associated protein with death domain (TRADD) are recruited to the receptor (Figure 
2.5). The formed complex, named death-inducing signalling complex (DISC; Scaffidi et al., 
1998), allows pro-caspases-8 and -10 dimerization and activation, which results in the 
processing of their down-stream effector caspases-3, -6 and -7 (McIlwain et al., 2013). 
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Figure 2.5 - Overview of the apoptosis pathways (Fulda and Vucic, 2012). Both external and internal stimuli are 
responsible for apoptosis pathway activation. The extrinsic pathway is induced by binding of death ligands to 
the cognate receptors. Upon ligand binding, cytoplasmic adapter proteins are recruited, thus forming the DISC. 
This complex is responsible for the auto-catalytic activation of initiator caspases triggering to the execution 
phase of apoptosis. The cross-talk between extrinsic and intrinsic pathways occurs at the mitochondria. When 
mitochondria undergo MOMP, the apoptosome is formed and activates the initiator caspase-9 thus propagating 
the apoptotic process. 
Although caspase-3 is capable of cleaving a number of substrates necessary for cell 
viability, the activation of caspase-8 and -3 is not always sufficient to kill cells. Cells are 
therefore divided in two groups: “type I” and “type II” (Ozoren and El-Deiry, 2002). While in 
“type I” cells the activation of the extrinsic pathway is sufficient to induce irreversible 
damage that crucially compromises cell viability, “type II” cells require the involvement of 
mitochondria to efficiently activate apoptosis (Figure 2.6). In these cells, caspase-8 cleaves 
BID, thereby generating the activated truncated form of BID, t-BID (Kantari and Walczak, 
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2011), which leads to MOMP via the direct activation of BAX and BAK. This step is therefore 
in common between the extrinsic and intrinsic pathways and allows their cross-talk.  
 
Figure 2.6 - Regulation of cell death by mitochondria (Tait and Green, 2010). The cross-talk between intrinsic 
and extrinsic apoptosis pathways is mediated by mitochondria and occurs after caspase-8-mediated cleavage 
and subsequent activation of BID (t-BID, hereafter). T-BID causes MOMP, which favours the release of various 
proteins from the mitochondrial intermembrane space, thus promoting caspase activation and apoptosis. 
2.2 IAPs:  Inhibitors of apoptosis proteins 
Extrinsic and intrinsic apoptotic signals are controlled by the inhibitor of apoptosis 
protein (IAP) family, which consists of eight members, called X-linked IAP (XIAP), cIAP1, 
cIAP2, neuronal-IAP (NAIP), Survivin, Livin (ML-IAP), Apollon (BRUCE) and ILP-2 (Figure 2.7). 
Although IAPs were initially described as being negative regulators of apoptosis, later works 
have clarified their role also in controlling several other cell features and mechanisms (Rothe 
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et al., 1995; Damgaard and Gyrd-Hansen, 2011). The activity on caspases has been confirmed 
only for 2-3 members of the family and it is likely to be restricted to limited settings (Choi et 
al., 2009; Eckelman et al., 2006). IAPs are ubiquitously expressed and their expression is 
deregulated in diseases and cancer cells, where they contribute to chemoresistance and poor 
prognosis (Gyrd-Hansen and Meier, 2010). For this reason, IAPs are considered potential 
targets in clinical oncology and many pharmacological approaches have been designed to 
inhibit the members of this family. 
2.2.1  IAP structure and conserved domains 
IAPs are characterized by the presence of one or three conserved motifs of about 70 
aminoacids, named baculoviral IAP repeat (BIR) domains (Birnbaum et al., 1994), originally 
identified in the baculoviral genome. Through this domain, IAPs, also called BIR‐containing 
proteins (BIRCs), interact with other proteins. XIAP, cIAP1, and cIAP2 are among the most 
characterized IAPs and contain three BIR domains (Figure 2.7) that mediate protein-protein 
interactions. Moreover, XIAP and cIAP1/2 bear a domain named really interesting new gene 
(RING), which confers the E3 ubiquitin ligase activity that allows the binding with the E2 
ubiquitin-conjugating enzymes and catalyzes the transfer of ubiquitin to a target substrate 
(Vaux and Silke, 2005). Therefore, the RING domain provides IAPs with the capability to 
polyubiquitinate proteins, such as caspases and many other substrates, and also to self-
ubiquitinate. Ubiquitination can induce either proteasomal degradation or regulation of the 
target proteins in several signalling cascades (Chen, 2012). Other two additional domains 
identify some IAPs: a caspase-associated recruitment domain (CARD) and an ubiquitin-
associated (UBA) domain. CARD regulates the E3 activity preventing RING domain 
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dimerization, which is essential for cIAP1 to exert its activity (Lopez et al., 2011). While cIAPs 
affect the apoptotic process only indirectly, XIAP is considered as a direct inhibitor of 
caspases. In particular, the BIR3 domain of XIAP interacts with caspase-9, preventing its 
activation, whereas activated caspase-3 and -7 are sequestered after the interaction with the 
BIR2 and the up-stream linker region (Chai et al., 2001; Datta et al., 2000; Riedl et al., 2001). 
 
Figure 2.7 - Structural domains of IAP family members. Adapted from (de Almagro and Vucic, 2012). The IAP 
family is constituted by eight members characterized by one or three BIR domains, typically located in the 
protein amino(N)-terminus. Several mammalian IAPs share the presence of the additional structural domain 
RING, which functions as an E3 ubiquitin ligase, while only cIAP1 and cIAP2 show the presence of CARD motif. 
UBA motif is shared by XIAP, cIAP1/2 and ILP-2.  Survivin has a single BIR domain combined with a COOH-
terminal alpha-helix coiled-coil domain. While, NAIP structure shows three BIR motifs together with the 
nucleotide-binding oligomerization (NACHT) and leucine-rich repeats (LRR) domains. 
Based on the capability to regulate caspases, BIR domains can be divided into two 
classes, I and II, where only type II can interact to caspases, while type I is responsible for the 
binding with other proteins, including TRAF1 and 2 (Gyrd-Hansen and Meier, 2010). Notably, 
type II BIRs are characterized by a conserved groove, which allows the interaction with a 
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region within caspases, called IAP binding motif (IBM; Wu et al., 2000). An example of IBM is 
constituted by the AVPI (Ala-Val-Pro-Ile) sequence which is located at the N terminus of the 
second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding 
protein with low pI (Smac/DIABLO), a mammalian natural antagonist of IAPs (Figure 2.8). 
Interestingly, after apoptotic stimuli, Smac/DIABLO is released from the mitochondria into 
the cytosol, where it binds to the XIAP-BIR3 domain thus relieving the inhibition of caspase-9 
and eventually allowing the activation of the executioner caspases-3 and -7.  
 
Figure 2.8 - Smac/DIABLO: the IAP natural antagonist (Fulda, 2015). The binding of Smac/DIABLO to XIAP 
neutralizes XIAP-mediated caspase inhibition, resulting in apoptosis cell death.  
2.2.2 The role of IAPs in cancer 
The crucial role of IAPs in oncogenesis derives from their capability to promote 
resistance against cell death and control many survival pathways. Not surprisingly, IAPs have 
been found aberrantly expressed in diverse types of tumour (Che et al., 2012; Hundsdoerfer 
et al., 2010). However, the prognostic significance of IAP over-expression remains not 
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completely clear. This is the case of XIAP, whose expression levels correlate with disease 
severity and prognosis in acute myelogenous leukemia (AML) and renal cell carcinoma, but 
not in non-small cell lung carcinoma or cervical carcinoma (LaCasse et al., 2008). Deregulated 
expression of IAPs can be a result of different events, such as gene amplifications, mutations 
or deletions and chromosomal translocations. For instance, amplification of 11q21-q23, in 
which both cIAP1 and cIAP2 are located, has been found in several tumours, including, 
glioblastoma, hepatocellular carcinoma, esophageal carcinoma, cervical cancer, liver cancer, 
non-small-cell lung cancer (NSCLC), and pancreatic cancer (LaCasse et al., 2008). Moreover, 
trans-activation and post-translational events are often responsible for the increase of IAP 
expression in tumours. For example, the t(11;18)(q21;q21) translocation event has been 
found in mucosa-associated lymphoid tissue (MALT) lymphoma and causes the fusion of the 
BIR domains of cIAP2 with the paracaspase MALT1 (Rosebeck et al., 2011). As a consequence 
of this phenomenon, the constitutive activation of the NF-κB signalling pathway (Darding et 
al., 2011) occurs thereby promoting oncogenesis and tumour progression. 
2.2.3 Smac mimetic-mediated targeting of IAPs 
Based on the capability to prevent apoptosis, IAPs represent possible targets for cancer 
therapy and this leads to the development of small compounds, which are specific for IAP 
domains. Hence, the elucidation of the biochemical structures involved in the IAP–
Smac/DIABLO interaction allowed the development of Smac-like molecules, called Smac 
mimetics (SMs). SMs resemble the N-terminal region of Smac/DIABLO and, in particular, 
mimic the IBM motif (Eckelman et al., 2008), which is directed against the XIAP BIR2- and 
BIR3-caspase interaction pocket, and prevent XIAP-mediated caspase inhibition. While 
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initially designed to target XIAP, SMs have been shown to affect cIAP1/2 E3 activity, driving 
their self-ubiquitination and proteasomal degradation (Figure 2.9). 
 
Figure 2.9 - SM-mediated activation of cIAPs (Feltham et al., 2011). The binding of SMs with cIAPs promotes 
the RING dimerization and activates the cIAP E3 ligase function, self- ubiquitination and proteasomal 
degradation.  
Notably, about 10-15 % of cancer cell lines are efficiently killed in vitro by SMs as 
standalones (Petersen et al., 2007; Figure 2.10) with low nanomolar EC50s, depending on the 
molecules used. In 2007, it has been reported by several groups that the cytotoxic effect of 
the SMs in monotherapy does not depend on their activity against XIAP, but it stems from a 
rapid SM-dependent depletion of cIAP1 and cIAP2. This event results in the autocrine 
production of TNF and subsequent cancer cell death (Petersen et al., 2007; Varfolomeev et 
al., 2007; Vince et al., 2007). 
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Figure 2.10 - SM response in a panel of lung cancer cell lines. Adapted from (Petersen et al., 2007). About the 
14 % of NSCLC cell lines is responsive to the SM treatment administered alone.  
SMs are usually considered not toxic in normal tissues and the anti-tumour activity of 
several SMs has been tested in phase I/II clinical trials (Fulda, 2015). They were developed 
either as monovalent compounds containing one tetrapeptide mimicking endogenous 
Smac/DIABLO, or as bivalent molecules having two mimicking sequences connected together 
by a chemical linker. Since the natural Smac/DIABLO protein acts as a dimer, bivalent SMs 
were realized to enhance the binding affinity compared to a monomer Smac AVPI-mimicking 
peptide. Of note, the binding of the Smac/DIABLO AVPI motif is stronger towards BIR3 
compared to BIR2, but the presence of two AVPI-like motifs ensures the formation of a very 
stable interaction between SMs and IAPs by targeting simultaneously two BIR domains within 
the same IAP (Lecis et al., 2012). As a consequence of this stable interaction (Cossu et al., 
2009b; Cossu et al., 2012), dimeric SMs have been shown to be much more effective both in 
vitro and in vivo (Fulda, 2014b) compared to monomeric ones. In addition, dimeric 
compounds are more efficient in causing the depletion of cIAP1 and cIAP2 (Varfolomeev et 
al., 2007). However, dimeric SMs are less “drug-like” compared to monomeric ones from a 
pharmacological viewpoint (Fulda, 2015). In fact, being smaller molecules, movalent SMs can 
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even be endowed with a good oral bioavailability, which provides an important advantage 
for their clinical application. Conversely, the bioavailability of bivalent SMs is limited by their 
molecular weight that requires the employment of other administration routes, such as 
intravenous injection.  
Unfortunately, the vast majority of cancer cells are usually resistant to SM employed 
in monotherapy, but the reason for this resistance is not fully understood. It has been 
reported that cIAP2 degradation occurs in a cIAP1 dependent manner (Darding et al., 2011). 
Upon SM treatment, cIAP2 is quickly replaced by newly synthesized protein that cannot be 
degraded anymore in the absence of cIAP1. Importantly, cIAP2 displays some common 
features with cIAP1 and its presence is sufficient to confer resistance to SM treatment 
(Darding et al., 2011). As SMs are very rarely cytotoxic in monotherapy, the efficacy should 
be enhanced by the combination with either death agonists, such as TNFα, TNF-related 
apoptosis-inducing ligand (TRAIL; Lecis et al., 2010), and FasL, or chemotherapy (Greer et al., 
2011), resulting in synergistic activity (Moller et al., 2014). SMs have been reported to 
synergise with chemotherapeutic drugs in solid tumours and hematologic malignancies. 
However, some side effects and unwanted toxicity caused especially by immune system 
activation and cytokine production have been revealed by in vivo experiments and the first 
clinical trials (Amaravadi et al., 2011; Infante et al., 2014; Sikic et al., 2011). 
SM efficacy has been tested in phase I/II clinical trials for solid and hematologic 
malignancies (Fulda, 2015), as monotherapy or in rational combinations with gemcitabine, 
daunorubicin, cytarabine, or Paclitaxel. Importantly, phase I trials indicate SM administration 
as a safety and well tolerated treatment, even if inducing an increase of cytokines in patients 
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(Fulda, 2014b). For instance, the up-regulation of inflammatory cytokines, that are NF-kB 
target genes, has been reported by Infante and colleagues after the administration of LCL161 
for the treatment of human advanced solid tumours (Infante et al., 2014). In the attempt to 
reduce possible risks linked to SM administration, the new compound Birinapant has been 
designed with reduced affinity for XIAP, but still conserving the same effect on cIAP1 and 
cIAP2 (Obexer and Ausserlechner, 2014). In fact, it has been reported that SM-triggered 
cytokine release stems from the inhibition of XIAP. Intriguingly, Birinapant treatment does 
not promote TNF production and results well tolerated (Allensworth et al., 2013; Condon et 
al., 2014). The efficacy of this compound has been also assessed together with other 
chemotherapeutics to analyse whether some clinical benefits may be obtained from the 
combinations (Krepler et al., 2013). Among SMs, the two monovalent compounds: LCL161 
(Novartis) and AT-406/Debio1143 (Ascenta Therapeutics; Figure 2.11) are currently tested in 
clinical trials, for the treatment of refractory multiple myeloma and advanced solid 
malignacies or metastatic NSCLC, respectively. 
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Figure 2.11 - Chemical structures of SMs (Bai et al., 2014). 
2.3 The TNF/TNF-R superfamily 
As already mentioned, SM-mediated autocrine production of TNF occurs in response 
of cIAP depletion leading to cell death.  TNF is a member of a large family of cytokines that 
exert pleiotropic functions among whom regulation of the immune system, control of cell 
proliferation, differentiation and apoptosis (Ashkenazi and Dixit, 1998). TNF is expressed as a 
transmembrane protein, membrane TNF (mTNF), which can be shed by the metalloprotease 
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TNF-converting enzyme (TACE) into a soluble factor (sTNF). While mTNF can activate both 
TNF-R1 and TNF-R2, the soluble form fully activates only TNF-R1, despite the high binding 
affinity with TNF-R2 (Richter et al., 2012). 
The members of the TNF-R superfamily are classified into two groups based on the 
presence of the death domain (DD; Walczak, 2013). Receptors belonging to the first group 
display an intracellular DD, which confers the capability to induce cell death. Conversely, 
members belonging to the second class lack this domain and cannot directly activate cell 
death, but need to interact with additional adaptor molecules, such as TNF-receptor-
associating factors (TRAFs) through the receptor TRAF-interacting motif (TIM; Dempsey et al., 
2003). The recruitment of adaptor proteins is crucial for the activation of the intracellular 
pathways triggered by the TNF superfamily ligands. Of note, the DDs are present only in a 
few adaptor proteins (MacEwan, 2002). In fact, TRADD and FADD exploit their DD to interact 
with the receptors and activate cell death, whilst other interactors, such as TRAFs, bind to 
the receptors either directly via the receptor TIM domain or indirectly by recruiting other 
adaptor proteins as intermediates (Hehlgans and Pfeffer, 2005). For its increased capability 
to induce cell death, TNF-R1 signalling has been studied more deeply than TNF-R2 in the 
cancer field. Therefore, several functions of the latter receptor still remain unclear. 
2.3.1 TNF-R1 complex and its signal transduction 
While the carboxyl (C)-terminal end of TNF-R1 is occupied by DD motif for the 
apoptosis signal transduction, the N-terminal region contains a cysteine-rich domain that 
favours the preassembly of the receptor into a trimeric complex (Hehlgans and Pfeffer, 
2005). TNF-R1 is constitutively expressed in all tissue and can activate a variety of cellular 
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processes, including cell proliferation, apoptosis or necroptosis, based on the cellular context 
(Wajant et al., 2003). Even though TNF-R1 usually activate the nuclear factor κB (NF-κB) and 
mitogen-activated protein kinase (MAPK) signalling pathways, TNF-R1 activation can result in 
different scenarios determined by the formation of two diverse complexes, named Complex I 
and II (Figure 2.7; Micheau and Tschopp, 2003). In the first scenario, TNF-R1 trimerizes within 
a few minutes upon TNF stimulation and recruits TRADD to the DD. Then, additional 
mediators, namely receptor-interacting protein 1 (RIP1; Wong et al., 2010), TRAF2 and/or 
TRAF5, are added to the complex and, in turn, cIAP1 and cIAP2 are assembled. The activation 
of NF-kB signalling pathway occurs after the recruitment of NF-κB essential modulator 
(NEMO; also known as IKKγ), TGFβ-activated kinase 1 (TAK1; also known as MAP3K7) and the 
TAK1-binding proteins (TAB1 and TAB2; Figure 2.12; Wajant and Scheurich, 2011). 
The second scenario occurs at late time-points of TNF-R1 stimulation or when NF-kB 
activation is specifically inhibited (Varfolomeev and Ashkenazi, 2004). Importantly, two 
different types of Complex II can be distinguished, named Complex IIa and IIb. Complex IIa 
requires the dissociation of RIP1, TRAF2, and TRADD from the receptor and the subsequent 
recruitment of FADD and caspase-8 (Micheau and Tschopp, 2003). Differently from Complex 
IIa, which drives to apoptosis, the Complex IIb is responsible for a distinct type of cell death, 
named necroptosis, which has recently been object of high interest. Necroptosis is both 
mechanistically and morphologically distinct from apoptosis. When caspase-8 is activated in 
Complex IIa, it cleaves and halts the activities of RIP1, RIP3, and the deubiquitinating enzyme 
CYLD. However, caspase-8 inhibitors (e.g. zVAD) or genetic deletion of caspase-8 or FADD 
impair RIP1 and RIP3 cleavage and lead to the Complex IIb formation and subsequent 
necroptosis. Importantly, the activation of necroptosis is tightly controlled by cIAPs, which 
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are responsible for the proteasome-dependent degradation of active RIP1/3 complexes, and 
therefore can block the execution of this process (Oberst, 2016). 
 
Figure 2.12 - Model of TNF-R1 signal transduction (Ofengeim and Yuan, 2013). Upon ligand binding, TNF-R1 
forms the Complex I through the recruitment of several factors, including TRADD, RIP1, TRAF2, cIAP1 and 2. This 
Complex leads to the recruitment of TAK1 and IKK and drives either to the activation of NF-κB, mediating IκB 
degradation, or to MAPK activation. Importantly, within 10–15 min after TNF stimulation, the deubiquitylation 
enzymes disrupt Complex I mediating the deubiquitination of its members. This results in the formation of 
alternative complexes, named Complex IIa or Complex IIb. Complex IIa includes FADD, caspase-8 and RIP1, and 
mediates apoptosis. However, the inhibition of caspase-8 leads to Complex IIb, which triggers necroptosis.  
2.3.2 TNF-R2 complex and its signal transduction 
Differently from TNF-R1, TNF-R2 expression is more restricted to specific cell types, 
including neurons, oligodendrocytes, microglia and astrocytes in the brain (McCoy and 
Tansey, 2008), endothelial cells, CD4+ and CD8+ T cells (Ware et al., 1991), cardiac myocytes 
(Irwin et al., 1999), thymocytes and human mesenchymal cells (Bocker et al., 2008). Even 
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though TNF-R2 lacks DD, it still interacts with TRAF2 and also this receptor can activate the 
NF-kB pathway in a TNF-R1-independent manner (Borghi et al., 2016). In details, TNF-R2 
trimerization allows the recruitment of TRAF2 and consequently of the TRAF2-associated 
proteins: TRAF1 and cIAPs, thus forming a complex, which interacts with TRAF3 (Figure 2.13). 
Most of the biological activities triggered by TNF-R2 depend on its interaction with TRAF2, 
which provides a mechanism for activation of NF-kB, whose translocation to the nucleus 
promotes the expression of pro-survival target genes, including IAPs and pro-survival BCL-2 
proteins (Pahl, 1999). Importantly, inhibition of TRAF2/3 or IAPs reverses the classical NF-κB 
activation pathway to the non-canonical one (Zarnegar et al., 2008). 
 
Figure 2.13 - TNF-R2 signal transduction (Cabal-Hierro and Lazo, 2012). TNF-R2 signalling is triggered by the 
binding with mTNF. This event prompts to the recruitment of TRAF2, which enables the generation of a 
signalling complex composed by TRAF3, cIAP1 and cIAP2.  
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2.4 The NF-kB signalling pathway 
It is generally accepted that the most important contribution of cIAPs to cell survival 
and tumourigenesis resides in their ability to regulate NF-κB signal transduction (Zarnegar et 
al., 2008). Despite its major role in cell survival, NF-κB is also recognised in the modulation of 
the inflammatory state and innate immunity, and in the control of different steps of cancer 
initiation and progression (Grilli et al., 1993). The NF-κB family is composed by p65 (RelA), 
RelB, c-Rel, NF-κB1 and NF-κB2 that associate to form homo- and hetero-dimeric complexes 
in almost any combination (Figure 2.14; Hayden and Ghosh, 2004). They all share structural 
features, including a Rel homology domain (RHD; Hoesel and Schmid, 2013), which is 
required for dimerization, DNA binding, interaction with IκBs, as well as nuclear 
translocation. In contrast, the transcription activation domain (TA) necessary for the target 
gene expression is present only in the C-terminus of p65, c-Rel, and RelB subunits (Figure 
2.13). Among the 15 potential homo-hetero dimers, three are not able to bind DNA 
(RelA:RelB, cRel:RelB and RelB:RelB), while other three bind DNA but lack the transcriptional 
activity (p50:p50, p52:p52, and p50:p52; O'Dea and Hoffmann, 2010). Upon stimulation, NF-
κB1 and NF-κB2, which are synthesized as pro-forms (p105 and p100), are proteolytically 
processed to p50 and p52, respectively. Since neither NF-kB1 nor NF-kB2 contains a TA 
domain, homo-dimers of p50 and p52 binding to gene promoters act as transcriptional 
repressors (Chen et al., 2000). However, when p50 or p52 are bound to other NF-κB family 
members containing a TA domain, such as p65 or RelB, they form a transcriptional activator 
(Wan and Lenardo, 2009). Different NF-kB subunits are responsible not only for the 
activation of diverse target genes, but also contain sites for phosphorylations and other post-
translational modifications, which enable the cross-talk with other signalling pathways. 
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Figure 2.14 - NF-kB family members. Adapted from (Hoesel and Schmid, 2013). NF-κB family is composed by 
five members, namely RelA (p65), RelB, c-Rel, NF-κB1 (p105), and NF-κB2 (p100). All the members contain a 
RHD, which allows their binding with DNA and the homo- and hetero-dimerization. The C-terminal TA domain is 
harboured only by the three members: RelA, RelB and c-Rel and mediates their transcriptional activity. The 
p105 and p100 members show the presence of ankyrin (ANK) repeats motif, which mediates the binding of IκBs 
to the NF-κB family of proteins and DD motif. The leucin-zipper-like domain (LZ) characterizes only RelB 
structure. 
2.4.1 Activation of the canonical NF-kB pathway 
In the canonical pathway, the activation can be mediated by binding of immune 
receptors including Toll-like receptors (TLRs), Interleukin-1 receptor (IL-1R), TNF-R and 
antigen receptors with their ligands, such as TNF and lipopolysaccharides (LPS; Ghosh and 
Hayden, 2008; Perkins, 2007). This interaction drives to the IκBα degradation, with the 
consequent release of NF-kB and nuclear translocation of p65-containing hetero-dimers, 
which results in the regulation of target genes (Figure 2.15).  
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Figure 2.15 - The canonical NF-kB signalling pathway (Ruland, 2011). After TNF binding, the recruitment of 
TRADD, TRAF2 and cIAP1/2 and RIP1 occurs at the receptor level. This event mediates the activation of IKK 
complex, which in turn phosphorylates IκBα, thus triggering its degradation. The loss of IκBα allows NF-κB 
nuclear translocation resulting in the activation of gene transcription. Among the NF-κB target genes there are 
those that encode for its negative regulators as IκBα. 
2.4.2 Non-canonical NF-kB pathway  
The molecular mechanisms underlying the non-canonical NF-kB signalling pathway 
have been investigated only recently. Differently from the canonical one, the activation of 
the non-canonical NF-kB signalling is slow (within hours) and responds to a different set of 
stimuli (Razani et al., 2011), e.g. B-cell activation factor (BAFFR), CD40, receptor activator for 
nuclear factor kappa B (RANK) or lymphtoxin β-receptor (LTβR). Upon stimulation, NIK, the 
apical inducer of non-canonical NF-kB signalling, phosphorylates and activates IKKα (Figure 
2.16), which in turn mediates the phosphorylation of p100 associated with RelB. This event 
leads to the partial processing of p100 and generation of p52-RelB complex (Sun, 2011). 
More in-depth, after receptor activation, the complex responsible for NIK degradation, 
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comprising TRAF3, TRAF2 and cIAP1/2, undergoes cIAP-mediated degradation with the 
consequent stabilization of NIK. Both TRAFs are responsible for the recruitment of cIAPs, but 
TRAF3 binds to NIK in a TRAF2-independent manner, while TRAF2 mainly interacts with 
cIAP1/2.  
 
Figure 2.16 - Non-canonical NF-kB signalling (Cildir et al., 2016). Under resting conditions, NIK is degraded by 
proteasome in a TRAF2/3-dependent manner. In fact, TRAF2 recruits cIAP1 and 2 and promotes NIK 
ubiquitination and degradation. Then, after the activation of the non-canonical NF-kB pathway, cIAP1 and 2 
mediate TRAF3 degradation therefore resulting in the stabilization of NIK. Once stabilized, NIK phosphorylates 
IKKα, which in turn phosphorylates p100 leading to its partial degradation to p52. Nuclear translocation of 
RelB–p52 hetero-dimers allows the expression of target genes. 
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2.5 IAPs and metastasis  
A still less described role of IAPs regards their involvement in the metastatic process. 
Through the regulation of NF-kB and MAPK signalling pathways, IAPs are able to modulate 
cell plasticity, motility and invasion (Fulda, 2014c), which are key steps in metastasization. 
The metastatic process consists of several steps that allow cancer spread from the primary 
site into the surrounding tissues, and eventually resulting in the colonisation of a secondary 
site where cells can grow and give secondary tumours (Figure 2.17). During the malignant 
progression, cancer cells acquire the ability to invade the basal lamina, surrounding tissues 
and capillaries as single cells (Giampieri et al., 2009) or clumps (Friedl and Gilmour, 2009), 
extravasate and colonise distant organs whose function is then compromised. 
 
Figure 2.17 - Cancer cell metastatic process (Chaffer and Weinberg, 2011). (A) First, the metastatic cascade 
initiates with cell detachment from the primary tumour. (B) Cancer cells invade the surrounding tissues and 
intravasate. (C) Once into the blood vessel, cells (CTCs) transit through the circulation to reach the distant 
organ. (D) At the distant organ, cells extravasate and invade the microenvironment of this secondary site to 
colonise the new tissue. (E) Cells evade the innate immune response and survive as a single cell or cluster. (F) To 
give macrometastasis, cancer cells must be able to proliferate and grow. 
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IAPs have been shown to regulate migration, invasion and metastasis, but the 
mechanisms underlying these processes are still controversial. On the one hand, several 
studies support the idea that the targeting of IAPs causes a reduction of cancer cell 
metastatic potential. These findings would therefore encourage the employment of SMs for 
the treatment of those types of tumour that are particularly aggressive. This is the case, for 
example, of triple negative breast cancers (TNBCs). Accordingly, Lopez J et al. (Lopez et al., 
2011) showed that cIAP1 deregulated activity can increase cell proliferation and migration, 
but SM administration is able to prevent this effect. Moreover, they demonstrated that cIAP1 
depletion results in vascular tree degeneration in vivo, indicating a possible role of cIAP1 in 
the maintenance of vascular integrity, which is essential for tumour growth and favours the 
migratory capacity of cancer cells. Nonetheless, it has also been reported that cIAPs regulate 
Ras related C3 botulinum toxin substrate (Rac1), which is a member of Ras family of small 
GTPases involved in the control of cell migration and invasion. Notably, XIAP and cIAP1 were 
shown to interact with Rac1 and lead to its proteasomal degradation (Oberoi-Khanuja et al., 
2013). In these settings, IAP depletion mediated by pharmacological or genetic tools would 
increase Rac1 protein levels, eventually enhancing cell motility and migration. Consistently, 
Fulda’s group (Tchoghandjian et al., 2013) published the effect of SM BV6 at non-toxic 
concentrations in glioblastoma cell lines, showing that its administration activates the non-
canonical NF-kB signalling and promotes cytoskeleton changes that enhance cell motility. 
2.5.1 Role of MAPKs in the metastatic process 
The activation of MAPK signalling pathways acts in a variety of cellular responses and 
mediates several processes such as growth, proliferation, differentiation, migration and 
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apoptosis (Dhillon et al., 2007). Notably, three distinct MAPK pathways have been 
characterized: extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal 
kinase/stress-activated protein kinase (JNK/SAPK) and p38 (Figure 2.18).  
 
Figure 2.18 - Schematic representation of the MAPK role in tumours (Reddy et al., 2003). A possible cross-talk 
exists among the three major MAPK cascades. Despite ERK is mainly responsible for cell invasion and 
metastasis, it also regulates other cellular processes such as tumour growth and inflammation. At the same 
times, other pathways besides ERK affect the metastatic process. 
Beyond their predominant role in the regulation of the NF-κB signalling pathway, 
IAPs, and in particular cIAP1 and 2, are also involved in the modulation of the MAPK cascade. 
Several reports demonstrate that the ubiquitin ligase activity of cIAPs plays a critical role for 
the efficient activation of MAPK signalling (Gardam et al., 2011; Karin and Gallagher, 2009). 
Indeed, it has been reported by Varfolomeev and colleagues (Varfolomeev et al., 2012) that 
the loss of cIAP1 and 2 upon treatment with the IAP antagonist BV6 drastically affects the 
activation of p38 and JNK.  
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Among MAPKs, the role of the ERK signalling pathway in the metastatic process has 
been widely studied. ERK controls a large variety of cellular processes, including proliferation, 
differentiation, survival, migration, angiogenesis and chromatin remodelling (Dunn et al., 
2005; Yoon and Seger, 2006), depending on the cellular settings. Focusing on the metastatic 
process, it has been shown that sustained ERK signalling enhances the accumulation of genes 
responsible for angiogenesis, cell migration and invasion. This pathway also favours 
metastasis formation (Reddy et al., 2003; Giehl, 2005) exerting profound effects on actin 
cytoskeleton organisation and adhesive structures. Moreover, the metastatic process is 
favoured by ERK signalling pathway in a double manner: via the apoptosis inhibition and 
through the increase of tumour cell migration. In the first case, MEK/ERK phosphorylate the 
pro-apoptotic protein BAD, which dissociates from BCL-2 and allows its anti-apoptotic 
response. Furthermore, ERK pathway favours the anti-apoptotic MCL-1 protein and inhibits 
the pro-apoptotic BIM protein, through their phosphorylation (Pachmayr et al., 2017). In the 
second case, MEK/ERK signalling enhances cell migration by promoting cell movement and 
contraction through the expression of genes involved in the epithelial mesenchimal 
transition (EMT) or in the remodelling of tumour microenvironment, such as matrix-
degrading proteases (Bae et al., 2013). Therefore, tumour initiation and progression are 
often caused by the aberrant activation of ERK signalling pathway, which is often caused by 
the epidermal growth factor receptor (EGFR) hyper-activation. 
2.6 EGFR signalling pathway in the metastatic process 
EGFR (also named ErbB-1, HER1) is a well-known proto-oncogene, in fact, many 
reports indicate its crucial role in cancer progression and metastasis. This receptor belongs to 
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the EGFR family, which comprises other three structurally similar receptors, namely HER2 
(ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4; Wieduwilt and Moasser, 2008). Particular interest 
has been focused on EGFR since its over-expression and/or hyper-activation characterize 
about 15–30 % breast carcinomas and is associated with poor patient outcomes (Sirkisoon et 
al., 2016). 
2.6.1 EGFR structure and down-stream pathways 
EGFR is endowed with a tyrosine kinase activity, which is crucial for the modulation of 
cellular pathways, which are essential in both normal and cancerous cells. The EGFR 
activation depends on its binding with specific ligands including epidermal growth factor 
(EGF), transforming growth factor α (TGFα), amphiregulin or neuregulin (Purba et al., 2017). 
This event can lead either to the formation of EGFR homo-dimers or hetero-dimers with the 
other three members of the family (Figure 2.19). 
 
Figure 2.19 - EGFR signal transduction (Martinelli et al., 2009). EGFR signalling pathway initiates upon ligand 
binding, which drives the formation of homo-dimer or hetero-dimer with other members of the family. The 
receptor dimerization causes conformational changes, which induces the EGFR tyrosine kinase activity and 
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results in the phosphorylation of specific tyrosine residues within the intracellular C-terminal domain. Upon 
phosphorylation, EGFR acquires the capability to enhance several cellular processes, such as cell proliferation, 
loss of differentiation, invasion and angiogenesis and block of apoptosis. 
The binding of the ligand activates the intracellular tyrosine kinase domain of the 
dimerized receptor, thus leading to the phosphorylation of specific tyrosine residues within 
the EGFR intracellular C- terminal domain (Martinelli et al., 2009). Upon phosphorylation, the 
tyrosine residues provide a docking site for proteins containing Src homology 2 (SH2) 
domains, such as Grb2, Shc1, p85, PLCγ and JAK1, and trigger the activation of down-stream 
signalling cascades including the Phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K/Akt), 
JAK/STAT, NF-κB, PLCγ/protein kinase-C (PKC), and RAS/MAPK/ERK (Lindsey and Langhans, 
2015). These effectors affect several cellular functions such as cell proliferation, loss of 
differentiation, motility, invasion, angiogenesis and blocking of apoptosis. 
Although in normal tissues the presence of EGFR ligands is tightly regulated to ensure 
the maintenance of cell homeostasis, EGFR is often chronically stimulated in tumour cells. In 
some cases, the aberrant activation of EGFR, and consequently of its down-stream effectors, 
is caused by the sustained production of EGFR ligands in the tumour microenvironment. 
Moreover, in cancer cells, EGFR can be either over-expressed or mutated, causing its 
constitutive activation. This is the case, for example of head and neck, breast, lung, 
colorectal, prostate, kidney, pancreas, ovary, brain and bladder tumours (Woodburn, 1999). 
Remarkably, the correlation between high EGFR expression and poor patient survival renders 
this receptor a strong prognosis factor in breast, ovarian and head and neck cancers (Fischer-
Colbrie et al., 1997; Ishitoya et al., 1989; Sebastian et al., 2006). Not surprisingly, EGFR has 
emerged as an important target for therapeutic intervention. 
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2.7 Breast cancer classification 
Breast cancers can be classified in five intrinsic subtypes called Luminal A, Luminal B, 
HER2-enriched, claudin-low and basal-like on the basis of expression levels of hormone 
estrogen (ER) and progesterone (PR) receptors, HER2, cytokeratins (CKs) 5/6, and claudins 
3/4/7 (Prat and Perou, 2011). Tumours positive for ERα and/or PR, but with a low expression 
of Ki67, are generally defined Luminal A and are responsive to hormone therapy and 
chemotherapy. Differently, a variable response to chemotherapy has been assessed for 
Luminal B tumours, which are distinguished from Luminal A tumours due to the higher levels 
of Ki67.  Moreover, the negative expression of ERα and PR characterize both the HER2-
enriched tumours and the TNBCs, with HER-enriched tumours expressing high levels of this 
receptor, while TNBCs are negative. The majority of TNBCs display a basal subtype 
characterized by strong expression of basal markers such as CK 5, 6 and 17 (Alluri and 
Newman, 2014). 
2.7.1 TNBC: molecular characterization and targeted therapies  
TNBCs accounts for about 20 % of the invasive breast cancer cases, characterized by 
high grade tumours, distant metastasis and low survival. Since TNBCs lack ER, PR and HER2 
(Figure 2.20), patients do not benefit from hormonal or trastuzumab-based therapies. 
Consequently, therapeutic intervention for TNBC women is very limited and patients often 
show a high risk of recurrence and disease progression. Additionally, TNBC is considered a 
highly heterogeneous disease and many attempts have been made for its classification. 
Recently, six molecular subtypes of TNBC have been identified, including basal-like 1, basal-
like 2, immunomodulatory, mesenchymal-like (ML), mesenchymal stem–like (MSL), and 
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luminal androgen receptor, with distinct gene expression profiles and canonical pathways 
(Lehmann et al., 2011). The high molecular heterogeneity of TNBC disease represents a 
further barrier in improving survival and in developing targeted therapy for patients (Figure 
2.20; Ahn et al., 2016). Currently, TNBC remains the only major type of breast tumour for 
which U.S. Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-
approved targeted therapy is not available, making invasive measures, such as surgery and 
chemotherapy, the only approaches for the treatment of TNBC patients (Lehmann and 
Pietenpol, 2015). 
 
Figure 2.20 - TNBC molecular classification (Zeichner et al., 2016). 
2.7.2 Targeting EGFR for anti-cancer treatment 
So far, two pharmacological approaches have been proposed to inhibit EGFR activity: 
neutralizing monoclonal antibodies and small tyrosine kinase inhibitor molecules.  
2.7.2.1 Monoclonal antibodies 
Among the monoclonal antibodies that have been developed, cetuximab (C225, 
Erbitux) and panitumumab are currently widely employed in cancer treatment. Cetuximab is 
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a chimeric IgG1 monoclonal antibody that targets the ligand-binding domain of the EGFR 
(Figure 2.21). Through its binding with EGFR, cetuximab prevents the receptor activation and 
subsequent dimerization, and therefore inhibits its signal transduction and hyper-
proliferative effects (Ferraro et al., 2013). This drug has been shown to prevent EGFR-
dependent primary tumour growth and metastasis. Hence, the employment of cetuximab for 
clinical use has been approved by FDA for the treatment of patients with wild-type (wt) KRAS, 
EGFR-expressing metastatic colorectal cancer (mCRC) and recurrent or metastatic head and 
neck cancers. Activity of cetuximab has been further tested for the treatment of metastatic 
NSCLC and breast tumours. Panitumumab is a fully human IgG2 targeting the extracellular 
domains of EGFR. It has been evaluated in clinical trials both in monotherapy and in 
combination with other agents for the treatment of various cancer types (colorectal and 
kidney tumours). Along with cetuximab, also panitumumab employment has been approved 
for treatment of colorectal cancer. 
2.7.2.2 Small-molecule EGFR tyrosine kinase inhibitors 
Structural studies have identified the ATP-binding site of the intracellular domain of 
EGFR as responsible for the receptor activity. This observation allowed the development of 
small-molecule EGFR tyrosine kinase inhibitors (Zhang et al., 2006; Yun et al., 2007). These 
compounds were designed to compete with the Adenosine 5’ triphosphate and inhibit the 
intracellular catalytic domain, eventually preventing the EGFR autophosphorylation and its 
down-stream signalling. These molecules differ in their abilities to bind the ATP-binding 
pocket—either reversibly or irreversibly—and in their capacities to interfere not only with 
EGFR but also with other members of the family (Janmaat and Giaccone, 2003). Among the 
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proposed EGFR inhibitors, gefitinib (Figure 2.21) and erlotinib, have been investigated in 
preclinical studies and exhibited an encouraging clinical response. 
  
Figure 2.21 - Blocking the EGFR signalling transduction (Graham et al., 2004). After dimerization, EGFR 
phosphorylated sites residues act as docking sites for several molecules, which cause the activation of diverse 
signalling pathways. To prevent this event, two strategies have been developed by designing EGFR-specific 
monoclonal antibodies and small-molecule tyrosine kinase inhibitors. 
2.8 EGFR drives metastasis via MAPK signalling pathways 
EGFR orchestrates several cellular responses including proliferation, cell motility, 
angiogenesis, cell survival, and differentiation through the activation of the RAS/MAPK 
cascade, together with the PI3K/Akt pathway (Schlessinger, 2000). Importantly, many 
findings provide evidence that MAPKs, and especially ERKs, are involved in cancer initiation 
and progression (Figure 2.22). In fact, EGFR leads to the activation of the RAS/RAF-MEK1/2-
ERK1/2 axis. These signalling pathways are deregulated in approximately one-third of all 
human cancers and are consequently intensively studied (Dhillon et al., 2007). 
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Figure 2.22 - EGFR regulation of cellular processes via ERK pathway. Modified from 
(https://courses.lumenlearning.com/wmopen-biology1/chapter/propagation-of-the-signal/). EGF activates the 
receptor intrinsic kinase, which in turn induces a large variety of down-stream intracellular signalling pathways. 
Among these, ERK activation strongly affects cancer behaviour, influencing cell growth, wound healing and 
tissue repair. 
Constitutive activation of ERK signalling, which is found in the vast majority of cancer-
associated lesions, is caused by: over-expressed or mutated receptor, sustained autocrine or 
paracrine production of activating ligands and mutated RAS or BRAF (Figure 2.23). Aberrant 
activation of the EGFR/MEK/ERK signalling pathway and high levels of ERK1/2 
phosphorylation, indicating an elevated activity, have been observed in metastatic sites of 
breast tumours (Adeyinka et al., 2002). In line with this consideration, MAPK signalling 
pathway is hyper-activated in TNBCs, where it is associated with both deregulated 
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proliferation and capability to migrate of malignant cells (Bartholomeusz et al., 2012). 
Moreover, activation of this pathway has also been linked to higher recurrence rate (Eralp et 
al., 2008). Finally, emerging evidence links the activation of ERK signalling pathway to the 
induction of EMT (Xie et al., 2004). 
 
Figure 2.23 - Cancer lesions associated with ERK signalling pathway deregulation (Dhillon et al., 2007). 
2.9 EMT process in tumour progression  
The essential features of EMT are associated with loss of cell-cell contact and 
decrease of epithelial features with gain of mesenchymal properties. Several studies have 
focused on the mechanisms underlying the EMT process supporting its role in tumour cell 
progression, invasion and metastasis. However, the importance of this process for tumour 
metastasis is still controversial (Fischer et al., 2015). During the EMT, the down-regulation of 
E-Cadherin is a crucial step (Acloque et al., 2008) for the reduction of intercellular adhesion 
junctions and consequent increase of cell detachment. This event is mediated by several E-
Cadherin repressors, such as SNAIL, SNAI2 (Batlle et al., 2000), twist family BHLH 
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transcription factor (TWIST) 1 and 2 (Yang et al., 2004), and the zinc-finger E box-binding 
homeobox (ZEB) 1 and 2 (Vandewalle et al., 2005). However, it is not clear if these EMT 
factors function independently or coordinately to activate the program. Notably, the most 
malignant cancers, including breast cancer, express high levels of Vimentin (mesenchymal 
marker) along with the decrease of E-Cadherin (epithelial-related), which correlates with 
poor prognosis (Thiery, 2002). TNBC tumours show high expression of genes associated with 
EMT (Jang et al., 2015) that are induced by several mediators and, in particular, by the 
constitutive activation of ERK (Figure 2.24), which sustains cell migration (Huang et al., 2004). 
 
Figure 2.24 - ERK-mediated regulation of SNAI2 expression. Adapted from (Kolch et al., 2015). ERK signalling 
pathway governs EMT by favouring the expression of genes, which are responsible for the regulation of this 
process, such as SNAIL1 and SNAI2/SLUG. Accordingly, the expression of SNAIL1 and SNAI2/SLUG is 
accompanied by the decrease of epithelial markers (E-Cadherin), along with the increase of mesenchymal ones 
(Vimentin).  
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2.9.1 The ERK signalling pathway promotes tumour aggressiveness 
ERK chemical and genetic inhibition results in the reduction of cell migration (Huang 
et al., 2004). Accordingly, tumour aggressiveness often relies on ERK-mediated 
phosphorylation of numerous targets, including kinases, phosphatases, transcription factors 
and cytoskeletal proteins (Dhillon et al., 2007). Notably, several mediators of the EMT 
process are found among these targets, e.g. SNAIL1, SNAI2 (Chang et al., 2011), TWIST1 and 
ZEB1, which are commonly high expressed in TNBCs (Figure 2.25). 
 
 
Figure 2.25 - EMT  features and molecular portrait (Shih and Yang, 2011). EMT is a crucial step for tumour 
progression and invasion and promotes metastasis formation, because of the increased cell motility that follows 
the acquisition of mesenchymal features. Furthermore, EMT favours apoptosis resistance to chemotherapeutic 
drugs and the expression of stem cell-like features. 
2.9.2 The role of SNAI2 in cancer metastasis 
The expression of the transcription factor SNAI2 is sustained by EGFR down-stream 
pathways, including PI3K-Akt and RAS-MAPK. SNAI2 belongs to the highly conserved 
 52 
 
Snail/Scratch superfamily and it is characterized by two domains: the highly conserved SNAG 
(Snail/Gfi) domain in the N-terminal region and the C2H2 type zinc fingers in its C-terminal 
region (Nieto, 2002) Figure 2.26). 
 
Figure 2.26 - Structural domains of SNAI2. Modified from (Shih and Yang, 2011). The zinc finger transcriptional 
factor SNAI2 contains an N-terminal SNAG domain and C-terminal zinc finger domains. Both of these domains 
are responsible for SNAI2 repressor activity. The NES domain allows the nuclear export signal. 
Several agents, including EGF, fibroblast growth factor (FGF), hepatocyte growth 
factor (HGF), transforming growth factor β (TGFβ), bone morphogenetic proteins (BMPs), 
WNTs and Notch (Figure 2.27), activate SNAI2 expression. Among these factors, EGF is 
important for SNAI2 high expression in TNBCs, which enhances cell motility, metastatic 
potential (Bailey et al., 2012; Phillips and Kuperwasser, 2014) and resistance to detachment-
induced cell death.  
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Figure 2.27 - Pathways responsible for SNAI2 expression (Barrallo-Gimeno and Nieto, 2005). The transcription 
factor SNAI2 is controlled by several pathways. Its modulation occurs not only at the transcriptional levels, but 
also through the regulation of its subcellular localization. 
Therefore, the association of SNAI2 with cancer aggressiveness and resistance to 
therapy renders this protein an attractive therapeutic target in breast cancers (Figure 2.28). 
However, only few compounds have been designed to directly target SNAI2 (Harney et al., 
2009) and some indirect approaches have been developed to inhibit its expression and/or 
activity (Ferrari-Amorotti et al., 2014; Ferrari-Amorotti et al., 2013). In this way, the invasive 
and migratory behaviours of cancer cells have been attenuated. 
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Figure 2.28 - Role of SNAI2 in tumour metastasis. Adapted from (Chimge and Frenkel, 2013). SNAI2 controls 
both early metastatic events including EMT, invasion, intravasation and late stages, thus favouring cancer cell 
colonisation of secondary sites. 
Beyond EMT regulation, SNAI2 increases cancer aggressiveness favouring cancer cell 
stem-like features (Luanpitpong et al., 2016). In fact, a correlation exists between EMT and 
cancer stem-like cell (CSC) enrichment, and in line with this findings, it has been reported 
that SNAI2 controls the levels of SOX2 (Samanta et al., 2016) and SOX9 (Luanpitpong et al., 
2016). These proteins belong to the SOX (Sry-related HMG Box) family, which is involved in 
the maintenance of self-renewal and pluripotency in embryonic stem cells, as well as in adult 
tissue progenitors (Sarkar and Hochedlinger, 2013). Therefore, SNAI2 plays a pivotal role in 
the regulation of cell motility, survival and cancer cell “stemness” and contributes to the 
dissemination of cancer cells from the primary tumours to the secondary sites. In light of 
these observations, it would be important to understand the molecular mechanisms of 
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action and regulation of SNAI2 in order to design novel approaches to interfere with its 
expression and contrast the metastatic process.  
2.10 EGFR intracellular trafficking 
So far, the mechanisms leading to EGFR over-expression in TNBCs are not completely 
clear. Increased levels of this receptor have been linked to the presence of mutated BRCA 
(Nakai et al., 2016), but also other aspects contribute to EGFR levels. For example, it has 
been shown that a reduced degradation can sustain its levels (Zhang et al., 2013). EGFR 
down-regulation occurs at the end of an intricate process resulting in signal attenuation, 
which derives from the removal of the receptor from the cell surface (Peschard and Park, 
2003). Upon ligand-binding, the major mechanism of EGFR internalization is clathrin-
mediated endocytosis (CME), through which the receptor is internalized by clathrin-coated 
pits and then directed to early endosomes where the cargo is delivered after fusion. 
Following the delivery to the early endosome, the receptor can be either recycled to the cell 
surface or sorted to late endosomes and lysosomes for being degraded. An alternative 
pathway for EGFR internalization is clathrin-independent and it is therefore called clathrin-
independent endocytosis (CIE; Sigismund et al., 2005). It has been published that high 
concentrations of EGF drives to CIE rather than CME (Figure 2.29). 
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Figure 2.29 - EGR endocytosis and endosomal sorting (Haglund and Dikic, 2012). Upon EGF binding, the 
receptor undergoes endocytosis, which can occur in a clathrin-indipendent (left) or clathrin-mediated (right) 
manner. In both cases, after being internalized, the receptor is routed to early endosomes and then sorted to 
late endosomes (MVE) for lysosomal degradation (ubiquitylated receptors) or recycled to the plasma 
membrane. 
2.11 EGFR ubiquitination is a crucial step for its degradation 
In addition to controlling localization, function and stability of target proteins, 
ubiquitination appears as a crucial event in EGFR endocytosis and degradation. Ubiquitinated 
EGFR is mainly degraded through lysosomal vesicles (Futter et al., 1996; Marmor and Yarden, 
2004) and not by “classical” proteasomal degradation. 
2.11.1 EGFR degradation induced by c-CBL  
Commonly known as being a negative regulator of various activated receptor tyrosine 
kinases (RTKs) such as EGFR and c-MET, c-CBL plays a crucial role in EGFR endocytic 
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trafficking. Notably, c-CBL is a member of the evolutionarily conserved Cbl family of 
cytoplasmic proteins and because of its crucial role in the attenuation of receptor signalling, 
c-CBL deregulation can lead to malignant diseases. Accordingly, Zhang J. et al. (Zhang et al., 
2013) reported that c-CBL inhibition correlates with poor prognosis in glioblastoma patients. 
Interestingly, it was shown that if c-CBL is unable to correctly regulate EGFR, this receptor 
does not undergo lysosomal degradation. This block eventually results in extended EGFR-
signalling activities (Figure 2.30). 
 
Figure 2.30 - c-CBL-mediated ubiquitination leads to EGFR endocytosis and degradation. Adapted from (Zhang 
et al., 2013). c-CBL crucially mediates EGFR ubiquitination and degradation. The impairment of c-CBL activity 
results in enhanced signalling which contributes to cancer progression. 
Upon ligand-binding, EGFR undergoes dimerization and autophosphorylation of 
several tyrosine residues in the cytoplasmic tail. These phosphorylations represent the 
prerequisite for clathrin-dependent endocytosis. In particular, phosphorylation of tyrosine 
1045 (Tyr-1045) is crucial for the direct binding of c-CBL to EGFR (Levkowitz et al., 1999). It 
has been recently reported that the hypophosphorylation at Tyr1045 allows EGFRvIII to 
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evade degradation (Grandal et al., 2007). In this setting, c-CBL is not recruited to EGFR, which 
therefore it is not ubiquitinated correctly (Figure 2.31). 
 
Figure 2.31 - Phosphorylation of Tyr-1045 is crucial for c-CBL-mediated EGFR degradation (Grandal et al., 
2007). The binding of c-CBL requires the phosphorylation of EGFR at Tyr-1045. Consequently, the mutant form 
of EGFR, named EGFRvIII, which is hypophosphorylated at Tyr-1045, avoids the ubiquitination by c-CBL and is 
less degraded.  
2.11.2 RAB family proteins regulate the EGFR endocytic trafficking 
Once EGFR is in early endosomes, it can be routed to the late endosome and 
lysosome for degradation, or recycled to the plasma membrane. If the receptor is targeted 
for degradation, it is first internalized in multivesicular body (MVB; Stahl and Barbieri, 2002), 
and subsequently released to the lysosomes. RAB proteins have been identified as key 
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regulators of EGFR endocytic trafficking and mediate this process. The RAB family consists of 
small GTPases proteins (Somsel Rodman and Wandinger-Ness, 2000) and is composed by 
over 60 members that are characterized by similar structure and properties, but exert 
different functions in the regulation of intracellular vesicles trafficking and fusion reactions. 
So far, only a few RAB proteins have been described as being regulators of EGFR endocytic 
trafficking (Ceresa, 2006) namely RAB5, RAB11 and RAB7. RAB5 and 11 are established 
markers of early (Barbieri et al., 2004; Konstantinopoulos et al., 2007) and recycling 
endosomes (Cullis et al., 2002), respectively. Conversely, RAB7 is a marker of late 
endosomes, and therefore drives EGFR to degradation (Ceresa, 2006; Figure 2.32). 
 
Figure 2.32 - Different RAB family members are responsible for EGFR recycling and degradation (Francavilla et 
al., 2016). Once in early endosomes, EGFR can be recycled to the cell surface or further routed to late 
endosomes and lysosomes for degradation. While RAB11 is a marker of the recycling process, RAB7 is a marker 
of late endosomes and co- localizes with degrading EGFR. 
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2.12 The role of LRIG1 in EGFR down-regulation 
Together with c-CBL, the leucine rich repeat and immunoglobulin-like domain 
protein-1 (LRIG1) has recently been identified as a negative regulator of c-MET and the ErbB 
family members (Figure 2.33). Particularly, Gur et al. reported the involvement of LRIG1 in 
increasing EGFR ubiquitination and degradation, which occurs by enhancing the recruitment 
of c-CBL to the receptor (Gur et al., 2004). However, while LRIG1 mediates EGFR degradation 
in a c-CBL dependent manner (Gur et al., 2004), c-MET degradation does not require 
ubiquitination and is mediated by LRIG1 in a c-CBL-independent manner (Shattuck et al., 
2007).  
 
Figure 2.33 - The role of LRIG1 in EGFR degradation (Wang et al., 2013). LRIG1 negatively regulates EGFR via 
enhancing its interaction with c-CBL. The presence of LRIG1, in fact, favours EGFR degradation by accelerating 
the recruitment of the E3 ligase c-CBL through a CBL-binding domain in the LRIG1 cytoplasmic tail. This 
mechanism enhances EGFR ubiquitination and lysosomal degradation. 
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LRIG1 has been described as a tumour suppressor due to its capability to inhibit cell 
proliferation and cancer growth (Hedman et al., 2002) and its expression has been analysed 
in many human cancers. Importantly, gene expression analysis of five cancers, including 
breast, lung, bladder, glioma and melanoma (Rouam et al., 2010), revealed that LRIG1 
decreased expression correlates with poor survival. Being a transcriptional target of estrogen 
receptor-alpha (ERα), LRIG1 expression is high in Luminal A (ER-positive) breast cancers and 
low in the basal-like subtype (Wang et al., 2013). Interestingly, LRIG1 low expression 
contributes to the aggressiveness of basal-like tumours. In fact, a negative correlation has 
been found between its expression and the presence of mesenchymal markers (Yokdang et 
al., 2016). 
2.13 EGFR and c-MET cross-talk 
Together with EGFR, also the activation of c-MET mediated by its ligand, the 
hepatocyte growth factor (HGF), is known to promote the survival of many cell types. 
Furthermore, c-MET enhances tumour invasion via increased ERK phosphorylation, and this 
results in a high metastatic potential of cancer cells. Importantly, the interaction between 
EGFR and c-MET has been found in tumour but not in normal cells (Jo et al., 2000). This 
evidence suggests that a tumour-specific cross-talk exists between EGFR and c-MET 
receptors and promotes the activation of their shared down-stream pathways (Figure 2.34). 
Many signalling pathways are in common between both receptors and therefore several 
studies support a possible synergism between EGFR and c-MET, which favours tumour 
growth and aggressiveness. However, the underlying mechanisms responsible for this 
functional interaction remain unknown. Furthermore, Engelman and colleagues reported 
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that patients affected by NSCLC are initially sensitive to treatment with the EGFR inhibitor 
gefitinib, but later become resistant because of c-MET gene amplification. Emerging evidence 
shows that about 20 % of acquired resistance to EGFR-targeted therapies derives from the 
amplification of the c-MET receptor (Corso and Giordano, 2013). Accordingly, breast cancer 
cells acquire resistance to EGFR TKIs after HGF exposure and the HGF-induced cell survival 
results abrogated in EGFR-depleted cells, indicating a critical role for EGFR/c-MET cross-talk 
(Mueller et al., 2012). Intriguingly, this information supports the employment of 
simultaneous treatment with anti-EGFR and anti-c-MET drugs to restore the sensitivity and 
efficiency of tumour treatment (Yu et al., 2013).  
 
Figure 2.34 - Functional interaction between EGFR and c-MET (Zhang et al., 2015). A cross-talk between EGFR 
and c-MET down-stream signalling pathways occurs thereby enhancing tumour malignant phenotype. The two 
receptors elicit similar signal transduction pathways and therefore their synergism increases the strength and 
duration of shared signalling pathways. EGFR and c-MET are often co-expressed in tumour with a high grade of 
aggressiveness and their combined activity promotes cell survival, proliferation and migration.  
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3 AIM OF THE STUDY 
Despite the progress in the understanding of the molecular and cellular basis driving 
to metastasis formation, this process remains the major cause of mortality. The central 
purpose of this study is therefore to characterize the role of IAPs in the metastatic cascade.  
The specific aims of this work are:  
 
 Investigate the effect of SM83-mediated depletion of IAPs on metastasis formation in 
vivo 
 
 Determine the mechanism of SM83-induced down-regulation of SNAI2 
 
 Study the role of IAPs, and in particular of cIAP1, in regulating EGFR-mediated SNAI2 
expression 
 
 Investigate the role of cIAP1 in regulating EGFR levels. 
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4  MATERIALS AND METHODS 
4.1 Reagents  
4.1.1 Buffers and Solutions 
Freezing solution 
 60 % RPMI or DMEM supplemented with 
 1 % L-Glutamine (LONZA)  
 1 % NEAA (LONZA)  
 1 % Sodium pyruvate (LONZA)  
 1 % Hepes (LONZA)  
 30 % FBS  
 10 % DMSO (Sigma-Aldrich) 
SDS lysis buffer 
 5 % SDS 
 125 mM Tris HCl pH 6,8  
 Milli-Q water up to volume 
Mix of proteases and phosphatases inhibitors 
 200 μg/ml Aprotinin  
 200 μg/ml Leupeptin  
 200 mM EDTA  
 200 mM β-glycerophosphate  
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 200 mM sodium fluoride  
 200 mM sodium orthovanadate  
 50 mM sodium pyrophosphate  
 Milli-Q water up to volume 
Protein loading buffer 10X (ZAP) 
 0.25 M Tris HCl pH 6.8  
 30 % glycerol  
 8 % SDS  
 0.02 % BFB  
 10 % β-mercaptoethanol  
 Milli-Q water up to volume 
Running Buffers 
MES and MOPS were purchased from Thermo Fisher Scientific  
Transfer buffer 
 NuPAGE Transfer Buffer 1X (Thermo Fisher Scientific) 
 20 % methanol  
 Milli-Q water up to volume  
PBS-T 
 PBS (LONZA, Cat. #17-516F) 
 0.1 % TWEEN 20 
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Blocking buffer  
 4 % non-fat dry milk (Blotting-Grade Blocker, BIO-RAD) 
 0.01 % Tween-20 (Sigma-Aldrich) 
 1X PBS 
ELB buffer 
 150 mM NaCl  
 50 mM Hepes  
 5 mM EDTA  
 0.5 % NP40  
 Milli-Q water up to volume 
 pH 7.5 
Nucleic acid loading dye 6X 
 0.25 % bromophenol blue powder  
 30 % glycerol  
 Milli-Q water up to volume 
TAE buffer 1X 
 20 mM Tris acetate  
 10 mM EDTA 
 2.85 % acetic acid 
 Milli-Q water up to volume 
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Antibody solution 
 5 % Albumin from Bovine Serum (BSA; Sigma-Aldrich), 
 0.01 % Tween-20, 
 0.01 % Sodium Azide purchased from Sigma-Aldrich, 
 1X PBS 
4.2 Cell cultures 
The human breast adenocarcinoma MDA-MB231, BT549, MDA-MB157, SkBr3 and 
HCC1937 cell lines were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium 
(LONZA Group, Basel, CH) supplemented with 10 % fetal bovine serum (FBS; EuroClone, 
Milan, IT), 2 mM L-glutamine, sodium pyruvate, non essential amino acids (NEAA) and 
penicillin (100 U/ml)/streptomycin (100 µg/ml; all from LONZA). SUM149 and SUM159, 
together with the human hTERT-mammary immortalized epithelial HME and MCF10A cell 
lines- parental and bearing the EGFR delE746A750 mutation (HME EGFR and MCF10A EGFR 
hereafter, respectively) -were cultured in Dulbecco's Modified Eagle's medium-F12 (DMEM-
F12; Gibco), supplemented with 10 % FBS, 2 mM L-glutamine, 20 ng/ml EGF (Cat. #GRF-
10544, Selleck Chemicals, Munich, D), 10 µg/ml insulin (Sigma-Aldrich, St. Louis, MO, USA), 
500 µg/ml hydrocortisone (Sigma-Aldrich). BT474, MDA-MB453, T47D and MDA-MB361 cell 
lines were maintained in DMEM (Gibco-Thermo Fisher Scientific, Massachusetts, USA) 
supplemented with 10 % FBS and 2 mM L-glutamine. HEK293FT (Thermo Fisher Scientific) 
highly transfectable cell line were cultured in DMEM with 10 % FBS and used for lentiviral 
production. All cells were grown at 37 °C in fully humidified atmosphere with 5 % CO2.  
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MDA-MB231 cell lines were purchased from American Type Culture Collection while all 
the other breast cancer cell lines employed for this thesis were kindly provided by Dr Elda 
Tagliabue. The mouse 4T1 mouse mammary carcinoma were a kind gift from Dr Mario 
Colombo, while human mammary immortalized epithelial HME and MCF10A cell lines were 
all kindly provided by Prof. Alberto Bardelli. All cell lines have been checked for their identity 
(STR characterization) and were mycoplasma-free as determined by Takara Mycoplasma 
Detection Kit (Clontech, Mountain View, CA, USA).  
4.3 Cell viability assay 
Cell viability was established using the CellTiter-Glo (Promega, Madison, USA). According 
to the manufacturer’s instructions, cells were seeded in white optical 96-well plates and 
treated as indicated. Medium was discarded at the end of the experiments and replaced with 
60 µl of reagent diluted 1:4 in phosphate-buffered saline PBS. After 15 min of shaking at RT, 
luminescence was measured with a Tecan Ultra plate reader. Viability of cells silenced with 
indicated siRNAs (Table 4.1) was shown as a percentage compared to untreated or mock 
treated cells.  
Pool Catalog Number Gene Symbol 
M-003155-02 MERTK 
M-005563-02 GPER 
M-017626-00 BDNF 
M-012633-02 CTGF 
M-009328-02 PTPRU 
M-016029-01 OSR1 
M-010911-00 KLHL3 
M-009900-01 RGS4 
M-008705-01 FOXQ1 
M-004788-00 HSDL1 
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M-025119-01 RNF144B 
M-017386-00 SNAI2 
M-005130-02 PAPPA 
D-001206-13 Non-targeting #1 
Table 4.1 - List of Dharmacon siRNA pools (GE Healthcare, Lafayette, CO, USA). 
4.4 Cell treatments 
To deplete cIAPs, cells were treated with 100 nM SM83 whose synthesis has recently 
been described (Manzoni et al., 2012). The activation of TNF-Rs was achieved by the 
administration of recombinant TNF (Emmerich et al., 2011) produced by the University of 
Milan using a plasmid encoding for tagged human TNF kindly provided by Prof. Henning 
Walczak. To specifically activate the non-canonical NF-κB pathway, the recombinant human 
TWEAK provided by Prof. Harald Wajant (Salzmann et al., 2013) was employed. In 
combination therapy with SM83 the necroptosis inhibitor Necrostatin-1 (Enzo Life Sciences, 
Plymouth Meeting, PA, USA) and Pan-caspase inhibitor z-VAD(OMe)-FMK (BIOMOL) were 
used. Cells were treated with the PI3K and AKT (LY294002 and Triciribine, Enzo Life Sciences), 
MEK (U0126, Calbiochem, Merck KGaA, Darmstadt, D) and p38 (SB203580, Selleck Chemicals) 
inhibitors. EGFR activation was induced through the administration of 20 ng/ml EGF (Cat. 
#GRF-10544, Selleck Chemicals) or TGFα (#100-16A, Peprotech, London, UK) in cells serum-
starved overnight using medium supplemented with 0.1 % FBS. Cetuximab employed to 
specifically block EGFR was provided by the pharmacy of the Fondazione IRCCS Istituto 
Nazionale dei Tumori (Milan, IT). When needed, protein levels were stabilised with the 
lysosomal inhibitor chloroquine (CLQ, #C6628) from Sigma-Aldrich, used at 100 μM and 
added to the cell growth medium 1 h before EGFR stimulation. The protein synthesis 
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inhibitor cycloheximide (CHX, #239764, Calbiochem) was added to BT549 cells at 100 μM 30 
min before treatments, while half of the dose was employed in MCF10A cells. 
4.5 In vivo experiments 
Experiments were approved by the Ethics Committee for Animal Experimentation of 
the Fondazione IRCCS Istituto Nazionale dei Tumori (INT) of Milan according to institutional 
guidelines and by the Italian Minister of Health (Projects INT_12_2011 and INT_02_2015). 
Mice were maintained in laminar flow rooms keeping temperature and humidity constant. 
Mice had free access to food and water and were weighted twice a week. 
In vivo effect of SM83 was assessed using the breast cancer xenograft models, non-
obese diabetic/severe combined immunodeficiency disease (NOD/SCID) mice. Animals were 
engrafted in the left flank by subcutaneous (sc) injection of 200 µl physiological saline 
containing 5x106 MDA-MB231. Randomization occurred at the day 13, when mice were 
treated with ip or iv injections with 5 mg/kg SM83, 5 times/week to a total of 15 injections. 
Tumour growth was evaluated by biweekly measurements of tumour diameter with a 
Vernier caliper and tumour volume (TV) was calculated according to the formula: 4/3 x 3.14 x 
(l/2) x (w/2) x (h/2) where l, w and h are length, width and height, respectively. Biochemical 
analysis and gene expression analysis of the primary tumour were performed in mice 
sacrificed 6 h after the last injection. In metastasis studies, NOD/SCID mice were killed 2 
weeks after the last SM83 administration and, together with subcutaneous nodules, lungs 
were collected and formalin-fixed/paraffin-embedded for IHC detection of metastasis with 
anti-human Vimentin antibody (M0725, DAKO-Agilent, Santa Clara, CA, USA). 
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The anti-metastasis effect of SM83 was also tested using immuno-competent BALB/c 
mice injected with 1 × 104 4T1(cl5) cells on day 0 into the mammary fat pad. After 13 days, 
mice were treated with ip injections of SM83 at a dose of 5 mg/kg body weight, three 
times/weeks for 2 weeks. The progression of metastasis was assessed 2 days after the last 
SM83 injection. 
4.6 Gene expression profiling and bioinformatics 
MDA-MB231 nodules were collected from NOD/SCID xenografts 6 h after the last 
injection of SM83 and cut in pieces. One piece was lysed for RNA extraction using RNeasy 
Mini Kit (Qiagen, Hilden, Germany) and then total RNA was retro-transcribed using 
SuperScript II Reverse Transcriptase kit (Thermo Fisher Scientific) for gene expression 
profiling (GEP). GEP was performed by the Functional Genomics and Bioinformatic Core 
Facility of INT using Illumina HumanHT-12 v4 Expression BeadChip arrays (Illumina, San 
Diego, CA, USA). 
Raw data were pre-processed using the R/Bioconductor package “lumi” (Du et al., 
2008) that provides statistical methods for analysis of Illumina microarray data. Data were 
Log2-transformed and normalized using the robust spline normalization method. Probes not 
annotated to HUGO gene symbols were filtered out. For the remaining probes only those 
with a detection p-value < 0.01 (a measure of the confidence that a probe is expressed above 
the background level, defined by negative control probes) in at least one sample were 
considered. Finally, multiple probes mapping to the same gene were collapsed selecting the 
probe detected in the highest number of samples.  
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Differential expression analysis was performed using the “limma” package (Phipson et 
al., 2016) that combines linear models with moderated t-statistic to identify differentially 
expressed genes across experimental conditions. The moderated t-statistics has the same 
interpretation as an ordinary t-statistic except that the standard errors are moderated across 
genes, i.e., squeezed towards a common value, using a simple Bayesian model. P-values 
obtained from limma were adjusted for multiple-testing using the Benjamini-Hochberg false 
discovery rate (FDR) to reduce the number of false positives. Genes showing an absolute 
fold change ≥ 1.5 and an FDR <0.05 were considered significantly differentially expressed. 
Expression profiles are deposited in the Gene Expression Omnibus (GEO) repository with 
accession number GSE98691. 
For public gene expression datasets, normalized data for breast cancer cell lines were 
downloaded from ArrayExpress repository (https://www.ebi.ac.uk/arrayexpress/) with 
accession number E-MTAB-181 (Heiser et al., 2012). RNA-Seq level-3 expression data for 
TCGA breast cancer patients were downloaded from Firehose portal 
(http://gdac.broadinstitute.org/) with accession date 2016-01-28. Data were normalized 
using the trigger mean of M-value method (Robinson and Oshlack, 2010) and transformed in 
logarithmic scale (base 2). Correlation between continuous variables was calculated using the 
Pearson’s correlation coefficient. 
4.7 Wound healing-based migration assay 
Wound healing experiments were performed using Culture-Insert in µ-Dish 35 mm 
(Ibidi). To assess cell migration, 4x104 MDA-MB231 cells were reverse transfected in the 
culture inserts in 12-well plates. After 72 h, inserts were removed, cells were washed once to 
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eliminate detached cells and multi-well plates were put in a Cell-IQ instrument (CM-
Technologies) to test cell motility. Images were taken every hour for 24 h and analysed with 
the provided software to measure the gap area.  
Wound healing assay was performed using the same protocol described above, also 
to compare the migration capability of MDA-MB231, BT549, HCC1937 and T47D cell lines and 
then to assess the effect of cIAP1 depletion on cell motility in BT549 and MCF10A, either wt 
or bearing mutated EGFR, stably silenced for cIAP1 compared to control. Data obtained by 
Cell-IQ instrument were analysed and used to draw a sigmoidal curve with GraphPad Prism 
thus determining the time necessary to close half of the wound area.   
4.8 Gene knock-down by silencing (reverse protocol) 
To achieve transient knock-down of target genes, cells were transfected with 
indicated short interfering RNAs (siRNAs, Table 4.2) using a reverse transfection protocol in 
which siRNAs (Qiagen) and RNAiMAX (Thermo Fisher Scientific) have been employed. A mix 
containing 3.25 µl of RNAiMAX in 100 µl Optimem (Gibco) and another one with 3.25 µl of 
siRNA (20 µM) stock were prepared, and after 5 min at RT were combined and left at RT for 
30-40 min. In the meantime, cells were trypsinized, counted and about 0.25 x 106 cells were 
cultured in a 6-well plate in a final volume of 2 ml medium without antibiotics. After the 
incubation, the siRNA/RNAiMAX mix was added on top of the cells in the culturing well. Cells 
were incubated for 72 h to have an efficient knock-down in all cases. If cells needed to be 
stimulated, 48 h after transfection cells were serum-starved for the following 24 h. In each 
experiment, scramble siRNAs (siCtr) were used as control and siRNA targeting an essential 
gene (ubiquitin, UBB) served to evaluate the transfection efficiency. For transfection in 96-
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well plates, mixes were prepared with 0.25 µl siRNAs plus 0.25 µl RNAiMAX and 104 cells 
were seeded in 100 µl final volume. 
Name Sequence  Source 
siLUC 5’- CGUACGCGGAAUACUUCGATT-3’ Eurofins 
 
Name Assay ID  Source 
sicIAP1 Hs_BIRC2_7 and 8  Qiagen 
sicIAP2 Hs_BIRC2_8 and 9 Qiagen 
siTNF Hs_TNF_1 Qiagen 
siTNF-R1 Hs_TNFRSF1A_5 Qiagen 
siTNF-R2 Hs_ TNFRSF1B_1 Qiagen 
siERK1 Hs_MAPK3_3 and 7 Qiagen 
siERK2 Hs_MAPK1_ 9 and 10 Qiagen 
siNFkB2 Hs_NFKB2_1 Qiagen 
siNF-kB1 Hs_NFKB1_3 Qiagen 
siRELA Hs_RELA_5 Qiagen 
siLRIG1 Hs_LRIG1_5 and 6 Qiagen 
siMET Hs_MET_6 Qiagen 
siGENOME SMARTpool for XIAP M-004098-01 Dharmacon 
siGENOME Non-Targeting siRNA Pool #1 NT1; D-001206-13 Dharmacon 
siGENOME SMARTpool for SNAI2 M-017386-00 Dharmacon 
Table 4.2 - List of siRNAs used in this thesis. 
4.9 Lentiviral transduction for stably knock-down 
MDA-MB231 cells were engineered to stably knock-down SNAI2 through lentiviral-
mediated gene delivery. Lentiviral particles containing the pGFP-C-shLenti SNAI2 
(NM_003068) were purchased from OriGene. Target cells (5×104 cells) were cultured with 
medium containing lentiviral particles for 48 h before addition of puromycin (0.5 μg/ml) for 
selection. After selection, transfection was confirmed by protein expression analyses. 
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To stably knock-down cIAP1, lentivirus was produced by transfection of HEK293FT 
packaging cells with the pLKO.1-cIAP1 shRNA (Cat. #44129, Addgene). Lentiviral particles 
were collected 48 h after transfection and filtered through a 0.45 μm filter.  
4.10 Gene over-expression 
To ectopically express EGFR and c-CBL, lentiviral plasmids were used to produce lentiviral 
particles in HEK293FT packaging cells. Viruses were obtained by reverse transfection of 
HEK293FT cells following manufacturer’s protocol. After 24 h, medium was replaced with 
fresh medium that was collected after further 24 h and used to transduce BT549 and 
MCF10A cells. The plasmid for human EGFR (Myc/Flag-tagged) ectopic expression was 
purchased by Origene Company (#RC217384L1; Rockville, MD, USA), while the c-CBL-
expressing vector (RRL-CMV-CBL) was kindly provided by Prof. Pier Paolo Di Fiore. 
To over-express wt and mutated cIAP1, cells were seeded the day before transfection, 
using a medium without antibiotics, in order to have 80-90 % of confluent cells the following 
day. BT549 cells were transfected with pcdna3.1 plasmids kindly provided by Jon Ashwell 
(Addgene plasmid #8311 and #8337, respectively), according to the manufacturer's 
instructions. Briefly, DNA was complexed with Opti-MEM, as well as Lipofectamine 2000 
(ratio DNA : Lipofectamine = 1 : 2). Mixtures were incubated 5 min at RT and then combined 
to allow the formation of the liposomes-DNA complexes; 30 min later, the solution was 
added to the cells and the desired protein expression was verified 48 h later. 
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4.11 Western blot analysis  
4.11.1 Preparation of total cell extracts 
Cells were trypsinized and harvested by centrifugation at 4500 rpm for 5 min at 4 °C. 
After washing with PBS supplemented with 0.1 mM Na3VO4 to inhibit phosphatase, cells 
were lysed by boiling in 60-100 μl SDS lysis buffer supplemented with the mix of 
phosphatases and proteases inhibitors. Samples were then sonicated with 20 % amplitude 
for 20 sec (Branson Digital Sonifier) to dissolve DNA molecules, and then centrifuged at 
13000 rpm for 20 min at room temperature (RT).  Cleared supernatants were transferred to a 
new tube and frozen at -20 °C.  
4.11.2 Quantification of total cell extracts 
Bicinchonic acid (BCA)-containing protein assay was used to determine the protein 
content of total cell extracts, according to the manufacturer’s instructions (QuantumMicro 
Protein, EuroClone). Briefly, 2 μl of lysate were incubated with 148 µl water and serial 
dilutions of bovine serum albumin (BSA) used as standard protein, in a 96-well plate. BCA 
solution was added in a 1:1 ratio. After incubation at RT, absorbance was measured at 485 
nm using Ultra microplate reader (Tecan). Protein concentration was determined by 
interpolation with the curve obtained with the standard BSA. 
4.11.3 SDS-PAGE  
Proteins were separated according to their molecular weight using pre-cast 4-12 % 
Bis-Tris NuPAGE gels (Thermo Fisher Scientific). Cell lysates were mixed with 4 x reducing 
SDS-Sample buffer and heated for 10 min at 99 °C. Before loading, protein samples were 
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prepared by adding ZAP solution to 20-50 μg of proteins and samples were denatured for 10 
min at 99 °C. As a molecular weight standard, Page Ruler Plus Pre-Stained Protein Ladder 
(EuroClone) was used. The electrophoretic separation was achieved by applying a constant 
voltage in MES or MOPS buffer. As suggested by the manufacturer, 500 μl of NuPAGE 
antioxidant were added to the chamber to protect reduced disulfide bonds and sensitive 
amino acids from oxidation, thus allowing proper protein migration in reducing conditions. 
Proteins within the gels were then blotted onto PVDF Immobilon-P Transfer Membrane 
(Millipore), previously activated with 100 % methanol, rehydrated in Milli-Q water, and 
equilibrated in transfer buffer. Transfer was carried out using the XCell II blot module 
(Thermo Fisher Scientific). Transfer sandwich was composed of three sponges; three 3MM 
wetted papers (Whatman), the gel, PVDF and three additional 3MM wetted papers. The 
sandwich was put into the XCell SureLock Mini-Cell, the blot module was filled with transfer 
buffer and the outside chamber with distilled water; transfer of proteins was carried out at 
180 mA for 2 h. Membranes were incubated with blocking buffer (4% non-fat milk dissolved 
in PBS plus tween 0.1 %, PBS-T) for 30 min and then incubated overnight with the indicated 
primary antibodies. Membranes were then washed 3 times in PBS-T and incubated 1 h with 
the appropriate horseradish peroxidase-conjugated secondary antibody (Sigma). After 
washing in PBS-T, proteins were detected by electrochemiluminescence (ECL) reaction, by 
exposure of films to the membranes after incubation with luminol-based chemiluminescent 
substrates (Pierce). 
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4.12 Immunoprecipitation 
Immunoprecipitation (IP) was performed in BT549 cells over-expressing FLAG-tagged 
EGFR for the identification of EGFR binding proteins (co-IP). To this end, cells were collected, 
washed 1 time with PBS supplemented with Na3VO4 and lysed in ice-cold ELB buffer 
supplemented with the mix of proteases and phosphatases inhibitors (hereafter ELB+), at 4 
°C with rotation for 30 min. Samples were then centrifuged at 13000 rpm for 15 min at 4 °C, 
supernatant was transferred in a new low-retention microcentrifuge tube and 1 mg of total 
protein extract was incubated at 4°C for 3 h with 30 µl of the 50 % slurry of anti-FLAG M2 
Affinity Gel (#A2220, Sigma-Aldrich) previously washed with ELB+ buffer three times. After 
the incubation time, resins were resuspended in 15 μl of SDS lysis buffer and 5 μl ZAP 
solution, denatured for 10 min at 99 °C and stored at −20 °C. The bound polypeptides were 
analysed by SDS-PAGE and immunoblotting with indicated antibodies (Table 4.3). 
Target antigen Cod. Immunoglobulin 
type 
Host 
organism 
Dilution Source 
cIAP1 #ab108361 polyclonal rabbit 1:1000 Abcam 
cIAP2 #552783 polyclonal rabbit 1:1000 Cell Signaling 
XIAP #610763 monoclonal mouse 1:5000 Sigma-Aldrich 
Cleaved PARP #5625 polyclonal rabbit 1:1000 Cell Signaling 
LRIG1 #12752 polyclonal rabbit 1:1000 Cell Signaling 
SNAI2 #9585 polyclonal rabbit 1:1000 Cell Signaling 
Cleaved Caspase-
3 
#9501 polyclonal rabbit 1:1000 Cell Signaling 
NIK #4994 polyclonal rabbit 1:1000 Cell Signaling 
NF-kB2 p100/p52 #4882 polyclonal rabbit 1:1000 Cell Signaling 
NF-kB1 p105/p50 #3035 polyclonal rabbit 1:1000 Cell Signaling 
Phospho-ERK1/2 #M8159 polyclonal rabbit 1:5000 Sigma-Aldrich 
Total ERK1/2 #M5670 monoclonal mouse 1:10000 Sigma-Aldrich 
pEGFR (Tyr1068) #2236 polyclonal rabbit 1:1000 Cell Signaling 
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Total-EGFR #ab30 polyclonal rabbit 1:1000 Abcam 
c-CBL #2747 polyclonal rabbit 1:1000 Cell Signaling 
Flag-tag #F1804 monoclonal mouse 1:1000 Sigma-Aldrich 
Clathrin #4796 polyclonal rabbit 1:1000 Cell Signaling 
Myc-tag #2278 polyclonal rabbit 1:1000 Cell Signaling 
EGFR pTyr-1045 #2237 polyclonal rabbit 1:1000 Cell Signaling 
Sprouty 1 #13013 polyclonal rabbit 1:1000 Cell Signaling 
RelA/p65 #3034 polyclonal rabbit 1:1000 Cell Signaling 
c-MET #sc10 polyclonal rabbit 1:1000 Sanza Cruz 
Biotechnology 
E-Cadherin #3195 polyclonal rabbit 1:1000 Cell Signaling 
COL6A2 #HPA007029 polyclonal rabbit 1:1000 Sigma-Aldrich 
SOX9 #82630 polyclonal rabbit 1:1000 Cell Signaling 
SOX2 #3579 polyclonal rabbit 1:1000 Cell Signaling 
PLEXIN-A1 #GTX62196 polyclonal rabbit 1:1000 GeneTex 
Actin #A1978 monoclonal mouse 1:10000 Sigma-Aldrich 
Vinculin #V9131 monoclonal mouse 1:10000 Sigma-Aldrich 
Table 4.3 - List of antibodies employed in this thesis. 
4.13 Stripping of western blot membranes 
Western blot membranes were incubated with stripping buffer at 37 °C for 30 min and 
then washed for 3 times with PBS-T, followed by incubation in blocking solution and a new 
round of probing. 
4.14 Immunofluorescence 
BT549 cells were trypsinized, resuspended in 3 ml of cold RPMI with 10 % FBS and 
spotted on glass microscope slides using cytospin (Cytospin 2, Shandon). According to 
Cytospin protocol, slides and filters were placed into appropriate slots in the cytospin with 
the cardboard filters facing the center of the cytospin.  About 100-200 l of cell suspension 
were put into each of the wells and spinned at 500 rpm for 5 min. Then slides were dried 
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overnight fixed with 4 % paraformaldehyde for 10 min, permeabilized for 10 min at RT with 
0.2 % Triton X-100 and blocked in PBS, 3 % BSA, 0.1 % Tween-20. Cover slips were then 
incubated overnight at 4 °C in a humidified chamber with the primary antibody diluted in PBS 
2 % BSA overnight. After three washes in PBS, the appropriate secondary fluorescent Alexa 
Fluor conjugated antibody (Thermo Fisher Scientific), diluted in PBS 2 % BSA was added to 
the cells for 1 h and the plate was kept in the dark. After incubation, three washes with PBS 
were performed and nuclei were counterstained with DAPI (0.5 µg/ml in PBS) for 10 min. 
Then coverslips were mounted on glass microscope slides with ProLong Gold reagent 
mounting solution (Thermo Fisher Scientific). Fluorescence images were acquired using a 
fluorescence microscopy and digital image acquisition on a Nikon Eclipse E1000 equipped 
with a DSU3 CCD camera.  
4.15 In situ Proximity Ligation Assay (PLA) 
Duo Link in Situ reagents (Duolink In Situ PLA; Sigma-Aldrich) were employed in this 
thesis following the manufacturer’s guidelines. Through the cytospin, BT549 cells were 
spotted on glass microscope slides and dried before being fixed with 4 % paraformaldehyde, 
and incubated with two primary antibodies raised in different species specific for the target 
proteins (Table 4.2). Glasses were incubated with primary antibodies diluted in PBS 3 % BSA 
in a humidity chamber for 2 h at RT. Then cells were stained with the PLA probes diluted 1:5 
in PBS 1 % BSA in a humidified chamber for 1 h at 37 °C. Since a short DNA strand is attached 
to each PLA probe, when protein targets are in close proximity, an enzymatic ligation and a 
subsequent rolling circle amplification  (at 37 °C for 100 min) occur after the addition of other 
circle-forming DNA oligonucleotides. At the end of the amplification step, glasses are washed 
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with the supplied buffers, dried and mounted with cover slips using Duo Link mounting 
solution containing DAPI. Glasses were stored at -20 °C until analysis, performed with 
fluorescence microscopy Nikon Eclipse E1000. Protein interactions result easy detectable as a 
distinct bright spot (Duo Link datasheet).  
 
 
 
 
 
Table 4.4 -  List of antibodies used for PLA. 
4.16  Real-Time PCR  
4.16.1 RNA extraction 
For Real-time qPCR, total RNA was extracted from cells with the miRNeasy mini 
columns (Qiagen), following the manufacturer's instructions. Briefly, cells were harvested 
and washed once with PBS before being lysed in QIAzol and stored at -80 °C. To proceed with 
the RNA extraction, 140 µl of chloroform were added to each sample and after centrifugation 
(15 min at 13000 rpm at 4 °C), the aqueous, upper phase, was recovered in a new 
microcentrifuge tube and mix with 1.5 volumes of 100 % ethanol. Then, samples were loaded 
into RNeasy Mini columns thus allowing the RNA isolation exploiting the affinity with the 
column membrane.  For this, columns were centrifuged and washed one time with the RWT 
buffer and, then, further two times with the RPE buffer, before being transferred to a new 
clean and sterile tube and added with 30 µl of RNase-free water to elute RNA. Following RNA 
extraction, the obtained RNA was quantified using the spectrophotometer NanoDrop 2000C 
Antibody Host organism Dilution Source 
EGFR mouse 1:200 Abcam 
cIAP1 rabbit 1:150 Cell Signaling 
RAB7 rabbit 1:150 Cell Signaling 
RAB11 rabbit 1:150 Cell Signaling 
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(Thermo Fisher Scientific). After quantification, 1 μg of RNA was subjected to electrophoresis 
(with 1 % agarose gel) to control the quality of the extracted RNA. 
4.16.2 RNA reverse transcription 
Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN, USA) was used 
for the RNA reverse transcription to obtain and amplify cDNA in a single step. According to 
the manufacturer’s instructions, a mix containing 1 µg RNA and 60 μM random examers was 
prepared and denatured at 65 °C for 10 min. After denaturation, a mix consisting in reaction 
buffer (containing 8 mM MgCl2), protector RNase inhibitor (20 U), dNTPs mix (1 mM each) 
and Transcriptor Reverse Transcriptase (10 U) was prepared and added to each sample to 
reach 20 µl final volume. 
The PCR program used was: 
25 °C   10 min    
50 °C   50 min 
85 °C   5 min 
Based on the RNA used and the volume of the reaction, the PCR products (cDNA) had a 
concentration of 50 ng/μl. cDNA was then stored at -20 °C until Real-Time PCR analysis. 
4.16.3 Quantitative Real-Time PCR  
The quantification of target gene mRNA was performed using Taqman standard curve 
method, which specifically amplified sequences encoding the gene of interest. Probes 
employed for this assay (Applied Biosystems- Thermo Fisher Scientific) had FAM as 
fluorescent dye in the 5’ position and were conjugated to the quencher TAMRA at the 3’. 
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During the Real-Time PCR, gene targets are identified by specific probes and therefore 
amplified. The intensity of light released by the probe during this reaction is measured in real 
time and reflects the expression levels of the gene in the analysed sample. For each reaction 
the total volume was 20 µL of a mix containing 10 µl of TaqMan Universal PCR Mastermix 
(Applied Biosystems #4304437), 1 µl of probe (dual labelled), 4 µl of RNase-free water and 
5µl of cDNA which is replaced with 5 µl of RNase-free water as a negative control (NTC). All 
standards, samples and negative controls were assayed in triplicate to ensure accurate 
results. PCR reaction was performed in 96-well plates (MicroAmp Fast Optical 96-Well 
Reaction Plate with Barcode, Applied Biosystems) covered with optical adhesive covers. The 
instrument used was ViiA™ 7 Real-Time PCR System (Applied Biosystems). 
Real time PCR was performed with FAST running method: 
Hold stage 
Step 1: 95 °C 20 sec 
PCR stage (40 cycles) 
Step 1: 95 °C 1 sec 
Step 2: 60 °C 20 sec 
Melting curve stage 
Step 1: 95 °C 15 sec 
Step 2: 60 °C 60 sec 
Step 3: 95 °C 15 sec (dissociation) 
The threshold cycle (Ct Value) is the intensity of fluorescence considered statistically 
significant above the baseline values. Relative expression levels were calculated using the 
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comparative Ct method and calibrated relative to the reference gene. The probes listed in 
Table 4.5 were used for Real-Time PCR: 
 
 
 
 
 
 
 
Table 4.5 - List of Taqman probes used for Real-Time PCR. 
4.17 Statistical and image analysis 
Graph and statistical analyses were performed using GraphPad Prism 5.02. For analysis of 
in vivo data two-tailed unpaired Student’s t-test was applied. Real-Time PCR data were 
analysed using two-tailed paired Student’s t-test with the date of the experiment as pairing 
factor. A p-value < 0.05 was considered statistically significant. Western blot densitometric 
analysis was performed with ImageQuant 5.2. GEP analysis was performed as previously 
described (Paragraph 4.6).  
Taqman probe Assay ID Source 
SNAI2  Hs00161904_m1 Applied Biosystems 
NIK Hs.PT.58.3867615 IDT 
LRIG1 Hs01006152_m1 Applied Biosystems 
EGFR Hs01076090_m1 Applied Biosystems 
ZEB1 Hs.PT.58.3948500 IDT 
TWIST1 Hs.PT.58.18940950 IDT 
E-Cadherin Hs.PT.58.3324071 IDT 
Vimentin Hs.PT.58.38906895 IDT 
MMP9 Hs.PT.58.22814824.g IDT 
GAPDH Hs02786624_g1 Applied Biosystems 
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5 RESULTS 
5.1 SM83-mediated cIAP1 depletion reduces the metastatic potential of 
TNBCs 
5.1.1  In vivo activity of SM83 on tumour growth 
The overall effect of IAP-depletion on cancer growth was investigated employing 
NOD/SCID mice subcutaneously engrafted with the TNBC cell line MDA-MB231. As shown in 
the experimental design (Figure 5.1A), when primary tumours became evident (13 days after 
the inoculum), animals were treated with intraperitoneal (ip) injections of SM83 (5 mg/Kg) 
until the end of the experiment (30 days). Notably, MDA-MB231 subcutaneous tumour 
volumes were reduced more than 50 % (Figure 5.1B) in SM83 treated mice compared to 
untreated mice, indicating an effective anti-tumour effect of SM83 administration. 
 
Figure 5. 1 - SM83 inhibits the primary tumour growth of human breast cancers in xenograft models. (A) 
Experimental design. (B) NOD/SCID mice engrafted subcutaneously with 5x10
6
 MDA-MB231 cells were ip 
injected with SM83 (5 mg/Kg, 5 times/week for 3 weeks) or left untreated (4 mice/group) until the end of the 
experiment. (Significant differences in days 24, 27 and 30. P = 0.0476, 0.0391 and 0.0344, respectively. 
Unpaired two-tailed t test). 
 86 
 
Aiming to evaluate the levels of SM83 targets, MDA-MB231 nodules were collected 6 
h after the last SM83 injection and protein lysates were tested by western blot. As expected, 
SM83 administration triggers the self-ubiquitination and proteasomal degradation of cIAP1 
and cIAP2, resulting in a strong reduction of cIAP1 and cIAP2 protein levels (Figure 5.2A). The 
treatment also affected XIAP levels and this effect is likely to be a consequence of cIAP1 
down-regulation rather than being a direct effect of SM83 treatment. In fact, the silencing of 
cIAP1 was sufficient to induce XIAP down-regulation in MDA-MB231 cells (Figure 5.2B). 
Western blots failed to detect any sign of activated apoptosis (Figure 5.2C). 
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Figure 5.2 - cIAP1, cIAP2 and XIAP are reduced by SM83 treatment. (A) MDA-MB231 nodules were collected 6 
h after the last injection and analysed by western blot. (B) MDA-MB231 cells were transfected in vitro with two 
siRNAs specific for cIAP1 and treated with 100 nM SM83 for 1 h. A reduction of cIAP1, cIAP2 and XIAP levels was 
assessed by western blot performed 72 h after transfection. Values show the fold levels of XIAP. (C) No sign of 
apoptosis (cleaved PARP) was detectable in MDA-MB231 primary tumours. Actin or Vinculin are shown as 
loading controls. 
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5.2 SM83 treatment reduces spontaneous lung metastasis in NOD/SCID 
mice xenografted with MDA-MB231 cells 
Since it has been shown that IAP can play a role in migration and invasion (Fulda, 
2014c), I hypothesised that SM83 could affect the metastatic process. In order to answer this 
question, NOD/SCID mice subcutaneously engrafted with MDA-MB231 cells were treated for 
three weeks with SM83 and then lungs were collected after further two weeks (Figure 5.3A). 
To investigate the SM83 effect on tumours and metastatic sites, at the end of the 
experiment, primary tumours, lymph nodes and lungs were collected and either lysed for 
RNA extraction and biochemical analysis, or paraffin-embedded for IHC. First, a delay of 
primary tumour growth was assessed after SM83 injection (Figure 5.3B), in accordance to my 
previous observation (Figure 5.1B). The inhibitory effect of SM83 on the growth of primary 
tumours was confirmed also employing intravenous (iv) injections. As shown in Figure 5.3B, 
the administration route (ip vs iv) did not influence drug efficacy and, moreover, the primary 
tumours of treated mice started growing as well as the untreated ones after the interruption 
of the injections. Importantly, a significant reduction in the number and size of lung 
metastasis was found in SM83 treated mice bearing MDA-MB231 tumours, which are known 
to spontaneously metastasize to lungs in NOD/SCID mice (Minn et al., 2005; Figure 5.3A-B). 
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Figure 5.3 - Treatment with SM83 affects metastasis formation in NOD/SCID mice engrafted with the highly 
metastatic MDA-MB231 cell line. (A) Experimental design. (B) NOD/SCID mice were engrafted subcutaneously 
with MDA-MB231 cells and, after two weeks, were treated for 3 weeks with ip and iv injections of SM83 (5 
mg/Kg, 5 times/week) in two independent experiments. Mice were killed 2 weeks after the last injection. Graph 
shows tumour volumes. (C) Number (untreated n = 7, SM83-treated mice n = 8; sum of two independent 
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experiments shown in Figure 5.1B and 5.3B; P = 0.0238. Unpaired two-tailed t test) and (D) size (35 
metastases/group; P = 0.0107. Unpaired two-tailed t test) of spontaneous MDA-MB231 lung metastases. 
Notably, the anti-metastatic effect was evident independently from the 
administration routes, i.e. iv and ip injections. Detection of micro- and macro-metastasis was 
allowed by the high expression of human Vimentin of MDA-MB231 (Figures 5.4A-C).  
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Figure 5.4 - SM83 treatment displays anti-metastasis activity independently from the administration route. 
(A) Lungs of NOD/SCID mice bearing MDA-MB231 tumours were collected 2 weeks after the last injection with 
SM83, formalin-fixed and paraffin-embedded. IHC of lungs with anti-human Vimentin antibody. (B) The graph 
 92 
 
shows the number of lung metastases (Untreated vs ip P = 0.0238, Untreated vs iv P = 0.0190, ip vs iv not 
significant; Unpaired two-tailed t test), whereas the table shows the metastasis-free MDA-MB231-bearing mice. 
(C) SM83 injections (5 mg/Kg, 5 times/week) were performed ip and iv in two independent experiments. Lungs 
were collected from NOD/SCID mice xenografted with MDA-MB231 cells and metastasis were detected through 
anti-Vimentin staining in IHC. 
5.3 SM83 treatment perturbs gene expression of MDA-MB231 tumours 
Having found a significant reduction of MDA-MB231 spontaneous lung metastasis in 
mice treated with SM83, I hypothesised that IAP targeting could perturb the expression of 
genes responsible for the metastatic process. To test this hypothesis, MDA-MB231 nodules 
were collected 6 h after the last SM83 injection and profiled for gene expression (Figure 5.5). 
Interestingly, 65 genes were significantly modulated by SM83 treatment and, among them, 
50 genes resulted up-regulated and 15 down-regulated, as compared to tumours collected 
from untreated mice. IAPs are known to be apical modulators of several receptor complexes 
and eventually control MAPK and NF-kB signalling pathways. Accordingly, the expression of a 
number of genes involved in the NF-kB signalling pathway (e.g. baculoviral IAP repeat 
containing 3/BIRC3, matrix metallopeptidase-9/MMP9, intercellular adhesion molecule 
1/ICAM1) or NF-kB targets (e.g. TRAF1, TRAF2, NFKBIA, NFKB2, RelB) were indeed altered. 
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Untreated SM83 
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Figure 5.5 - SM83 administration perturbs the gene expression of MDA-MB231 primary tumours. MDA-
MB231 primary tumours were subjected to microarray analysis. Heat map shows the expression levels of the 65 
genes significantly modulated by SM83 injection compared to the control (expression values are in log2 scale. 
Red indicates higher expression; green lower expression). 
In order to select the genes whose down-regulation could be responsible for the 
SM83-mediated anti-metastatic effect, each down-regulated gene was individually knocked-
down in MDA-MB231 cells and wound healing assay was performed (Figure 5.6A). 
Importantly, I found that the depletion of SNAI2 was the most effective in reducing the 
capability of cells to migrate (Figure 5.6B), whereas the viability was only slightly affected 
(Figure 5.6C).  
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Figure 5.6 - Loss of SNAI2 reduces MDA-MB231 cell motility. (A) The 15 genes down-regulated in subcutaneous 
MDA-MB231 nodules upon treatment with SM83 were individually silenced in MDA-MB231 cells. To assess cell 
motility, 4x10
4
 cells were seeded in Ibidi chambers and cultured overnight to perform wound-healing 
experiments. After the removal of the insert, images were acquired every hour in a Cell-IQ instrument and 
analysed with the integrated software. Graphs represent the percentage of gap closure after 24 h of migration 
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and show the average of at least four independent experiments. (B) The graph shows the same experiment 
illustrated in Figure 5.6A, but focused on the effect of SNAI2 depletion. The percentage of gap closure was 
calculated after 24 h of migration for MDA-MB231 cells transfected with control (NT1) or SNAI2-specific siRNAs. 
(n = 4, P = 0.0033, Unpaired two-tailed t test). (C) MDA-MB231 cells transfected in the same way were also 
seeded in 96-well plates and viability assessed by CellTiter-Glo assay, 5 days after transfection.  
Since GEP analysis revealed that SM83 administration down-regulates SNAI2, its 
protein level was detected in primary tumours collected from mice treated with SM83 or left 
untreated (Figure 5.7A). Western blot analysis confirmed the strong reduction of SNAI2 
protein in primary tumours treated by SM83. Of note, LRIG1, an ubiquitin-ligase which is 
known to be induced by SM administration and that I found up-regulated in GEP, showed an 
opposite regulation by SM83 compared to SNAI2 (Figures 5.7A-B). 
 
Figure 5.7 - SM83 treatment down-regulates SNAI2 and up-regulates LRIG1 levels in vivo. (A) The levels of 
SNAI2, down-regulated in GEP (Figure 5.5), and the up-regulation of LRIG1, were assessed by western blot 
performed on MDA-MB231 nodules. (B) The graph shows the fold levels of SNAI2 and LRIG1 measured by 
densitometric analysis of western blot and normalized to Actin levels. LRIG1: Untreated vs SM83 P = 0.046; 
SNAI2: Untreated vs SM83 P = 0.0143; Unpaired two-tailed t test. 
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5.4  cIAP1, but neither cIAP2 nor XIAP, controls  SNAI2 expression 
As SM83 targets different IAPs, I studied which one was responsible for SNAI2 down-
regulation. To this end, I silenced cIAP1, cIAP2 and XIAP through siRNAs and I found that 
cIAP1, and not cIAP2 or XIAP depletion, was sufficient to reduce SNAI2 levels both in MDA-
MB231 and BT549 cell lines (Figure 5.8A). Then, to further address these results, two 
different siRNAs targeting cIAP1 were employed in a panel of TNBC cell lines (MDA-MB231, 
BT549, MDA-MB157 and SUM159) showing a widely valid regulation of SNAI2 mediated by 
this IAP (Figure 5.8B). Taken together these results show that cIAP1 is responsible for 
sustaining the expression of the pro-metastastatic gene SNAI2. 
 98 
 
 
Figure 5.8 - cIAP1 is the sole SM target responsible for supporting SNAI2 expression. (A) SNAI2 levels were 
detected by western blot in MDA-MB231 cells transfected with siRNAs targeting cIAP1, cIAP2 or XIAP, and in 
BT549 cells silenced for cIAP1 or XIAP. After 72 h, cells were treated for further 6 h with 100 nM SM83. (B) 
SNAI2 protein levels were detected in MDA-MB231, BT549, MDA-MB157 and SUM159 cells knocked-down for 
cIAP1 using two different siRNAs.  
Since SM83 killed a small percentage of cancer cells when administered in 
monotherapy, I checked if SNAI2 down-regulation was a consequence of SM83-related 
toxicity. Therefore, viability test was performed treating the same panel of TNBC cell lines 
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described above (Figure 5.8B) with 200 nM SM83, thus finding that MDA-MB231 and BT549 
cells were sensitive to the treatment (Figure 5.9A). Nonetheless, SNAI2 down-regulation 
occurred even when cells were treated with half of the SM83 dose and also after pre-
treatment with inhibitors of apoptosis (z-VAD) and necroptosis (Nec-1; Figures 5.9B-C). 
Accordingly, I concluded that SNAI2 reduction is dependent on cIAP1 targeting and is not a 
side effect of SM83 toxicity. 
 
Figure 5.9 - SNAI2 down-regulation is not a side effect of SM83 toxicity. (A) Cell viability was tested by 
CellTiter-Glo in the same cell lines employed in Figure 5.8B. Cells were treated with 200 nM SM83 and viability 
was assessed 24 h later. (B) MDA-MB231 cells were treated with half of the dose of SM83 (100 nM) employed 
in Figure 5.9A and, pre-treated or not for 1 h with caspase inhibitor z-VAD or RIP1 inhibitor Nec-1 (left panel). 
The treatment with z-VAD was performed also in BT549 cells (right panel). Western blot was performed to 
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detect the total levels of SNAI2 and cIAP1, and the cleaved form of Caspase-3. Values show the fold levels of 
SNAI2 relative to untreated cells. 
5.5 SM83 dependent activation of the non-canonical NF-kB pathway 
correlates with SNAI2 down-regulation 
These findings suggest that SM83 anti-metastasis effect could occur via the down-
regulation of SNAI2. However, specific effectors directly involved in the cIAP1/SNAI2 axis 
have not been identified yet. Notoriously, cIAPs are components of several receptor 
complexes as the TNF-R superfamily, and allow the subsequent activation of TNF-R down-
stream pathways. Therefore, I investigated the underlying mechanisms through which cIAPs, 
particularly cIAP1, could promote SNAI2 expression focusing on the TNF-dependent 
activation of NF-kB and MAPK signalling pathways.  
5.5.1 TNF-R2, but not TNF-R1, is responsible for SNAI2 expression  
To assess if the activity of TNF-Rs promotes SNAI2 expression, the endogenous ligand 
TNF and its receptors, TNF-R1 and 2, were knocked-down through specific siRNAs in MDA-
MB231 and BT549 cell lines. Western blot analysis revealed that in both cell lines a strong 
down-regulation of SNAI2 occurred after TNF and TNF-R2 depletion, while TNF-R1 seems to 
play only a marginal role in SNAI2 expression (Figure 5.10).  
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Figure 5.10 - Depletion of TNF-R2 affects SNAI2 expression. MDA-MB231 and BT549 cells were transfected 
with siRNAs targeting TNF, TNF-R1 and TNF-R2. Cells were harvested 72 h after transfection and western blot 
was performed to detect SNAI2 levels. Actin is shown as a loading control. 
Consequently, to investigate the mechanisms through which cIAP1 promotes SNAI2 
expression, I examined the role of the non-canonical NF-kB pathway whose activation is 
thought to be triggered by SM-mediated IAP depletion (Gyrd-Hansen and Meier, 2010). 
Therefore, MDA-MB231 cells were treated with SM83 for 6 h after being knocked-down for 
different NF-kB-related effectors (Figure 5.11A). In accordance to my previous findings, 
SNAI2 levels were reduced by the treatment, while protein stability was increased by NIK and 
NF-kB2 depletion upon SM83 treatment, thereby suggesting the non-canonical NF-kB 
pathway as a possible suppressor of SNAI2. To detail the role of cIAP1 in the regulation of the 
non-canonical NF-kB pathway, Real-Time PCR was performed in two different TNBC cell lines, 
MDA-MB231 and BT549. In both cases, cIAP1 depletion enhanced NIK mRNA, indicating that 
this IAP not only reduces the protein stability mediating ubiquitination of NIK (Zarnegar et al., 
2008), but also inhibits its expression (Figure 5.11B), thus preventing the activation of the 
non-canonical NF-kB pathway.  
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Figure 5.11 - cIAP1 depletion induces NIK and consequently non-canonical NF-kB pathway. (A) Several 
mediators and regulators of the NF-kB pathway were knocked-down using specific siRNAs in MDA-MB231 cells. 
After 72 h, cells were treated with 100 nM SM83 for 6 h and harvested. Western blot shows that the depletion 
of NIK and NF-kB2 prevented the non-canonical NF-kB activation and blocked SM83-mediated SNAI2 down-
regulation. Vinculin is shown as a loading control. (B) Real-Time PCR was performed in MDA-MB231 and BT549 
cells transiently silenced for cIAP1. NIK mRNA was evaluated as fold expression change relative to GAPDH, in 
cells depleted for cIAP1 compared to controls. MDA-MB231 P = 0.0464; n = 4 siCtr vs sicIAP1; Paired two-tailed t 
test. BT549: P = 0.0487; n = 4 siCtr vs sicIAP1; Paired two-tailed t test.   
Indeed, time-course experiments performed in MDA-MB231 cells treated with SM83 
at different time-points confirmed the negative correlation between SNAI2 expression and 
NF-kB2 activation (Figure 5.12A). This result was also observed in TNBC primary tumours 
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from The Cancer Genome Atlas (TCGA; Figure 5.12B). MDA-MB231 cells were also stimulated 
by TWEAK, a ligand of the TNF family, which preferentially activates the non-canonical NF-kB 
pathway. As shown in Figure 5.12C, the activation of the non-canonical NF-kB pathway 
seems to be followed by SNAI2 down-regulation, leading me to hypothesise a possible 
inhibition of SNAI2 mediated by this pathway.  
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Figure 5.12 - SNAI2 down-regulation correlates with the activation of the non-canonical NF-kB pathway.  (A) 
Time-course experiments performed in MDA-MB231 cells showing the reduction of SNAI2 after 100 nM SM83 
administration, along with the activation of the non-canonical NF-kB. Actin is shown as a loading control. (B) NF-
kB2, which recapitulates the activation of non-canonical NF-kB pathway, negatively correlates with SNAI2 
expression levels in TNBC patients from TCGA dataset (Pearson’s correlation: -0.24; p-value: 9.6e-03). 
Expression values are expressed as log2 counts per million transcripts. (C) Time-course experiment was 
performed in MDA-MB231 cell line treated with 200 ng/ml TWEAK, a specific ligand for the non-canonical NF-kB 
pathway activation.  
However, the silencing of NF-kB2 (Figures 5.11A-5.13) by itself did not result in the 
expected increase of SNAI2, leading me to investigate the involvement of other pathways in 
SNAI2 regulation. Hence, I focused on the role of MAPKs to establish if cIAP1 supports SNAI2 
expression mediating the regulation of these signalling pathways. 
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Figure 5.13 - The targeting of NF-kB2 does not increase SNAI2 levels. Western blot was performed to detect 
SNAI2 levels in BT549 cells transfected with siRNAs targeting TNF-R2 and NF-kB2. Actin is shown as a loading 
control. 
5.6 Loss of cIAP1 prevents SNAI2 accumulation through the inhibition of 
MEK signalling pathways 
To identify which down-stream pathway is responsible for cIAP1-dependent 
expression of SNAI2, MDA-MB231, BT549 and MDA-MB157 cell lines were pre-treated for 2 h 
with LY294002, Triciribine, UO126 and SB203580, which target PI3K, AKT, MEK and p38 
respectively. As shown in Figure 5.14A, the MEK inhibitor UO126 strongly reduced SNAI2 
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expression in all cell lines, and the same effect was obtained through the silencing of ERK1 
and 2 (Figure 5.14B), thus confirming that MAPK effectors ERK1/2 regulate SNAI2. The Figure 
5.14C shows that SM83 treatment decreased SNAI2 levels and also affected ERK 
phosphorylation. However, ERK activation did not appear to be dependent on TNF 
stimulation at these time-points. 
 
Figure 5.14 - SNAI2 expression is promoted by MAPK signalling pathway. (A) MDA-MB231, BT549 and MDA-
MB157 cells were treated for 2 h with 10 μM inhibitor of PI3K (LY294002), AKT (Triciribine), MEK (UO126) and 
p38 (SB203580). SNAI2 levels were detected by western blot. (B) MDA-MB231 were transfected with siRNAs 
targeting cIAP1, ERK1 and ERK2 for 72 h. Western blot shows SNAI2 levels. cIAP1 and ERK1/2 are shown as 
transfection controls.  (C) Time-course experiments were performed in MDA-MB231 cells pre-treated with 100 
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nM SM83 for 1 h and then stimulated with 50 ng/ml TNF, for different time-points. SNAI2 levels were detected 
together with pERK1/2. Actin is used as a loading control. 
Moreover, when MDA-MB231 cells were stimulated with TNF 50 ng/ml for 15 min 
and 4 h (Figures 5.15A-B), SNAI2 levels did not change. Overall, these data suggest that, in 
this setting, TNF did not exert any significant effect on SNAI2 expression, which appeared to 
be induced by ERK activation. Therefore, I speculated that other exogenous stimuli could be 
involved.
 
Figure 5.15 - ERK-mediated induction of SNAI2 is not dependent on TNF stimulation. (A) MDA-MB231 cells 
were transfected with siRNA targeting cIAP1 and, after 72 h, were treated with 50 ng/ml TNF, for 15 min and 4 
h, and harvested. Western blot was performed to evaluate SNAI2 levels. (B) The MDA-MB231 cell line was 
silenced for cIAP1 and, 72 h after transfection, cells were pre-treated for 2 h with 10 μM inhibitor of MEK 
(UO126) and, then, stimulated with 50 ng/ml TNF for 4 h. Western blot shows the effect of ERK inhibition 
and/or TNF stimulation on SNAI2.  Actin is shown as a loading control. 
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5.7 Targeting of cIAP1 affects the EGFR down-stream pathways thus 
inhibiting SNAI2 expression 
5.7.1 SNAI2 expression is induced in response to EGFR activation 
According to several studies showing that SNAI2 is expressed in an EGF-dependent 
manner (Lee et al., 2008; Kusewitt et al., 2009), I observed a correlation between EGFR and 
SNAI2 expression in breast cancer patients from TCGA (Figure 5.16A). Moreover, in a gene 
expression dataset of breast cancer cell lines (Heiser et al., 2012), I noticed a significant up-
regulation of SNAI2 and EGFR in TNBC cells compared to Luminal ones (Figure 5.16B). Based 
on these observations, SNAI2 levels were detected by western blotting in a panel of breast 
cancer cell lines and the highest expression of this pro-metastatic factor was found in TNBC 
cell lines:  MDA-MB231, MDA-MB157, SUM159, BT549 and HCC1937 (Figure 5.16C). Finally, 
wound-healing assay showed that the TNBC cells MDA-MB231, BT549 and HCC1937 migrated 
faster than the Luminal T47D (Figure 5.16D), thus suggesting that high levels of SNAI2 
promotes cell motility and tumour aggressiveness.  
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Figure 5.16 - SNAI2 expression correlates with EGFR levels. (A) Scatter plot showing the relationship between 
SNAI2 and EGFR expression in breast cancer primary tumours from TCGA dataset. A significant correlation was 
observed (Pearson’s correlation coefficient= 0.47, p-value= 1.1e-59). Expression values are expressed as log2 
counts per million transcripts. (B) Box plots showing a higher expression of SNAI2 and EGFR in TNBC versus 
Luminal cell lines from publicly available gene expression data.  (C) A panel of breast cancer cell lines was tested 
to compare the levels of SNAI2. TNBC: MDA-MB231, MDA-MB157, SUM159, BT549, HCC1937, SUM149; 
Luminal: T47D, MDA-MB361, BT474, SkBr3, MDA-MB453. These cell lines were classified in accordance to Neve 
et al. classification (Neve et al., 2006). (D) Motility of different cell lines expressing diverse levels of SNAI2 was 
tested in wound-healing experiments by seeding 4x10
4
 cells in Ibidi chambers. Images were acquired every hour 
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in a Cell-IQ instrument and analysed with the integrated software. The graph shows the percentage of gap 
closure after 12 h of migration and represents the average of at least four independent experiments. MDA-
MB231 vs T47D P<0.0001; BT549 vs T47D P=0.0005; HCC1937 vs T47D P=0.0003; Unpaired two-tailed t test. 
Then, BT549 cells were stimulated with two specific ligands of EGFR (EGF and TGFα) 
and, as expected, a significant increase of SNAI2 level was observed, in particular after 2-3 h 
(Figure 5.17A). Furthermore, SNAI2 accumulation was detected in non-malignant epithelial 
cell lines, MCF10A and HME, upon EGFR stimulation or in the presence of a constitutive 
activated mutant of EGFR (Figure 5.17B), supporting the EGFR-dependent expression of 
SNAI2. As shown in Figure 5.17C, TGFα exposure increased ERK phosphorylation, suggesting 
that ERK activation occurred in response to EGFR stimulation. 
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Figure 5.17 - EGFR activation promotes SNAI2 expression. (A) For time-course experiments, BT549 cells were 
serum-starved overnight and then stimulated with 20 ng/ml EGF and TGFα. SNAI2 levels are shown together 
with total and activated levels of EGFR. (B) In human mammary epithelial cell lines, both parental and mutated 
for EGFR, SNAI2 levels were assessed by western blot. After overnight serum starvation, cells were stimulated 
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with 20 ng/ml EGF for the indicated times. (C) Time-course experiments show SNAI2 levels upon TGFα 
stimulation. SNAI2 up-regulation is shown together with the total and activated amount of EGFR and, activated 
ERK. Vinculin is shown as a loading control.  
Moreover, to further test that SNAI2 up-regulation resulted from EGFR activation, 
cells were treated with cetuximab, a monoclonal antibody that targets the EGFR extracellular 
domain thus impeding the binding with its ligand and consequently preventing EGFR 
activation. Given that EGFR signalling involves a plethora of effectors among which MAPKs, I 
focused on ERK pathway since my data supported its crucial role in SNAI2 regulation (Figures 
5.14A-B). Western blot analysis revealed that EGFR inhibition mediated by cetuximab 
abolished SNAI2 accumulation by preventing the activation of ERK signalling pathway 
(Figures 5.18 A-B) both in MDA-MB231 and BT549 cell lines.  
 
Figure 5.18 - EGFR inhibition prevents SNAI2 up-regulation. (A) MDA-MB231 and (B) BT549 cells were pre-
treated with 100 μg/ml cetuximab for 1 h, after being serum-starved for 24 h. Next, cells were stimulated with 
20 ng/ml EGF for the indicated time-points and SNAI2 levels were detected by western blot, together with total 
and phosphorylated ERK1/2 and EGFR. Values show the fold levels of SNAI2 relative to untreated cells.  
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5.7.2 cIAP1 sustains the EGFR-mediated expression of SNAI2 
At this step, I asked whether the loss of cIAP1 affects the EGFR-mediated regulation 
of ERK signalling pathway. Therefore, MDA-MB231 and BT549 cells were silenced for cIAP1 
and western blot analysis was performed after EGF exposure. Notably, a strong reduction of 
ERK activation could be detectable also at basal conditions in both cell lines (Figures 5.19A-
B), and, interestingly, the up-regulation of SNAI2 was impaired even after EGF and TGFα 
stimulation, in the absence of cIAP1 (Figure 5.19C). Moreover, SNAI2 induction was also 
abolished in normal mammary epithelial cells either wt or bearing mutated EGFR (Figure 
5.19D), supporting the idea that cIAP1 enhances the EGFR-dependent expression of SNAI2 by 
favouring the activation of ERK signalling pathway. 
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Figure 5.19 - The targeting of cIAP1 hinders EGFR-mediated expression of SNAI2. (A) MDA-MB231 and (B) 
BT549 cells were knocked-down for cIAP1 through specific siRNAs and, 48 h after transfection, starved 
overnight. SNAI2 levels were detected by western blot in unstimulated cells or stimulated with 20 ng/ml EGF for 
the indicated time-points. Detection of ERK1/2 and cIAP1 levels confirms the transfection efficiency. (C) 
Western blot analysis was performed to evaluate SNAI2 expression in BT549 and (D) MCF10A - wt or bearing 
 115 
 
mutated EGFR. Cells were transfected as in Figure 5.19A and stimulated with the indicated EGFR ligands (20 
ng/ml). 
5.7.3 cIAP1 regulates SNAI2 at transcription level 
Since cells silenced for cIAP1 showed lower levels of SNAI2 compared to control cells, 
I investigated whether the absence of cIAP1 causes a decrease of SNAI2 protein stability. To 
this aim, SNAI2 protein half-life was evaluated in MDA-MB231 cells treated with 
cycloheximide, an inhibitor of protein synthesis (Figure 5.20A). Although SNAI2 was less 
expressed in cells knocked-down for cIAP1 (sicIAP1), the protein was found to be more stable 
in these cells compared to the control (siCtr). Therefore, I evaluated if a transcriptional 
regulation of SNAI2 is mediated by cIAP1. Real-Time PCR was performed in BT549 and 
MCF10A cells, and SNAI2 expression level was evaluated in cIAP1-depleted cells compared to 
control (Figure 5.20B). Interestingly, the analysis revealed that cIAP1-targeting by specific 
siRNAs or IAP inhibitors (Figure 5.20B and 5.5, respectively) both resulted in the reduction of 
SNAI2 levels. Indeed, cIAP1 depletion not only affected SNAI2 expression at basal levels, but 
also impaired its up-regulation upon EGFR-stimulation. Hence, these results indicate that 
cIAP1 promotes SNAI2 expression, resulting in a decrease of its protein levels in the absence 
of cIAP1 (Figure 5.20C). 
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Figure 5.20 - cIAP1 regulates SNAI2 mRNA levels. (A) MDA-MB231 cells were treated with 100 μg/ml 
cycloheximide in the presence or absence of cIAP1 and harvested at the indicated time points. Western blot 
was performed to assess SNAI2 levels. cIAP1 was detected as a control of silencing efficacy, while Actin as a 
loading control. (B) BT549 and MCF10A cells were silenced for cIAP1 as described before. After serum 
starvation, cells were stimulated for 3 h with 20 ng/ml EGF and lysed to extract RNA. Real-Time PCR was 
performed to evaluate SNAI2 fold expression relative to GAPDH. BT549: Unstimulated siCtr vs sicIAP1 P = 
0.0137, EGF 3 h siCtr vs sicIAP1 P = 0.0558; n = 3; Paired two-tailed t test. MCF10A: Unstimulated siCtr vs sicIAP1 
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P = 0.0784, EGF 3 h siCtr vs sicIAP1 P = 0.0742; n = 4; Paired two-tailed t test. (C) SNAI2 levels were assessed by 
western blot together with EGFR total and activated levels, in BT549 and MCF10A cell lines. After 48 h from 
transfection with control siRNA (siCtr) or siRNAs specific for cIAP1 (sicIAP1), cells were serum-starved overnight 
and then stimulated with 20 ng/ml EGF for the indicated time-points. 
Having demonstrated that cIAP1 supports the expression of this pro-metastasis gene, 
I speculated that the loss of this IAP might be responsible for the SM83 anti-metastasis effect 
(Figures 5.3-4). Herein, in vitro motility assay was performed to test the possible cell motility 
variation that might occur in the absence of cIAP1 in BT549 and in MCF10A cells, wt and 
carrying EGFR mutation (Figure 5.21).  
 
Figure 5.21 - Depletion of cIAP1 reduces cell motility. Wound healing assay was performed as described in 
Figure 5.6B. Motility assay was carried out using scramble-shRNA and cIAP1-shRNA transduced BT549, MCF10A 
and MCF10A bearing mutated EGFR cells. Graphs show the percentages of gap closure after 12 h of migration. 
shCtr vs shcIAP1 BT549: P= 0.0043, n=12, Paired two-tailed t test; shCtr vs shcIAP1 MCF10A: P= 0.0102, MCF10A 
EGFR: P= 0.0029, n= 4, Paired two-tailed t test. 
Based on the reduction of in vitro cell motility (Figure 5.21) and in vivo metastasis 
formation (Figures 5.3-4) mediated by IAP-depletion, the effect of SM83 administration was 
assessed also by using a syngenic mouse model injecting the highly metastatic 4T1 murine 
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cells in BALB/c mice (Figure 5.22). In contrast with what I expected, SM83 administration 
does not affect the metastatic potential of this cell line. This result can be explained by the 
fact that 4T1 cells express low levels of SNAI2 (Ferrari-Amorotti et al., 2013) and therefore 
they metastasize in a SNAI2-independent manner. Consequently, SM83-mediated down-
regulation of SNAI2 cannot impact on 4T1 metastatic potential. 
  
 
Figure 5.22 - SM administration does not affect 4T1 metastatic potential. 4T1 murine cells were inoculated in 
syngeneic BALB/c mice that were treated with vehicle or SM83. Graph shows the number of metastatic 
colonies. 
5.8 cIAP1 modulates not only EGFR signalling, but also its protein levels 
5.8.1 EGFR levels are affected by cIAP1 depletion  
 The strong inhibition of ERK1/2 signalling pathway that occurred after targeting 
cIAP1, led me to investigate whether this IAP only promotes EGFR signalling or also regulates 
the receptor levels. Intriguingly, I noticed that cIAP1 depletion resulted in a marked reduction 
of EGFR levels in both cancer and normal mammary epithelial cell lines (Figures 5.20C and 
5.23A-B), that further decreased upon EGFR stimulation. Indeed, immunofluorescence 
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analysis highlighted that the loss of cIAP1 strongly abrogated the number of EGFR foci 
induced by stimulation with its ligand, suggesting an impaired capability to transduce the 
receptor signals (Figure 5.23C). Having shown that cIAP1 depletion results in the reduction of 
EGFR protein levels, I investigated whether this is due to a direct effect of cIAP1 on receptor 
stability or if it is caused indirectly through the regulation of the EGFR inhibitors LRIG1 and/or 
c-CBL (Fry et al., 2009).  
 
Figure 5.23 - cIAP1 depletion decreases EGFR levels. (A) BT549 and (B) MCF10A cells knocked-down for cIAP1 
were stimulated with 20 ng/ml EGF under serum-starved (basal) conditions, and EGFR, cIAP1 and SNAI2 levels 
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were analyzed by western blot. (C) BT549 cells were transfected with control or cIAP1-specific siRNAs before 
being overnight serum-starved and stimulated for 30 min with 20 ng/ml EGF. Cells were fixed and incubated 
with anti-EGFR antibody and nuclei stained with DAPI. Images were obtained with a 60x magnification. 
5.8.2 cIAP1 targeting destabilizes endogenous EGFR in an LRIG1-independent 
manner 
It has been shown that LRIG1 up-regulation represents an acquired mechanism for 
SM resistance (Bai et al., 2012). GEP and western blot analyses confirmed that LRIG1 up-
regulation occurred at transcriptional and protein level (Figures 5.5 and 5.7A-B, respectively) 
in MDA-MB231 subcutaneous tumours treated with SM83. To determine whether LRIG1 
increase is a result of cIAP1 depletion, I targeted this IAP through siRNAs and, then, I 
performed Real-Time PCR and western blot analyses to examine LRIG1 mRNA and protein 
level, respectively. Although LRIG1 resulted up-regulated both at transcriptional and protein 
level in the absence of cIAP1 (Figures 5.24A-B), surprisingly, LRIG1 knock-down did not 
significantly increase EGFR (Figure 5.24C). Furthermore, in sharp contrast with the strong 
reduction of the receptor levels (Figures 5.20C and 5.23B), the up-regulation of LRIG1 was 
not evident in MCF10A cells lacking cIAP1 (Figure 5.24D). The latter evidence strongly 
supports the idea that the observed reduction of EGFR does not stem from LRIG1 up-
regulation. 
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Figure 5.24 - LRIG1 up-regulation mediated by cIAP1 has a limited effect on EGFR levels. (A) Real-Time PCR 
was performed in BT549 cells transfected with control (siCtr) or cIAP1-targeting (sicIAP1) siRNAs to assess LRIG1 
expression levels. After 48 h from transfection, cells were serum-starved overnight and stimulated with 20 
ng/ml EGF. Unstimulated siCtr vs sicIAP1 P = 0.0175, EGF 3 h siCtr vs sicIAP1 P = 0.0341; n = 3; Paired two-tailed 
t test. (B) Western blot shows SNAI2 and LRIG1 levels in BT549 cells silenced for cIAP1 and stimulated with 20 
ng/ml EGF. cIAP1 was detected as control of the transfection efficiency. (C) EGFR levels were assessed in BT549 
cells silenced for cIAP1 and LRIG1, stimulated with 20 ng/ml EGF after overnight serum starvation. (D) LRIG1 
expression levels were evaluated by Real-Time PCR in MCF10A cells under the same conditions described in 
Figure 5.24A. Unstimulated siCtr vs sicIAP1 P = 0.4585, EGF 3 h siCtr vs sicIAP1 P = 0.5052; n = 4; Paired two-
tailed t test. 
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5.8.3 cIAP1 interacts with EGFR and modulates its stability  
Having demonstrated that the absence of cIAP1 reduces EGFR levels and that LRIG1 is 
only partially involved, I investigated other possible mechanisms through which cIAP1 could 
regulate EGFR stability. I firstly evaluated the interaction between EGFR and cIAP1 using two 
different approaches: PLA and co-IP. Through PLA endogenous EGFR–cIAP1 protein 
complexes could be visualized as a single bright spot in BT549 cells (Figure 5.25A). This result 
was fur/Flagaddressed performing co-IP of ectopically expressed Myc/Flag-tagged EGFR and 
endogenous cIAP1 (Figure 5.25B), confirming the interaction between EGFR and its negative 
regulator c-CBL, which increased after EGFR stimulation.  
 
Figure 5.25 - EGFR physically interacts with cIAP1. (A) The cIAP1/EGFR interaction was tested in the BT549 cell 
line by PLA (red spots). DAPI staining was used to label cell nuclei (blue). Images were acquired with a 60x 
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magnification. (B) Co-IP was performed in BT549 cells stably expressing Myc/Flag-tagged EGFR. Cells were 
serum-starved overnight and then stimulated with 20 ng/ml EGF at the indicated time-points. Cells were lysed 
and EGFR was immunoprecipitated with anti-Flag antibody. The interaction of ectopic EGFR with cIAP1 and c-
CBL was tested through western blot. 
Next, to assess whether cIAP1 plays a role in the EGFR degradation, BT549 cells 
transfected with siCtr and sicIAP1 were pre-treated with chloroquine, in order to block 
lysosomal degradation. Chloroquine administration prevented the EGFR down-regulation 
that occurred in the absence of cIAP1, even after EGF exposure (Figure 5.26), thus suggesting 
that cIAP1 could affect the receptor lysosomal degradation.  
 
Figure 5.26 - cIAP1 affects the lysosome-dependent degradation of EGFR. BT549 cells were first transfected 
with control or cIAP1-specific siRNAs. After 48 h from transfection, cells were serum-starved overnight and 
exposed to 100 µM lysosome inhibitor chloroquine for 1 h and subsequently stimulated with 20 ng/ml EGF for 3 
h.  
Considering that the main pathway of EGFR internalization is mediated by Clathrin, 
which drives the receptor to its degradation (Sigismund et al., 2008), I also evaluated if cIAP1 
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affects Clathrin expression. Unexpectedly, Clathrin levels were reduced, rather than 
increased, by targeting of cIAP1, as shown in Figure 5.26. In accordance to this result, 
immunofluorescence analysis (Figure 5.27) highlighted the reduction of EGFR internalization 
rates caused by cIAP1 silencing. Furthermore, labelling cells with an antibody against Clathrin 
showed a decreased organization of the endocytic structures in cIAP1-depleted cells, 
whereas a clear signal resulted visible in siCtr cells before and after EGFR stimulation.  
Indeed, these observations prompted me to speculate that cIAP1 targeting does not trigger 
EGFR degradation but, instead increased its stability.  
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Figure 5.27 - The targeting of cIAP1 reduces Clathrin dependent EGFR endocytosis. BT549 cells treated with 
control or cIAP1 targeting siRNAs were serum-starved overnight and incubated with 20 ng/ml EGF for 15 or 30 
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min. After fixation, cells were analyzed for endocytosis and therefore incubated with an antibody against EGFR 
and Clathrin. Results are representative of at least three independent experiments. Images were acquired with 
a 60x magnification. 
5.8.4 The targeting of cIAP1 increases EGFR protein stability  
To substantiate the effect of cIAP1 on EGFR stability, I examined the receptor levels in 
BT549 and MCF10A cells ectopically expressing Myc-tagged EGFR. As shown in Figure 5.28A, 
cIAP1 depletion did not reduce EGFR protein levels, but rather increased them. Basing on this 
result, I further investigated the effect of cIAP1 depletion on EGFR stability. To this aim, 
BT549 and MCF10A cells were pre-treated with cycloheximide and stimulated using EGF for 
different time-points. Strikingly, cIAP1 depletion promoted the receptors stability upon EGF 
exposure, thus enhancing its half-life and supporting the idea that cIAP1 promotes EGFR 
degradation (Figure 5.28B).  
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Figure 5.28 - Ectopic EGFR fails to be degraded in the absence of cIAP1. (A) BT549 cells stably expressing 
Myc/Flag-tagged EGFR were grown in serum starvation for 24 h and then stimulated with 20 ng/ml EGF for 3 h. 
EGFR, SNAI2 and LRIG1 levels were assessed by western blot. Ectopic EGFR was detected with anti-Myc 
antibody. (B) Myc/Flag-tagged EGFR was stably expressed in BT549 and MCF10A cell lines. Cells were serum-
starved overnight and pre-treated with 100 (BT549) or 50 (MCF10A) µg/ml cycloheximide for 30 min before 
being stimulated with 20 ng/ml EGF for the indicated times.  
 128 
 
The effect of EGFR stabilization exerted by cIAP1 loss was further sustained by the 
observation obtained over-expressing an ubiquitin-ligase inactive form of cIAP1 which 
inhibited the degradation of EGFR (Figure 5.29), supporting the notion that the catalytic 
activity of cIAP1 triggers to receptor degradation.  
 
Figure 5.29 - cIAP1 ubiquitin-ligase activity triggers EGFR degradation. BT549 cells transiently transfected with 
wt or mutated cIAP1 were employed to evaluate EGFR ectopic levels by western blot.  
5.8.5 c-CBL reduction mediated by the lack of cIAP1 enhances EGFR stability 
Since post-translational modifications including phosphorylation and ubiquitination 
are events that regulate EGFR endocytosis, the effect of cIAP1 on the ubiquitin ligase c-CBL 
was tested. In fact, I hypothesised that loss of cIAP1 could enhance the receptor stability 
through the reduction of c-CBL capability to trigger EGFR degradation. To this end, Myc-
tagged EGFR was co-immunoprecipitated with c-CBL in BT549 cells stimulated with EGF for 
30 min, in the presence or absence of cIAP1 (Figure 5.30A). These experiments showed that 
c-CBL co-immunoprecipitated with EGFR mainly upon EGF stimulation and the interaction 
between these two proteins was slightly reduced in cells silenced for cIAP1 (Figure 5.30A). 
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Conversely, c-CBL over-expression limited EGFR stabilization caused by cIAP1 depletion 
(Figure 5.30B). 
 
Figure 5.30 - cIAP1 depletion stabilizes EGFR reducing its c-CBL-mediated degradation. (A) Ectopic EGFR was 
immunoprecipitated as described in Figure 5.24B from BT549 cells transfected with control and cIAP1-specific 
siRNAs. Total levels of c-CBL and the amount of c-CBL interacting with EGFR were evaluated by western blot. (B) 
Lentiviral vectors were employed to transduce MCF10A and BT549 to stably express Myc/Flag-tagged EGFR. 
Then, cells were further transduced to over-express c-CBL or GFP as a control, in cells depleted for cIAP1 
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employing specific siRNAs. After overnight serum starvation, both cell lines were stimulated with 20 ng/ml EGF 
and analysed by western blot to evaluate the levels of ectopic EGFR employing a Myc-tagged specific antibody.  
I then investigated the phosphorylation of EGFR at the Tyr-1045 residue, which is 
crucial for c-CBL/EGFR interaction upon EGF stimulation. I observed that, despite the fact 
that total levels of EGFR were reduced upon cIAP1 silencing (Figure 5.31, upper panel), the 
ratio of EGFR phosphorylated was increased (Figure 5.31, bottom panel). This suggests that 
the reduced amount of c-CBL impairs the cell capacity to degrade EGFR.  
To further study the mechanisms through which cIAP1 controls EGFR levels, I also 
assessed the effect of cIAP1 depletion on the expression of another EGFR antagonist, named 
Sprouty1. Despite its role as an EGFR inhibitor, the suppression of Sprouty1 in TNBC 
correlates with inhibition of cell growth, invasion and metastasis (He et al., 2016). Notably, 
immunoblotting analysis performed in BT549 cells showed that Sprouty1 is considerably 
reduced in cIAP1-silenced cells compared to control cells (Figure 5.31, upper panel). 
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Figure 5.31 - cIAP1 knock-down enhances EGFR phosphorylation at the c-CBL binding site Tyr-1045. BT549 
cells were silenced for cIAP1 through specific siRNAs and starved for 24 h before being stimulated with 20 ng/ml 
EGF for the indicated time-points. Sprouty 1, EGFR total levels and EGFR phosphorylation at the Tyr-1045 were 
assessed by western blot (upper panel). Densitometric analysis was performed on western blots and graphs 
(bottom panel) show the levels of EGFR phosphorylated in Tyr-1045 normalized by the total levels of the 
receptor. 
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5.8.6 Possible role of cIAP1 in regulating the degradation and the recycling of 
EGFR  
After endocytosis, EGFR is guided to early endosomes where the receptor fate is 
decided: it is either recycled back to the cell surface or further led to late endosomes and 
lysosomes for degradation. To determine which endocytic route is affected by cIAP1, I 
studied the interaction between EGFR and RAB family proteins, with a particular focus on 
RAB11 and RAB7, which play a role in recycling and late endosomes, respectively (Ceresa, 
2006). By PLA assay, I found that cIAP1 silencing slightly increases the interaction between 
EGFR and RAB11 (Figure 5.32A), while dramatically reducing the interaction of this receptor 
with RAB7 (Figure 5.32B). Taking into account that cIAP1 silencing reduces the total levels of 
EGFR (Figures 5.20C and 5.23A-B), these findings support the idea that cIAP1 depletion could 
promote EGFR recycling rather than its endocytosis in late vesicles. Nonetheless, further 
experiments are needed to clarify the role of cIAP1 in these processes. 
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Figure 5.32 - Loss of cIAP1 promotes EGFR recycling. (A) BT549 cells were transfected with control or cIAP1 
siRNAs. After 48 h post-transfection, cells were serum-starved overnight and then stimulated with 20 ng/ml 
EGF. At the indicated time points, fixed cells were tested using PLA to assess interaction between EGFR and 
RAB11 or (B) RAB7. Images were acquired with a 60x magnification and are representative of three 
independent experiments. Graphs on the right panels show the number of foci counted in 50 cells. 
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5.8.7 Depletion of cIAP1 inhibits EGFR transcription  
Despite the increased protein stability of EGFR, the overall effect of cIAP1 targeting 
was a strong reduction of the receptor levels. In light of these findings, I tested whether 
cIAP1 controls EGFR in a transcriptional manner and, therefore, the receptor expression 
levels were assessed through Real-Time PCR in BT549 and MCF10A cells, silenced or not for 
cIAP1. The analysis revealed a significant down-regulation of EGFR mRNA in the absence of 
cIAP1 (Figure 5.33), therefore suggesting that the observed downregulation of EGFR could 
stem, at least in part, from the reduced expression of EGFR gene.  
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Figure 5.33 - Loss of cIAP1 inhibits EGFR transcription. BT549 (upper panel) and MCF10A (bottom panel) cells 
were silenced for cIAP1 and stimulated with EGF (20 ng/ml) for 3 h after overnight serum starvation. Real-Time 
PCR was performed to quantify the levels of EGFR expression relative to GAPDH. BT549: Unstimulated siCtr vs 
sicIAP1 P = 0.0134, EGF 3 h siCtr vs sicIAP1 P = 0.0270; n = 3; Paired two-tailed t test. MCF10A: Unstimulated 
siCtr vs sicIAP1 P = 0.004, EGF 3 h siCtr vs sicIAP1 P = 0.0183; n = 4; Paired two-tailed t test. 
To further investigate the mechanisms through which cIAP1 transcriptionally induced 
EGFR, I focused on NF-kB signalling pathway that is regulated by IAPs. I first found that 
silencing of p65/RelA resulted in a strong reduction of EGFR (Figure 5.34), suggesting that 
EGFR is expressed in a NF-kB-dependent manner. Therefore, as cIAP1 promotes the NF-kB 
canonical pathway, and EGFR expression is promoted by NF-kB, it is possible that the 
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reduced EGFR levels observed upon cIAP1 depletion is a consequence of an impaired 
activation of NF-kB. 
 
Figure 5.34 - cIAP1 supports EGFR transcriptionally in an NF-kB dependent manner. MDA-MB231 cells were 
transfected with a control siRNA or siRNAs specific for NF-kB1, NF-kB2 and RelA and analysed by western blot to 
detect the levels of endogenous EGFR. 
 
5.9 cIAP1 promotes the EGFR/c-MET cross-talk  
 To understand more deeply the role of cIAP1 in the regulation of EGFR activity, I 
focused my attention also on c-MET, a receptor which is known to cross-talk with EGFR 
(Mueller et al., 2010). Importantly, the synergism of EGFR and c-MET pathways is implicated 
in the development and progression of cancer favouring cell cycle progression, motility and 
metastasis. In order to examine whether cIAP1 also controls c-MET levels, BT549 were 
depleted for cIAP1 and stimulated with the c-MET specific ligand, HGF. Compared with 
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control cells, c-MET levels resulted stabilized by the loss of cIAP1 even after HGF stimulation 
(Figure 5.35A). Furthermore, in response to c-MET depletion, cIAP1 was significantly reduced 
(Figure 5.35B). Based on these preliminary data, I concluded that cIAP1 might represent a 
functional link also between EGFR and c-MET, and that cIAP1 levels are controlled by c-MET. 
 
Figure 5.35 - Loss of cIAP1 induces c-MET stabilization. (A) BT549 cells were serum-starved overnight and 
stimulated with recombinant human HGF 20 ng/ml or with EGF 20 ng/ml (B) for the indicated time-points. 
Thereafter, cell lysates were collected and loaded for western blot with the indicated antibodies. Actin was 
used as a loading control.  
HGF (h): 
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5.10 Role of cIAP1 in the regulation of EMT-inducing factors  
5.10.1 Targeting of cIAP1 increases, rather than inhibiting, ZEB1 expression 
Having demonstrated that IAP-depletion perturbs the gene expression of SNAI2, 
which is an EMT-inducing factor (Phillips and Kuperwasser, 2014), I investigated if cIAP1 also 
controls the expression of other members involved in this process. Real-Time PCR performed 
both in MDA-MB231 and BT549 cells silenced for cIAP1 showed that this IAP did not support, 
but rather inhibited, the expression of another EMT-activator, named ZEB1 (Lehmann et al., 
2016; Figure 5.36A). However, the expression of TWIST1 (Garg, 2013) was slightly reduced in 
the absence of cIAP1 in BT549 cells, as shown in Figure 5.36B, and it was not detectable in 
MDA-MB231 cells, as confirmed by western blot analysis (Figure 5.36C). Therefore, cIAP1 
regulates in different manners the diverse EMT mediators: on the one hand this IAP 
promotes SNAI2 expression, on the other hand is responsible for ZEB1 inhibition. 
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Figure 5.36 - cIAP1 inhibits the expression of ZEB1 EMT-regulator. (A) Real-Time PCR was performed as 
described in Figure 36 to quantify the levels of ZEB1 in MDA-MB231 and BT549 cells. MDA-MB231: siCtr vs 
sicIAP1 P = 0.0121; BT549: P = 0.0713; n = 5; Paired two-tailed t test. (B) TWIST1 mRNA was evaluated by Real-
Time PCR performed in MDA-MB231 and BT549 cells. MDA-MB231 siCtr vs sicIAP1: not detectable; BT549 siCtr 
vs sicIAP1: P = 0.1023; n = 5; Paired two-tailed t test. (C) Western blot analysis was performed to detect SNAI2, 
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ZEB1, TWIST1 and SOX2 protein levels, in BT549 cell knocked-down for cIAP1 compared to Ctr. Actin was 
employed as a loading control. 
5.10.2 SNAI2 down-regulation mediated by targeting of cIAP1 does not affect the 
epithelial marker E- Cadherin 
To clarify whether cIAP1 regulates the capability of breast cancer cells to undergo 
EMT, MDA-MB231 cells were stably transduced using three specific shRNAs targeting SNAI2. 
As shown in Figure 5.37, SNAI2 was efficiently knocked-down in cells transduced with 
sequences B and C. Although SNAI2 expression has been reported to strongly correlate with 
the loss of E-Cadherin, which is an important EMT mediator (Vergara et al., 2015), my results 
showed that cells depleted for SNAI2 failed to increase the epithelial marker E-Cadherin, but 
rather down-regulated it (Figure 5.37).  
 
Figure 5.37 - Effect of SNAI2 depletion on different EMT targets. MDA-MB231 cells were stably silenced for 
SNAI2 employing lentiviral particles. Levels of E-Cadherin, Collagen 6A2 (COL6A2), SOX9 and SOX2 were 
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detected in shcIAP1 cells compared to the scrambled (shCtr), by western blot. SNAI2 and Actin levels are used 
as a transduction and loading control, respectively. 
To further validate the previous finding, I studied the effect of cIAP1-mediated SNAI2 
down-regulation on the expression of E-Cadherin and Vimentin, which is a mesenchymal 
marker (Figures 5.38A-B). By using the MDA-MB231 and BT549 models, I found that the 
depletion of cIAP1 inhibits E-Cadherin mRNA (Figure 5.38A), whereas the mesenchymal 
marker is not significantly modified (Figure 5.38B).  
 
Figure 5.38 - cIAP1 depletion down-regulates rather than increases E-Cadherin expression. (A) Real-Time PCR 
performed in MDA-MB231 and BT549cells transfected with control or specific-cIAP1 siRNAs to assess E-
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Cadherin expression levels. MDA-MB231 siCtr vs sicIAP1: P= 0.0688; BT549 siCtr vs sicIAP1:  P= 0.0052, n = 3; 
Paired two-tailed t test. (B) Vimentin expression was evaluated as described above. MDA-MB231 siCtr vs 
sicIAP1: P= 0.5694; BT549 siCtr vs sicIAP1: P= 0.4219; n = 3; Paired two-tailed t test. 
5.11 Targeting of SNAI2 affects the transcriptional regulators of cancer stem 
cells SOX2 and SOX9  
Recently, it has been reported a correlation between SNAI2 and SOX9, which are key 
determinants of stem cell state (Luanpitpong et al., 2016), supporting the role of SNAI2 as a 
key regulator of human breast cancer stem cells. In light of these findings, I evaluated the 
effect of SNAI2 depletion on the expression of two regulators SOX2 and 9, which are both 
implied in tumour progression and malignancy, thus linking stem/progenitor signalling with 
oncogenesis in cancer. My data supported the mechanistic relationship between SNAI2 and 
SOX2/9 that was confirmed employing MDA-MB231 cells stably silenced for SNAI2 (shSNAI2), 
which showed a strong decrease of both factors in the absence of SNAI2 (Figure 5.37). 
Furthermore, SOX2 down-regulation occurred also in MDA-MB231 and BT549 cells depleted 
for cIAP1 (Figure 5.36C), supporting the existence of a regulatory axis consisting of 
cIAP1/SNAI2/SOX2. 
5.12 Effect of cIAP1/SNAI2 axis on SM83-up-regulated genes 
Notably, GEP analysis revealed that SM83 treatment up-regulated several genes, 
including some matrix-remodelling (MMP9) or collagen-encoding (COL6A1 and COL6A2) 
genes (Figure 5.5), thereby suggesting a possible role of IAPs in the remodelling of tumour 
extracellular matrix (ECM). Importantly, Real-Time PCR showed that the up-regulation of 
MMP9 observed in primary tumours collected from SM83-treated mice also occurred in 
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MDA-MB231 and BT549 cells depleted for cIAP1 (Figure 5.39A). Then, to identify if a link 
exists between SM83-mediated IAP depletion and the cIAP1-mediated SNAI2 down-
regulation, I evaluated the effect of SNAI2 depletion on some of those genes resulted up-
regulated by SM83 treatment. SNAI2 was stably depleted in MDA-MB231 cells using the 
most efficient shRNA targeting SNAI2 (shSNAI2 #B, Figure 5.37). Importantly, SNAI2 depletion 
enhances COL6A2 levels supporting the hypothesis that its up-regulation occurred as a result 
of SM83-mediated SNAI2 down-regulation (Figure 5.39B). Furthermore, shSNAI2 cells also 
showed an increase of PLEXIN-A1, another gene resulted up-regulated by SM83 
administration. Collectively, these data document a possible role of the cIAP1/SNAI2 axis in 
the regulation of a number of genes found up-regulated in MDA-MB231 primary tumours 
collected from SM83-treated mice (Figure 5.5). 
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Figure 5.39 - SM83 administration increases the expression of several genes modulated by the cIAP1/SNAI2 
axis. (A) Real-Time PCR performed in MDA-MB231 and BT549 cells silenced using Ctr or cIAP1-specific siRNAs to 
evaluate MMP9 expression. MDA-MB231: siCtr vs sicIAP1 P= 0.0312; BT549 siCtr vs sicIAP1:  P= 0.2750; n = 3; 
Paired two-tailed t test. (B) Stable knock-down of SNAI2 in MDA-MB231 cells were analysed by western blot to 
assess the level of COL6A2 and PLEXIN-A1 protein levels.  
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Figure 5.40 - Schematic of the proposed mechanism for SM83 anti-metastatic activity. 
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6  DISCUSSION 
In this thesis, I focused on the comprehension of the role of IAPs in regulating the 
metastatic process. Beyond their largely described anti-apoptosis activity, IAPs act in the 
modulation of several receptor signalling pathways as being components of different 
receptor complexes, such as TNF-R superfamily members (Varfolomeev et al., 2012) and 
pattern recognition receptors (PRRs; Vandenabeele and Bertrand, 2012). Therefore, IAP 
depletion not only triggers cancer cell death, but also perturbs numerous signalling pathways 
including MAPK and NF-kB cascades (Varfolomeev et al., 2012). This eventually results in the 
modification of the expression of several genes (Chesi et al., 2016; Beug et al., 2017). Since 
2007, our laboratory has contributed to the development of a class of compounds designed 
to inhibit IAPs and named Smac mimetics (SMs). Due to their capability to target well-known 
inhibitors of apoptosis and increase the cytotoxic activity of traditional chemotherapies, SMs 
have raised great interest for cancer therapy and their employment is currently tested in 
clinical trials (Fulda, 2014a). Initially considered as specific XIAP inhibitors (Sun et al., 2007), 
SMs were later reported to target others members of IAP family, including cIAP1, cIAP2 and 
ML-IAP (Condon et al., 2014; Cossu et al., 2009a), thereby resulting in diverse activities and 
treatment outcomes. Nonetheless, the efficacy of SM administration is still limited and there 
is hence the need to fully understand the mechanisms of SM activity in order to define the 
right settings for their successful employment and to fully exploit the potential anti-cancer 
effect of this class of compounds.  
In my PhD studies, I decided to investigate the role of IAPs in the metastatic process. 
To this purpose, I took advantage of a library of about 140 SMs, which has been developed 
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and characterized by our laboratory in collaboration with the University of Milan. All these 
compounds have been tested in vitro to evaluate their affinity for cIAP1, cIAP2 and XIAP, and 
to measure their cytotoxic activity in a panel of cancer cell lines. According to its in vitro 
activity and pharmacokinetic profile, I decided to perform my experiments with the 
compound SM83, also termed 9a in our previous publications (Lecis et al., 2012; Lecis et al., 
2013). Notably, SM83 is a dimeric compound able to bind simultaneously with two BIR 
domains within the same IAP with nanomolar affinities. Indeed, in vitro tests have 
demonstrated a potent cytotoxic effect of SM83 in sensitive cancer cells and highlighted its 
capability to synergise with other compounds, thus enhancing their effect both in vitro and in 
vivo (Lecis et al., 2012). By using our SM, in my PhD work, I provide evidence that the 
targeting of IAPs could be a possible approach to hinder the formation of metastasis (Figure 
5.40). 
My data show that SM83 administration reduces MDA-MB231 spontaneous lung 
metastasis (Minn et al., 2005), in number and size. Although this result confirms that the 
targeting of IAPs can affect the aggressiveness of cancer cells as already shown by other 
groups, the underlying mechanism are still largely unknown. In fact, SM83 anti-metastasis 
effect may derive from many different mechanisms, such as direct killing of cancer cells, 
effect on tumour microenvironment (Lecis et al., 2013) and the associated blood vessels 
(Witt et al., 2015), as well as perturbation of gene expression. In my work, I mainly focused 
on the latter aspect. Indeed, by gene expression profiling of primary tumours collected from 
mice injected with SM83, I identified the genes whose expression was altered by treatment 
and suggested new potential insights regarding the role of IAPs in the metastatic process. 
Bioinformatic analysis showed that the in vivo administration of SM83 perturbed 65 genes in 
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primary MDA-MB231 nodules. Among the modified genes, 50 were up-regulated, whilst 15 
down-regulated. In accordance with other studies and confirming the role of IAPs in the 
regulation of the NF-kB pathway, the majority of the perturbed genes are well-known targets 
of the NF-kB cascade (e.g. TRAF1, TRAF2, NFKBIA, NFKB2, RelB; Chesi et al., 2016). To identify 
the genes that could play a role in the pro-metastatic activity of IAPs, I employed an unbiased 
approach by silencing all the genes down-regulated by SM83 treatment in vivo and 
performing wound-healing migration assays. In this way, I demonstrated that SNAI2 down-
regulation, which was a consequence of IAP-targeting, results in the reduction of cell motility 
and, partially, cell proliferation. In light of this result, I hypothesised that the decrease of 
SNAI2 levels found in treated tumours could contribute to SM83 anti-metastatic potential. 
Importantly, among the SM83 targets, I identified cIAP1 as the sole responsible of SNAI2 
expression since only its depletion, and not XIAP or cIAP2 targeting, inhibits SNAI2 
expression. Wound healing assay performed using different cell lines (BT549, MCF10A wt or 
bearing EGFR mutation) further supported the idea that cIAP1 promotes cell motility in 
various tumour cell lines therefore suggesting that this is not a cell-type specific 
phenomenon.  
Furthermore, my results suggest a novel role of cIAP1 as a regulator of SNAI2 
expression, at least in breast cancer cells. As this transcription factor is a well-known 
promoter of metastasis and the in vivo experiments showed a massive down-regulation of 
SNAI2 upon SM83 administration, these findings could provide a novel link between IAPs and 
the metastatic process. In fact, although SM83 administration also reduces the volume of 
primary tumors, and this could obviously affect the number of circulating cancer cells, this 
effect is only marginal and it is unlikely to be sufficient to explain the dramatically reduction 
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of number and size of lung metastasis detected at the end of my experiments. Moreover, the 
down-regulation of SNAI2 could be itself a consequence of SM83 toxicity and I therefore 
investigated this point. Nonetheless, several experiments support that SNAI2 is a direct effect 
of cIAP1 targeting and not a toxicity side effect. In fact, not only SM83 administration, but 
also cIAP1 silencing (confirmed by using more than one sequence) resulted in SNAI2 
reduction. These findings were also confirmed by pre-treating cells with pan-caspase or 
necroptosis inhibitors and validated in cell lines resistant to SM treatment at any dose. 
Importantly, the capability of cIAP1 to induce SNAI2 expression via the modulation of 
NF-kB and MAPK signalling has been examined. First, I noticed that a negative correlation 
exists between SNAI2 and NF-kB2, which is a marker of activation of the non-canonical NF-KB 
pathway. Indeed, the triggering of the non-canonical NF-kB pathway in cells treated with 
SM83 or TWEAK, which is a specific activator of the non-canonical NF-kB pathway, is 
paralleled by SNAI2 down-regulation. However, further analyses revealed that the major 
effect on SNAI2 levels derives from the activation of ERK pathway (Chen et al., 2009). 
Nevertheless, in our models the activation of ERK by TNF seemed to be only marginal and 
therefore I tested the effect of other stimuli responsible for activation of ERK. 
To this end, a panel of TNBC cell lines has been employed, as these cells are highly 
aggressive and therefore represent a favourite model for dissecting the metastatic process. 
Of note, SNAI2 is often highly expressed in invasive tumours, such as aggressive TNBC cells, 
and it therefore very likely to play an important role in the aggressive phenotype of this 
tumour subtype. Importantly, the role of the transcription factor SNAI2 in the metastatic 
process has been widely described by several groups: SNAI2 was shown to promote 
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metastasis and to be linked to stem features, and its expression was demonstrated to be 
associated with poor prognosis and cancer relapse (Harney et al., 2009). Interestingly, my 
work suggests that cIAP1 supports SNAI2 expression in a broadly valid manner, excluding a 
cell line-specific effect. Based on my results, cIAP1 could support TNBC aggressiveness by 
allowing the expression of high levels of the metastasis-promoting gene SNAI2. IAPs have 
been shown to favour the pro-metastatic features of cancer cells independently of their 
capability to control apoptosis (Mehrotra et al., 2010) and therefore SM treatment could 
represent a possible approach to reduce SNAI2-mediated metastasis, through the reduction 
of its apical regulator cIAP1. 
To check this hypothesis, I have studied the signalling cascade controlled by cIAP1 and 
focused on EGFR. In fact, hyper-activation and/or over-expression of EGFR characterize the 
TNBC subtype, which is also distinguished by high levels of SNAI2. Moreover, EGFR is known 
to control ERK signalling which promotes SNAI2 expression. Intriguingly, cIAP1 and cIAP2 
have recently been shown to interact also with EGFRvIII, an oncogenic mutant expressed in 
glioblastoma multiforme (GBM; Puliyappadamba et al., 2013), but the biological function of 
this interaction is still largely unknown. In our settings, I found that loss of cIAP1 inhibits 
SNAI2 expression upon EGFR stimulation because of prevention of ERK activation. Therefore, 
my data provide new insights on EGFR regulation and show for the first time the mechanistic 
role of cIAP1 in mediating the EGFR-dependent expression of SNAI2 via activation of ERK 
signalling pathway. 
Moreover, I provide evidence that the loss of cIAP1 hinders EGFR activity also by 
reducing its levels. In fact, the silencing of cIAP1 causes a reduction of EGFR transcription. 
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These findings further support the employment of SMs in cancer treatment, sustaining the 
idea that SM-mediated IAP depletion may attenuate EGFR signalling also preventing its 
expression. Importantly, it is well documented that only a small percentage of cancer cell 
lines are killed by SMs in monotherapy (Petersen et al., 2007), while the vast majority is 
resistant to these compounds independently of the dose employed. Nonetheless, later works 
have shown that also intrinsically sensitive cancer cells can acquire resistance and this 
depends on the up-regulation of LRIG1, which is triggered by SM treatment (Bai et al., 2012). 
This ubiquitin-ligase is a negative regulator of several receptors, including EGFR (Miller et al., 
2008) and c-MET (Shattuck et al., 2007). Therefore, I investigated whether LRIG1 up-
regulation could be responsible, together with the reduction of gene expression, for the 
reduction of EGFR observed in cells depleted for cIAP1. Paradoxically, EGFR protein stability 
is increased in lack of cIAP1. I then investigated whether this IAP promotes EGFR degradation 
by direct ubiquitination or by controlling the levels of other EGFR inhibitors, such as c-CBL. In 
fact, numerous studies have defined the role of c-CBL as a regulator of ligand-induced down-
regulation of EGFR (Duan et al., 2003) and proved that c-CBL regulates the cascade of events 
that trigger EGFR endocytosis and degradation (Haglund and Dikic, 2012). Interestingly, c-CBL 
physically interacts with EGFR and binds to its phosphorylated Tyr-1045 residue. This event 
has been shown to be crucial for EGFR degradation. In fact, several works have shown that 
EGFR degradation is impaired when the Tyr-1045F mutant is ectopically expressed. My data 
showed that the Tyr-1045 residue is more phosphorylated and this should correlate with 
increased degradation of EGFR in the absence of cIAP1. As already mentioned, the reduction 
of cIAP1 was associated with increased stability of this receptor, rather than augmented 
degradation. Thus, I hypothesised that EGFR, even if correctly phosphorylated on Tyr-1045, 
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could be degraded less efficiently in the absence of cIAP1 due to a reduction of c-CBL levels 
or activity. In agreement with this notion, I found that the targeting of cIAP1 causes a slight 
reduction of both c-CBL total levels and of the portion recruited to the EGFR complex. This 
evidence could explain at least in part the enhanced stability of EGFR when IAPs are targeted. 
Altogether these results demonstrated that cIAP1 depletion on the one hand reduces the 
expression of EGFR gene and on the other increases its protein stability. 
In my work, I also studied the role of Sprouty1, which is another negative regulator of 
EGFR. Despite its role as an EGFR inhibitor, loss of Sprouty1 has been recently reported to 
affect EGFR-mediated mesenchymal phenotype (He et al., 2016). In particular, high 
expression of Sprouty1 in TNBCs has been reported to be responsible for their aggressive 
phenotype and promote cell migration, invasion, and anchorage-dependent and -
independent growth. Accordingly, Sprouty1 depletion impairs the induction of SNAIL and 
SNAI2 expression by EGF, and this effect is associated with increased EGFR degradation in 
MDA-MB231 cells. Intriguingly, my work reveals a massive down-regulation of Sprouty1 in 
BT549 TNBC cells in the absence of cIAP1. This evidence may provide a further explanation 
regarding the mechanisms through which cIAP1 controls SNAI2 expression and the observed 
increase of EGFR stability in cells depleted for this IAP. 
Previous reports support the importance of c-CBL-dependent ubiquitination for 
Clathrin-mediated endocytosis of EGFR (Jiang and Sorkin, 2003; Stang et al., 2004), which is a 
mechanism for RTK signal attenuation, by allowing the removal of RTKs from the cell surface 
(Haglund and Dikic, 2012). Interestingly, by immunofluorescence analyses, I found that the 
EGFR foci detected in control cells upon stimulation with EGF are abrogated by cIAP1 knock-
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down. This event is also accompanied by the reduction of Clathrin expression. Since the 
covalent addition of ubiquitin to the EGFR receptor represents the major signal which drives 
to EGFR endocytosis (Haglund et al., 2003), I evaluated the effect of cIAP1 E3-ubiquitin ligase 
activity. The ectopic expression of an ubiquitin ligase inactive form of cIAP1 resulted in the 
increase of EGFR levels, supporting the notion that cIAP1 catalytic activity promotes the 
degradation of EGFR. Moreover, the observation that cIAP1 regulates also the levels of 
Clathrin suggests that this IAP tightly regulates the internalization process of EGFR. 
After endocytosis, EGFR can follow two main trails: it can be recycled back to the cell 
surface or routed to late endosomes for lysosomal degradation. Although the importance of 
ubiquitination in targeting activated EGFR for degradation is established, emerging evidence 
show that EGFR can evade the ubiquitin-mediated degradation through the recycling to the 
plasma membrane. Hence, my data support the idea that cIAP1 directs EGFR to degradation 
while preventing its recycling after receptor endocytosis. Accordingly, by PLA, I show that the 
interaction between EGFR and the recycling endosome marker RAB11 is not affected by the 
absence of cIAP1. Conversely, loss of this IAP impairs the interaction between EGFR and late 
endosome marker RAB7, meaning reduced receptor degradation, in this condition.  
Altogether, my thesis work supports the idea that SMs could be useful in clinics for 
the treatment of tumours expressing high levels of EGFR, either in monotherapy or in 
combination with EGFR-targeted therapy (Nakai et al., 2016). Despite the fact that SNAI2 is a 
well-known regulator of metastasis and tumour aggressiveness, making it a promising target 
for anti-cancer treatment, SNAI2-specific therapy is still lacking. In fact, so far, only proof-of-
concept molecules (Harney et al., 2009) or compounds targeting SNAI2 interactors have been 
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described (Ferrari-Amorotti et al., 2013). Therefore, the indirect inhibition of SNAI2 mediated 
by SM-induced IAP depletion could represent a novel strategy to prevent metastasis 
formation and resistance to therapy. Accordingly, a large amount of evidence supports the 
role of SNAI2 in promoting cell migration and dissemination to distal organs by reducing their 
stem-like properties and EMT features (Kao et al., 2014). 
EMT is responsible for several cellular processes, including cell proliferation, 
programmed cell death and differentiation during early developmental stages and tissue 
morphogenesis. Furthermore, many works showed a role of EMT, and of its mediator SNAI2, 
in metastasization even if recent works have questioned the importance of EMT in 
metastasis formation (Fischer et al., 2015), also proposing a negligible role of SNAI2 in cancer 
cell metastatic properties (Ye et al., 2015). Although transcription factors such as SNAIL, 
SNAI2, ZEB1, and ZEB2 are usually considered as being direct inhibitors of E-Cadherin, this 
point is still under debate (Cano et al., 2000). In my, experiments, I found no correlation 
between SNAI2 and E-Cadherin, suggesting that SNAI2 does not regulate it in all conditions. 
This could be due to the different cellular contexts in which the experiments were 
performed. Intriguingly, in our settings, the depletion of cIAP1 resulted in the up-regulation 
of another mediator of EMT, i.e. ZEB1 (Lehmann et al., 2016). This further support the notion 
that IAPs, and in particular cIAP1, play a role in EMT regulation and allows me to speculate 
that SNAI2 down-regulation is counteracted by the increase of ZEB1. E-Cadherin levels could 
therefore be determined by the balance between these two opposing effects.  
SNAI2 also promotes CSC-like features contributing to the aggressive tumour 
phenotype (Luanpitpong et al., 2016). In my study, I have confirmed that SNAI2 regulates 
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SOX2 and SOX9 showing that the knock-down of SNAI2 reduces SOX2 and 9 protein levels. 
This is consistent with the down-regulation of both SOX proteins that I have found in cIAP1-
depleted cells, thus highlighting the importance of cIAP1/SNAI2 axis in the regulation of SOX2 
and 9. Since CSCs are critical for dissemination of tumour cells and metastases formation 
(Luanpitpong et al., 2016), the effect of cIAP1 depletion could result in an anti-metastasic 
effect mediated by the decrease of SNAI2 dependent effect on CSCs and not on the EMT 
process. However, further work is necessary to clarify the role of cIAP1/SNAI2 regulatory axis 
in breast CSCs in order to evaluate whether its targeting could represent a therapeutic 
opportunity for advanced and recurrent cancers. 
Finally, I investigated whether the up-regulation of PLEXIN-A1 and COLA6A2 genes in 
MDA-MB231 nodules revealed by GEP analysis may be linked to the SM-mediated down-
regulation of SNAI2. In agreement with this hypothesis, my results show that cells stably 
depleted for SNAI2 increase PLEXIN-A1 and COL6A2 protein levels, indicating them as SNAI2 
targets. The study of SNAI2 down-stream pathway represents another important field to be 
explored in order to evaluate the effect of cIAP1 targeting-mediated SNAI2 inhibition. For 
instance, the up-regulation of COL6A2 could influence tumour matrix remodelling. 
Conversely, the role of PLEXIN-A1 is poorly studied. It belongs to the PLEXIN receptor family 
and can form complexes with RTKs, such as ErbB2, VEGFR2 or c-MET, even if the molecular 
mechanisms controlling these multimeric receptor complexes are poorly understood 
(Rizzolio and Tamagnone, 2007). These receptor complexes are diversely expressed in 
different phases of tumour progression and invasive growth, thereby leading to the 
formation of signalling complexes eliciting differential (and potentially antagonistic) 
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pathways. Therefore, SMs could represent a new tool to investigate their regulation and 
activity in tumour cells.  
6.1 Conclusions and future research 
In my PhD study, cIAP1 has been defined as a crucial determinant of the EGFR/SNAI2 
axis, and this finding has been validated in a panel of breast cancer cell lines, even bearing 
different mutations, and in normal epithelial cells, parental or with active EGFR. Moreover, 
my study supports the importance of IAPs, particularly of cIAP1, in tumour dissemination and 
contributes to the knowledge of the mechanisms underlying cancer cell metastatic potential.  
The important roles of EGFR in several cancer cell processes suggest that its targeting 
may provide a strategy to reduce tumour aggressiveness. Therefore, several approaches 
have been proposed to target EGFR, whose efficacy is frustrated by various mechanisms of 
resistance both primary and acquired: EGFR mutation, aberrant activation of down-stream 
molecules, EMT and redundant kinase signalling pathway (Luo and Fu, 2014). In the last case, 
a well-documented mechanism of resistance to the treatment with EGFR inhibitors is c-MET 
activation (Boccaccio et al., 2014). Accordingly, several studies provided the proof of 
principle that the combination of EGFR and c-MET inhibitors could be beneficial for the 
treatment of those types of cancer characterized by EGFR hyper-activity. In this regard, I 
have started to evaluate the effect of IAP targeting also on c-MET activity aiming to 
investigate a possible role of cIAP1 in mediating EGFR and c-MET cross-talk. Of note, my 
preliminary results indicate a stabilization of c-MET in cells depleted for cIAP1 and this event 
could be a consequence of decreased EGFR levels. Further experiments should be performed 
to elucidate the role of cIAP1 in this complex scenario to identify the most efficient 
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combination treatment capable to reduce the mechanisms of resistance to EGFR-directed 
treatment and to evaluate the efficacy of SMs in clinics. 
Moreover, recent findings show that SMs not only target cancer cells, but also affects 
a number of immune cell populations including natural killers, myeloid cells and 
macrophages (Lecis et al., 2013). In my work, the capability of SM83 to perturb the tumour 
microenvironment has not been investigated, but the comprehension of this phenomenon is 
of crucial importance. In this regard, my preliminary data support the notion that SM 
administration could affect tumour microenvironment through the up-regulation of genes 
encoding for ECM components. For instance, in MDA-MB231 nodules collected from 
NOD/SCID mice treated with SM83, I found an increase of MMP9 expression along with 
COL6A2 up-regulation. Of note, matrix degradation is not the only activity of MMP9, which 
also regulates the availability of pro-inflammatory cytokines, chemokines and other proteins 
therefore regulating several aspects of inflammation and immunity. Therefore, the 
investigation of how IAPs influence the cross-talk between tumour cells and tumour 
microenviroment, including stromal cells, ECM and immune cells, is crucial to develop new 
therapeutic approaches.   
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7  LIST OF ABBREVIATIONS 
ANK  Ankyrin repeats motif 
APAF-1  Apoptotic protease activating factor 1 
ATP  Adenosine triphosphate 
AVPI  Alanine-Valine-Proline-Isoleucine 
BAFFR  B-cell activation factor 
BAK  Bcl-2 homologous antagonist/killer 
BAX  Bcl-2-associated X protein 
BCA  Bicinchoninic acid 
BCL-2  B-cell lymphoma-2 
BH3  Bcl-2 homology domain 3 
BID  BH3 interacting-domain death agonist  
BIR  Baculoviral IAP repeat 
BMP  Bone morphogenetic protein 
BRCA  Breast cancer susceptibility genes 
BSA  Bovine serum albumin 
CARD  Caspase recruitment domain 
Caspases Cysteine-dependent aspartate-directed proteases 
cDNA  Complementary DNA 
CHX  Cycloheximide 
cIAP  Cellular IAP 
CIE  Clathrin-independent endocytosis 
CK  Cytokeratin 
CLQ  Chloroquine 
CME  Clathrin-mediated endocytosis 
CSC  Cancer stem-like cell 
DAPI  4’,6-Diamidino-2-phenylindole dihydrochloride 
DED  Death effector domain 
DD  Death domains 
DISC  Death inducing signaling complex 
DMEM  Dulbecco's Modified Eagle's medium 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DNTPs   Deoxynucleotide triphosphates 
DR  Death receptor 
ECL  Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
EMA  European Medicines Agency  
EMT  Epithelial to mesenchymal transition 
ER  Estrogen Receptor 
ERK  Extracellular signal-regulated kinase 
FADD  Fas-associated protein with death domain 
FBS  Fetal bovine serum 
FDA  Food and Drug Administration 
FDR  False Discovery Rate 
FGF  Fibroblast growth factor 
GEP  Gene expression profiling 
HER2  Human epidermal growth factor receptor 2 
HEPES  N’-2-hydroxyethylpiperazine-N’-2 ethanesulphonic acid 
HGF  Hepatocyte growth factor 
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HME  Human mammary epithelial 
IAP  Inhibitor of apoptosis protein 
IBM  IAP binding motif 
ICAD  Inhibitor of caspase activated DNase 
ICAM1  Intercellular adhesion molecule 1 
IF  Immunofluorescence 
IHC  Immunohistochemistry 
IkB  Inhibitor of NF-kB 
IKK   Inhibitor of NF-kB kinase 
IL  Interleukin 
IL-1R  Interleukin-1 receptor 
ip  Intraperitoneal 
iv  Intravenous 
JNK/SAPK c-Jun N-terminal kinase/stress-activated protein kinase 
LPS  Lipopolysaccharides 
LRIG1  Leucine-rich repeats and immunoglobulin-like domains protein 1 
LTβR  Lymphtoxin β-receptor 
LZ  Leucin-zipper-like domain 
MAPK  Mitogen-activated protein kinases 
MCL-1  Induced myeloid leukemia cell differentiation protein 
mCRC  Metastatic colorectal cancer 
MEK  MAPK/ERK kinase 
ML  Mesenchymal-like 
ML-IAP  Melanoma-IAP 
MMP9  Matrix metallopeptidase-9 
MOMP  Mitochondrial outer membrane permeabilization 
MSL  Mesenchymal stem–like 
mRNA  Messenger RNA 
mTNF  Membrane TNF 
NAIP  Neuronal-IAP 
NEAA  Non essential amino acids 
NEMO  NF-kB essential modulator 
NF-kB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIK  NF-kB inducing kinase 
NOD  Nucleotide-binding oligomerization 
NOD/SCID Non-obese diabetic/severe combined immunodeficiency disease 
NSCLC  Non-small cell lung cancer 
PARP  Poly-ADP ribose polymerase 
Pen/Strep Penicillin, Streptomycin 
PBS  Phosphate-buffered saline 
PBS-T  PBS-Tween 
PCR  Polymerase chain reaction 
PI3K   Phosphatidylinositol 4,5-bisphosphate 3-kinase 
PLA  Proximity ligation assay 
PRRs  Pattern recognition receptors 
PR  Progesterone receptor 
PVDF  Polyvinylidene difluoride 
Rac1  Ras related C3 botulinum toxin substrate 
RANK  Receptor activator for nuclear factor kappa B 
RING  Really interesting new gene 
RHD  Rel homology domain 
RIP1  Receptor interacting protein 1 
RNA  Ribonucleic acid 
rpm  Revolution per minute 
RPMI-1640 Roswell Park Memorial Institute-1640 
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RT  Room temperature 
RTK  Receptor tyrosine kinases 
sc  Subcutaneous 
SDS  Sodium dodecyl sulfate 
siRNA  Short interfering (siRNA) 
Smac/DIABLO Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding 
protein with low pI 
SM  Smac mimetic 
sTNF  Soluble TNF 
TA  Transcription activation domain 
TAB  TGF-beta-activated kinase 1-binding protein 3 
TAK  TNF-associated kinase 
TCGA  The Cancer Genome Atlas   
TGF  Transforming growth factor 
TIM  TRAF-interacting motif 
TLR  Toll-like receptors 
TNBC  Triple negative breast cancer 
TNF  Tumour necrosis factor 
TNF-R  TNF-receptor 
TNF-RS  TNF-R superfamily 
TRADD  TNF-R1-associated death domain 
TRAF  TNF-receptor-associating factors   
TRAIL  TNF-related apoptosis-inducing ligand 
TV  Tumour volume 
TWEAK  TNF-related weak inducer of apoptosis 
UBA  Ubiquitin-associated domain 
XIAP  X-linked IAP 
wt  Wild-type 
ZEB  Zinc-finger E box-binding homeobox 
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a b s t r a c t
Using a high-throughput approach, we identiﬁed lemur tyrosine kinase 2 (LMTK2) as a novel determi-
nant of cell sensitivity to TRAIL. LMTK2 is a poorly characterized serine/threonine kinase believed to play
a role in endosomal membrane trafﬁcking and neuronal physiology, and recently found to be mutated in
diverse tumor types. We show that LMTK2 silencing sensitizes immortalized epithelial cells and cancer
cells to TRAIL, and this phenomenon is accompanied by changes in the expression of BCL2 family
members. In epithelial cells, LMTK2 targeting causes the down-regulation of the BCL2 and BCL-xL anti-
apoptotic proteins and the reciprocal up-regulation of the pro-apoptotic protein BIM, while, in cancer
cells, LMTK2 knock-down reduces BCL2 without increasing BIM levels. We provide evidence that both
BIM and BCL2 proteins are regulated by LMTK2 in a GSK3b- and PP1A-dependent manner and that their
perturbation, together with BCL-xL reduction, determines an increased sensitivity not only to TRAIL, but
also to other compounds. Overall, our ﬁndings suggest a broad function of LMTK2 in the regulation of the
apoptotic pathway and highlight LMTK2 as a novel candidate target to increase the cytotoxic activity of
chemotherapeutic compounds.
© 2016 Elsevier Ireland Ltd. All rights reserved.
Introduction
Among the several approaches and molecules that have been
proposed in anti-cancer treatment, tumor necrosis factor-related
apoptosis inducing ligand (TRAIL) has raised great expectations
owing to its in vitro and in vivo cytotoxic activity towards cancer
cells [1,2], while sparing normal tissues [3]. Unfortunately, later
studies demonstrated that cancer cells develop resistance to TRAIL-
induced apoptosis through several mechanisms, thus limiting its
therapeutic efﬁcacy [2]. Indeed, high levels of the caspase-8 and
caspase-3/-7/-9 inhibitors FLIP and XIAP, hyper-activation of many
pro-survival pathways (e.g. NF-kB) and aberrant expression of the
BCL2 family members BCL2, BCL-xL and MCL-1, prevent TRAIL-
mediated apoptosis [2]. In pathological settings, TRAIL adminis-
tration could even paradoxically sustain cancer cell aggressiveness
and promote invasion and metastasis formation [4,5]. Hence, can-
cer cells need to be primed to death with combination therapy and,
to this end, several approaches have been pursued [6e8].
Lemur Tyrosine Kinase 2 (LMTK2) is a poorly characterized
serine/threonine kinase initially identiﬁed as an interactor of PP1A
[9], one of the four PP1 catalytic isoforms [10]. Little is known about
the physiological function of LMTK2, except for its role in the
maturation of germ cells [11] and in endosomal membrane traf-
ﬁcking through the interaction with myosin VI [12,13]. LMTK2 is a
target of CDK5 [14] and has been shown to control Smad2 signaling
by regulating PP1A and GSK3b [15]. The latter kinase is constitu-
tively active in unstimulated cells [16], but can undergo a rapid and
reversible repression in response to extracellular signals. The
regulation of GSK3b is mainly posttranslational and, in particular,
dependent on inhibitory phosphorylation. Among the
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phosphorylated residues identiﬁed, Ser9 is a known target of AKT
[17] while Thr43 of ERK [18].
Due to the interaction of LMTK2 with two proteins involved in
numerous processes within the nervous system, i.e. PP1A and
CDK5, it is conceivable that LMTK2 may play a role in neuro-
degeneration [14]. Nonetheless, several LMTK2 mutations have
recently been identiﬁed also in cancer, and in particular in pul-
monary sarcomatoid carcinomas [19], lung adenocarcinomas [20]
and prostate cancer [21,22]. Of note, in in vitro models of prostate
cancer, LMTK2 was shown to regulate the androgen receptor (AR)
[23], prostate speciﬁc antigen (PSA) and vascular endothelial
growth factor (VEGF) secretion [24], and transforming growth
factor beta (TGFb) signaling [15], and could therefore contribute to
cancer susceptibility and progression [21].
In this study, we performed a siRNA-based high-throughput
screening, targeting 714 kinases and 598 ubiquitin-related proteins,
with the ultimate goal of identifying new modulators of TRAIL
sensitivity. We found that LMTK2 is a determinant of TRAIL sensi-
tivity and described for the ﬁrst time its role in the regulation of the
BCL-2 family proteins and the underlying mechanisms. Finally, we
investigated the effect of LMTK2 silencing in a panel of premalig-
nant and cancer cell lines, conﬁrming a broad effect of LMTK2 in the
regulation of the apoptotic pathway triggered not only by TRAIL,
but also by other cytotoxic compounds.
Materials and methods
Cell culture and chemicals
Human mammary epithelial HME and MCF10A cell lines parental or bearing the
EGFR delE746A750 mutation (HME EGFR and MCF10A EGFR, respectively), and
colorectal HCT116 and DLD-1 cell lines were cultured as already described [25].
MDA-MB231 and BT549 cells were cultured in RPMI 1640 medium (Lonza Group,
Basel, CH) supplemented with 10% fetal bovine serum (FBS; EuroClone, Milan, IT) at
37 C and 5% CO2 in fully humidiﬁed atmosphere. Cells were treated with the NF-kB
(BAY117082; Selleck Chemicals, Munich, D), the AKT, MEK and GSK3b inhibitors
(Triciribine, U0126 and AR-A014418; Enzo Life Sciences, Plymouth Meeting, PA,
USA), ABT737 (Calbiochem, Merck KGaA, Darmstadt, D) and staurosporine (Sigma-
eAldrich, St Louis, MO, USA).
High-throughput screening and viability assay
On day 0, HME cells bearing the EGFR delE746A750mutation (named HME EGFR
hereafter) were transfected with siRNAs, arrayed on 384-well plates, using a reverse
transfection protocol at a ﬁnal siRNA concentration of 50 nM. The siRNA pools used
for the screening corresponded to the human protein kinases and ubiquitin conju-
gation subsets (1, 2 and 3) sub-libraries (total 1312 gene targets, 4 siRNAs per gene
target; siGENOME SMARTPool technology, GE Healthcare Dharmacon, Lafayette, CO,
USA). siRNA transfection was performed with Lipofectamine RNAiMAX Transfection
Reagent (Thermo Fisher Scientiﬁc, Waltham, MA, USA), according to the manufac-
turer's instructions. After 48 h, cells were treated with Smac mimetic (SM83) [26,27]
in combination with isoleucine-zipper TRAIL (izTRAIL) [28] at a ﬁnal concentration
of 100 nM and 0.5 ng/ml, respectively; a parallel set of transfected cells was left
untreated. After further 48 h, cell viability was evaluated by measuring cellular ATP
content, with CellTiter-Glo (Promega, Madison, WI, USA), according to manufac-
turer's protocol. Two independent experiments were performed. Luminescence
values were normalized to the sample median, on a per plate basis, and untrea-
ted:treated ratios were calculated for each knock-down.
Validation experiments of the 20 candidate genes indentiﬁed in the screening
were performed by transfecting the HME EGFR cells with the 4 individual siRNAs
that composed the corresponding siRNA pools (siGENOME, Dharmacon). Experi-
ments were performed in 96 well plates and viability tested using the conditions
applied in the screening.
Silencing and ectopic expression
Silencing experiments were performed by reverse transfection using Lipofect-
amine RNAiMAX Transfection Reagent and siRNAs dissolved in Opti-MEM (Thermo
Fisher Scientiﬁc). The ﬁnal siRNA concentration was 50 nM. When a single knock-
down was compared to a double knock-down, 25 nM non-targeting siRNA was
added to the single targeting siRNA to reach the same ﬁnal concentration in all the
reactions. The individual siRNAs employed were purchased from Dharmacon (NT#1
siGENOME Non-Targeting siRNA Pool #1 D-001206-13, NT#5 siGENOME Non-
Targeting siRNA #5 D-001210-05; LMTK2 D-003149-06 and D-003149-21; ERN1
D-004951-02 and 004951-03; CDK5 D-003239-07 and D-003239-08) and QIAGEN
(siRelA/p65 Hs_RELA_5; siGSK3b Hs_GSK3B_5; siPP1A Hs_PPP1CA_9; siPP1R2
Hs_PPP1R2_6; siPP1C Hs_PPP1CC_5; siBIM#5 Hs_BCL2L11_5 and siBIM#15
Hs_BCL2L11_15; QIAGEN, Hilden, DE). The control siRNAs (siCtr) used in western
blots and viability tests were synthesized by Euroﬁns Genomics (sequence 50-
CGUACGCGGAAUACUUCGATT-30).
To ectopically express BCL2 and BCL-xL in combination with LMTK2 silencing,
HME EGFR cells were seeded (2  104 cells/well in 96 wells) and left adhere over-
night. The day after, a mix containing 0.25 ml siRNA 20 mM (control or LMTK2 spe-
ciﬁc), plus 0.2 mg plasmid (pcDNA-GFP, pCMV6-Entry-BCL2-Myc; Origene
#RC204498 and pCMV6-Entry-BCL-xL-Myc; Origene #RC201314) and 0.35 ml Lip-
ofectamine2000 Transfection Reagent was added to each well. After 48 h, cells were
treated with 500 ng/mL izTRAIL for 24 h and then viability assessed by CellTiter-Glo.
For western blots, cells were seeded in 12-well plates and reagents scaled-up ac-
cording to well surface (13).
Caspase activity
Apoptosis induction was measured by CellEvent Caspase-3/7 Green Detection
Reagent (Thermo Fisher Scientiﬁc) which was dissolved in the culturing medium 1 h
before administration of izTRAIL. Caspase activity was detected in time-course ex-
periments by ﬂuorescence and phase contrast image acquisition using a Cell-IQ SLF
instrument (CM Technology Oy, Tampere, Finland). Green ﬂuorescence-positive cells
were identiﬁed and counted using the integrated Cell-IQ Imagen software.
Western blot
To detect protein levels, cells were trypsinized, washed in 1 PBS and boiled in
lysis buffer (125 mM Tris HCl pH 6.8, 5% sodium dodecyl sulfate/SDS) for 10 min.
Protease and phosphatase inhibitors were added to samples, which were then
sonicated and centrifuged at 11,000 rpm for 15min at RT. Cleared supernatants were
separated by SDS-PAGE on precast 4e12% BiseTris NuPAGE gels (Thermo Fisher
Scientiﬁc) and blotted onto PVDF membranes (Merck Millipore, Darmstadt, Ger-
many) using the XCell II blot module (Thermo Fisher Scientiﬁc). Membranes were
saturated in Tris-buffered saline (TBS) with 4% BSA for 30 min and then incubated
overnight with the following primary antibodies: ERN1 #3294, BAX #2772, BAD
#9292, XBP-1s #12782, PUMA #4976, BID #2002, p-p65 #3031, GSK3b, #12456,
pGSK3b #5558, pPP1A #2581, PP1A #2582, Cleaved PARP #9541, Cleaved Caspase3
#9664, phospho-Akt Ser473 #9271, Akt #2920, Phospho-MEK1/2 #9121, MEK1/2
#4694, Myc-Tag #2278 (Cell Signaling Technology, Danvers, MA, USA), MCL1 sc-819
(Santa Cruz Biotechnology; Dallas, TX 75220, USA), NOXA #OP180 (Merck Millipore;
Darmstadt, DE), BIM #559685 (BD Biosciences; 9320 Erembodegem, Belgium),
phospho-ERK1/2 #M8159, ERK1/2 #M5670, LMTK2 SAB4500900, Actin #A1978,
Vinculin #V9131 (SigmaeAldrich). Antibodies speciﬁc for BCL2 [29] and BCL-xL [30]
have been described previously. After 1 h incubation with the appropriate horse-
radish peroxidase-conjugated secondary antibody (SigmaeAldrich), proteins were
detected by electrochemiluminescence (ECL) reaction (EuroClone). Band density has
been calculated by ImageQuant 5.2 and normalized to Actin. An arbitrary value of 1
has been assigned to the appropriate control sample and the others have been
expressed as fold values.
Statistical analysis
Statistical analysis and graphs were performed using GraphPad Prism 5.02. P
values were calculated by paired two-tailed t-test. A value of P < 0.05 was consid-
ered statistically signiﬁcant.
Results
Identiﬁcation of new modulators of cell sensitivity to TRAIL using a
high-throughput RNAi screening approach
To identify genes whose knock-down increases the cytotoxicity
of TRAIL, we performed a siRNA-based high-throughput screening
using the HME EGFR cell line. Cells were transfected with a library
of human siRNAs (pools of 4 siRNAs per target gene) targeting 714
kinases and 598 ubiquitin-related proteins, and then were either
left untreated or treated with SM83 in combinationwith izTRAIL at
sub-toxic concentrations. Cell viability was determined 48 h later
by measuring cellular ATP content, using a luciferase-based assay
(Fig. 1a). For each target gene, sensitivity to izTRAIL/SM83 treat-
ment was assessed by comparing the viability of untreated cells
with that of cells treatedwith izTRAIL/SM83 (Fig.1b). Genes leading
to at least 3-fold reduction of viability in the presence of izTRAIL/
SM83 (untreated:izTRAIL/SM83 ratio >3) were selected. The siRNA
pools which resulted in cell viability <80% in untreated conditions
were considered toxic and excluded from further analysis. Using
these criteria, we selected 20 candidate genes (Fig. 1a and c, and
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Table 1), which were further validated in deconvolution experi-
ments using the 4 independent siRNAs that composed the siRNA
pools tested initially (Supplementary Fig. S1). Genes were validated
and considered true hits only if 2 or more individual siRNAs
reproduced the effect observed by the siRNA pools, i.e. the ratio
treated:untreated was <0.33 (16 genes out of 20 genes were vali-
dated, green in Supplementary Fig. S1): LRSAM1, LMTK2, PRKD2,
RNF183, ERN1, RAB40B, WDR24, PMVK, SYVN1, FGFR3, DTX3L,
Fig. 1. High-throughput screening to identify novel determinants of cell sensitivity to TRAIL. (a) Schematic of the RNAi screening to identify determinants of TRAIL sensitivity. On day 0,
HME EGFR cells were transfected with siRNA pools targeting human protein kinases and ubiquitin-related enzymes. On day 2, cells were treated with SM83 and izTRAIL and, on day
4, cell viability was evaluated. (b) Distribution of the ratio between the viability of cells silenced for each speciﬁc siRNA untreated and treated with izTRAIL/SM83. (c) Viability of
HME EGFR cells transfected with the siRNAs against the 20 candidate genes identiﬁed in the primary screening and treated with SM83/izTRAIL; results of untreated (blue) and cells
treated with izTRAIL/SM83 (red) are shown; NT#1 and NT#5 indicate two non-targeting siRNAs which were used as controls. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
List of the top scoring siRNA pools increasing the sensitivity of HME EGFR cells to treatment. HME EGFR cells were transfected with a library of siRNAs targeting kinases and
ubiquitin-related enzymes (total 1312 gene targets; pools of 4 siRNAs per gene target) and treated with izTRAIL and SM83 combination.
Gene ID Entrez ID Gene name Untreated SM83/TRAIL Untreated vs
SM83/TRAIL
LRSAM1 90678 Leucine rich repeat and sterile alpha motif containing 1 0,914 0,197 4,640
LMTK2 22853 Lemur tyrosine kinase 2 1,122 0,265 4,242
PRKD2 25865 Protein kinase D2 0,900 0,224 4,018
RNF183 138065 Ring ﬁnger protein 183 0,814 0,206 3,959
LMO7 4008 LIM domain 7 0,812 0,212 3,830
ERN1 2081 Endoplasmic reticulum to nucleus signaling 1 0,953 0,254 3,752
RAB40B 10966 RAB40B, member RAS oncogene family 0,995 0,270 3,683
WDR24 84219 WD repeat domain 24 0,827 0,230 3,603
CSF1R 1436 Colony stimulating factor 1 receptor 0,921 0,256 3,598
PMVK 10654 Phosphomevalonate kinase 0,950 0,270 3,517
SYVN1 84447 Synovial apoptosis inhibitor 1, synoviolin 0,860 0,248 3,466
FGFR3 2261 Fibroblast growth factor receptor 3 0,849 0,250 3,394
DTX3L 151636 Deltex 3-like (Drosophila) 0,855 0,259 3,301
MAP2K7 5609 Mitogen-activated protein kinase kinase 7 0,972 0,297 3,273
BAHD1 22893 Bromo adjacent homology domain containing 1 0,940 0,288 3,268
CSNK1G1 53944 Casein kinase 1, gamma 1 0,885 0,272 3,252
RNF4 6047 Ring ﬁnger protein 4 0,920 0,287 3,211
DTX3 196403 Deltex homolog 3 (Drosophila) 1,248 0,402 3,104
CDK5 1020 Cyclin-dependent kinase 5 0,929 0,300 3,102
MAP4K3 8491 Mitogen-activated protein kinase kinase kinase kinase 3 0,918 0,304 3,020
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MAP2K7, CSNK1G1, DTX3, CDK5 and MAP4K3. On the contrary,
LM07, CSF1R, BAHD1, and RNF4 were excluded at this stage (red in
Supplementary Fig. S1).
LMTK2 affects the expression of BIM, BCL2 and BCL-xL
Next, we checked the effect of the silencing of the validated 16
hits on several mediators of the apoptotic pathway to infer a po-
tential mechanism for the observed sensitization. We focused
mainly on LMTK2 and CDK5, which are known to interact with each
other and to play a role in some common pathways [14], and ERN1,
already known to affect sensitivity toTRAIL (Fig. 2a) by causing DR5
mRNA decay. Accordingly, the silencing of ERN1 was shown to
result in increased levels of TRAIL receptor [31]. As no major dif-
ferences were observed upon CDK5 silencing which could explain
the increased sensitivity to TRAIL, following this analysis, we
selected LMTK2, a still poorly characterized kinase. In fact, the
down-regulation of LMTK2 caused the reduction of the anti-
apoptotic BCL2 and BCL-xL proteins, and the up-regulation of the
pro-apoptotic protein BIM. The HME EGFR cells were also charac-
terized by FACS analysis for the expression of the TRAIL receptors
(R1, R2 and decoy R3 and R4), since their modulation could affect
the sensitivity to TRAIL. However, only TRAIL-R2 was detectable in
HME cells and its levels were not increased by LMTK2 silencing
(data not shown).
As TRAIL is known to activate the NF-kB pathway [4], we
checked whether this occurs also in HME EGFR cells and found that
TRAIL-dependent phosphorylation of the NF-kB component p65
(Fig. 2b) was more pronounced upon LMTK2 silencing. We there-
fore questioned whether NF-kB could be responsible for the mod-
ulation of BIM levels, as suggested in other settings [32], but neither
the treatment with an inhibitor of the NF-kB pathway (BAY117082;
Fig. 2c), nor p65 knock-down (Fig. 2d), prevented the LMTK2
silencing-dependent up-regulation of BIM. Therefore, the silencing
of LMTK2 results in the modulation of diverse members of the BCL2
family, causing the down-regulation of the anti-apoptotic proteins
BCL2 and BCL-xL, and the accumulation of BIM in a NF-kB-
independent manner.
The sensitization effect to TRAIL upon LMTK2 targeting is
independent of EGFR status and is valid also in cancer cells
As the screening was performed by employing normal epithelial
HME cells bearing oncogenic EGFR, we asked whether our obser-
vations could be validated in other cell lines and were dependent
onmutated EGFR. For this purpose, LMTK2 was silenced both in the
HME and MCF10A cell lines, expressing wild type or mutated EGFR,
and viability was evaluated in doseeresponse experiments
(Fig. 3aed). In both human mammary epithelial cell lines, the
depletion of LMTK2 enhanced the killing activity of TRAIL in an
equivalent manner (compare Fig. 3a vs 3c, and 3b vs 3d). Moreover,
the sensitization effect was independent of EGFR status as both the
parental cell lines and those bearing oncogenic EGFR were killed to
a similar extent upon TRAIL administration (compare Fig. 3a vs 3b,
and 3c vs 3d). The ﬁnding that LMTK2 silencing enhances the
sensitivity to TRAIL in immortalized mammary epithelial cell lines
led us to investigate whether this effect could also be observed in
fully transformed cancer cells. To this end, we selected a panel of
cancer cell lines, such as triple negative breast cancers (MDA-
MB231 and BT549) and colon cancers (HCT116 and DLD-1), which,
together with prostate and cervical tumors, often express high
levels of LMTK2. We silenced LMTK2 in all these cancer cell lines
and tested their sensitivity to TRAIL. Although differing in their
intrinsic sensitivity to izTRAIL, all the cell lines became more sen-
sitive to the treatment upon LMTK2 knock-down (Fig. 3eeh), sug-
gesting that LMTK2 is a determinant of TRAIL sensitivity in multiple
Fig. 2. LMTK2 controls the levels of several regulators of the apoptotic pathway in an NF-kB-independent manner. (a) HME EGFR cells were transfected with siRNAs targeting ERN1,
CDK5 and LMTK2 (two siRNAs per gene, 50 nM ﬁnal concentration). After 72 h, cells were tested in western blots to evaluate the levels of several mediators of the apoptotic
pathway. (b) The phosphorylation status of the NF-kB member p65 and the total levels of BIM and BCL2 proteins were evaluated after silencing of LMTK2 in the HME EGFR cell line
and treatment with izTRAIL (500 ng/ml) at the indicated time points. The levels of BIM and BCL2 were evaluated also after (c) treatment with the NF-kB inhibitor BAY117082
(25 mM) and (d) silencing of p65 in the presence or absence of LMTK2 silencing. Actin was used as loading control.
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cell types. Therefore, the down-regulation of LMTK2 enhances the
cytotoxic effect of izTRAIL independently of EGFR mutation and is
not cell-line speciﬁc.
As BIM up-regulation was observed in HME EGFR cells upon
LMTK2 silencing, we checkedwhether this was true also inMCF10A
EGFR. Interestingly, BIM was up-regulated also in these cells, while
expression of BCL2 did not vary signiﬁcantly (Fig. 3i). Then, we
checked the effect of LMTK2 silencing in the cancer cells lines
described above. In clear contrast towhat was observed in HME and
MCF10A EGFR cells, LMTK2 knock-down decreased the levels of
BIM in MDA-MB231, HCT116 and DLD-1 cells, while in the BT549
cell line it had no effect (Fig. 3i). Nonetheless, BCL2 expression was
reduced upon LMTK2 silencing in all the four cell lines tested in
accordance to HME EGFR cells. Overall, LMTK2-dependent regula-
tion of BIM is more evident in non-cancer cell lines, while other
members of the BCL2 family, such as BCL2 and BCL-xL (Figs. 2a and
3i), could be regulated by LMTK2 mainly in fully transformed
cancer cells.
Silencing of LMTK2 affects AKT and ERK signaling
In an attempt to understand the mechanisms by which LMTK2
regulates the above described BCL2 family members and the
sensitivity to TRAIL, we investigated the activation of AKT and
ERK1/2, known to be induced by TRAIL [4], in control and LMTK2-
silenced cells, treated with izTRAIL alone. In fact, we observed that
LMTK2 silencing enhances the cytotoxic activity of TRAIL even in
the absence of SM83 and therefore we studied the function of this
kinase employing TRAIL in monotherapy. LMTK2 silencing resulted
in a reduction of AKT and ERK1/2 phosphorylation (Fig. 4aeb)
compatible with a decrease of their activity in unstimulated con-
ditions. To understand whether the modulation of these pathways
was responsible for BIM regulation, we treated the cells with in-
hibitors of AKT (Triciribine) or compounds that prevent ERK acti-
vation (U0126). All of these treatments increased BIM expression
upon LMTK2 silencing (Fig. 4aeb) in untreated conditions. There-
fore, LMTK2 silencing reduces the activation of AKT and ERK1/2 and
this correlates to increased levels of BIM. Moreover, the chemical
inhibition of these kinases further contributes to the increase of
BIM levels.
As LMTK2 was shown to regulate GSK3b [15] and this kinase is
inhibited by AKT and ERK [17,18], we checked whether GSK3b could
play a role in the regulation of BIM. Therefore, cells silenced or not
for LMTK2 were treated with the GSK3b inhibitor AR-A014418 and
analyzed in time-course experiments for BIM expression. In control
cells, the low basal expression of BIMwasweakly affected by GSK3b
Fig. 3. Sensitization to TRAIL treatment by LMTK2 silencing is independent of EGFR mutational status and is not cell-line speciﬁc. (aed) The capability of LMTK2 silencing to enhance the
cytotoxic activity of izTRAIL was tested in the parental (aec) and EGFR mutated (bed) HME and MCF10A cells. Cells were transfected with non-targeting siRNAs (blue) and siRNAs
speciﬁc for LMTK2 (red) and, 48 h later, treated with the indicated concentrations of izTRAIL. Viability was assessed after further 24 h (eef) Breast and (geh) colorectal cancer cell
lines were transfected either with non-targeting or LMTK2-speciﬁc siRNAs and, after 48 h, treated with the indicated concentrations of izTRAIL. Viability was measured 24 h later.
Results are representative of two independent experiments. (i) BIM and BCL2 levels in MCF10A EGFR, MDA-MB231, BT549, DLD-1 and HCT116 cells were detected by western blot
72 h after silencing of LMTK2. Actin is shown as loading control. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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inhibition with AR-A014418, but BIM expression was markedly
reduced in LMTK2-silenced cells (Fig. 4ced) which expressed
higher levels of BIM (Figs. 2a and 4). Importantly, the down-
regulation of BIM caused by GSK3b inhibition was paralleled by
the up-regulation of BCL2 (Fig. 4ced). Altogether, our ﬁndings
support the notion that the depletion of LMTK2 results in the in-
hibition of the AKT and ERK pathways and promotes the accumu-
lation of BIM and the reduction of BCL2 and BCL-xL in a GSK3b-
dependent fashion.
LMTK2 controls BIM levels through the engagement of GSK3b and
PP1A
Then, we investigated the role of PP1A, which is known to
interact with LMTK2 and mediate its effect on GSK3b [15], and
found that LMTK2 silencing decreases the phosphorylation of PP1A
(Fig. 5a, right panel, and 5b) and this correlated with a reduction of
GSK3b phosphorylation (Fig. 5a, right panel, and 5b). The latter
effect of LMTK2 silencing was more pronounced after the
administration of izTRAIL (Fig. 5b), which resulted in less phos-
phorylation of GSK3b on Ser9 (i.e. increased activation). Interest-
ingly, the silencing of PP1A slightly augmented GSK3b
phosphorylation in untreated conditions (Fig. 5aeb), but pro-
foundly after TRAIL treatment. This suggests that PP1A promotes
GSK3b activity by reducing its inhibitory phosphorylation, but also
counteracts its effect on BIM. Accordingly, BIM was regulated in a
positive manner by GSK3b, but negatively by LMTK2 and PP1A
(Fig. 5aeb).
PP1A is not the only phosphatase that regulates BIM, since the
knock-down of PP1C and PP1R2, both known to interact with
LMTK2 [9,33,34], also increased BIM expression (Fig. 5c). Interest-
ingly, PP1A silencing sensitized cells to TRAIL to the same extent as
LMTK2 silencing and the double knock-down showed no additive
or synergistic effect on TRAIL toxicity (Fig. 5d) suggesting that these
proteins play a role in the same pathway. Altogether, our ﬁndings
indicate that LMTK2 promotes the inhibitory phosphorylation of
PP1A which in turn is not able to dephosphorylate GSK3b at Ser9.
When LMTK2 is silenced, this results in increased activity of GSK3b,
Fig. 4. Effect of LMTK2 silencing on AKT, ERK and GSK3b signaling. (aeb) HME EGFR cells silenced with control siRNAs and siLMTK2 for 72 h were pre-treated with the AKT (20 mM
Triciribine) and MEK (25 mM U0126) inhibitors for 1 h and then treated with izTRAIL for an additional 2 h to detect the activation of AKT and ERK1/2, and its correlation with BIM
levels. (c) HME EGFR cells were transfected with siRNAs targeting LMTK2 for 72 h and then treated with 50 mM GSK3b inhibitor AR-A014418 for the indicated periods. Western blot
was performed to evaluate the levels of BIM (upper panel), and BCL2 and GSK3b (lower panel). Actin was used as loading control. (d) BIM (upper graph) and BCL2 (lower graph)
levels calculated by densitometric analysis of western blot shown in Fig. 4c. Levels of BIM and BCL2 in cells not treated with AR-A014418 and trasfected with control siRNA were
arbitrarily set as 1.
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which favors the accumulation of BIM. GSK3b and PP1A mutually
regulate each other, but the former is a promoter of BIM accumu-
lation, whereas the latter had an opposite effect.
The perturbation of the BCL2 family members caused by LMTK2
silencing contributes to the increased sensitivity to TRAIL
The observation that LMTK2 silencing causes BIM accumulation
and increases the sensitivity to TRAIL, prompted us to investigate
the existence of a causal relationship between these events. To this
end, BIM was silenced using two different siRNAs (Fig. 6a) alone or
in combination with LMTK2 silencing. Interestingly, while LMTK2
knock-down, as expected, sensitized cells to izTRAIL, LMTK2/BIM
double knock-down partially, but signiﬁcantly, protected cells from
the treatment. The increased cell viability (Fig. 6a) correlated with a
reduced accumulation of cleaved PARP and caspase-3 proteins
(Fig. 6b), and lower activity of caspases-3 and -7, as measured by
ﬂuorometric assay (Fig. 6c). Therefore, the accumulation of BIM
contributes to the observed increased sensitivity to TRAIL, but the
regulation of other proteins such as the BCL2 family members
(Fig. 2a) could also affect the sensitization.
For this reason, we also investigated the effect of BCL2 and BCL-
xL, which are both reduced by siLMTK2. BCL2 and BCL-xL were
ectopically expressed in HME EGFR cells silenced for LMTK2 or with
control siRNAs (Fig. 6d) and treated with TRAIL. In agreement with
our hypothesis, the ectopic expression of both BCL2 and BCL-xL
partially protected from TRAIL treatment (Fig. 6d), suggesting that
their reduction upon LMTK2 targeting contributes, together with
BIM up-regulation, to the increased sensitivity.
Therefore, the partial rescue effect obtained by the ectopic
expression of BCL2 and BCL-xL suggests that both proteins, together
with BIM, play a role in the increased sensitivity to the treatment.
Nonetheless, their role could be underestimated in our experi-
mental conditions as the transfection efﬁciency for over-expression
was approximately 30e40% (Fig. 6e).
The sensitizing effect of LMTK2 is not limited to TRAIL
As the members of the BCL2 family are general regulators of the
apoptotic pathway and are not speciﬁcally appointed to sensitivity
to TRAIL, we tested whether LMTK2 silencing could affect the
cytotoxic effect of other chemotherapeutic compounds. First, we
treated the HME EGFR cells and two cancer cell lines with the BCL2
and BCL-xL inhibitor ABT737, and found that the down-regulation
of LMTK2 increases the cytotoxic effect of the treatment in at
least 2 out of the 3 tested cell lines (Fig. 7aec and Table 2). More-
over, we tested if these observations were valid also for other
cytotoxic agents such as staurosporine, cisplatin and etoposide. We
found that in all cases LMTK2 silencing led to increased sensitivity
to treatments and reduced cell viability, with the exception of
MDA-MB231 cells treated with etoposide, which were not affected
by LMTK2 silencing (Table 2). Thus, LMTK2 targeting affects the cell
response to several cytotoxic agents and therefore this kinase could
be considered as a new determinant of sensitivity to cell death.
Fig. 5. LMTK2 regulates BIM levels in a GSK3b- and PP1-dependent manner. (a) LMTK2, PP1A and GSK3b were silenced in HME EGFR cells and, after 72 h, the levels of BIM, the
inhibitory phosphorylation status of PP1A and GSK3b, and their total levels, were investigated by western blot. NT: non-transfected control. (b) HME EGFR cells were transfected
with siRNAs targeting LMTK2, PP1A, and the combination of them. After 72 h, cells were treated with 500 ng/ml izTRAIL for 4 h and tested in western blot to evaluate the levels of
LMTK2, BIM, PP1A, GSK3b and the phosphorylation of PP1A and GSK3b. (c) The levels of BIM were evaluated 72 h after transfection with siRNAs targeting LMTK2, PP1A and its
interactors PP1R2 and PP1C. The silencing of BIM is shown as control of antibody speciﬁcity and actin was used as loading control. (d) HME EGFR cells were transfected with siRNAs
targeting LMTK2, PP1A and their combination. After 48 h, cells were treated with 500 ng/ml izTRAIL for 24 h and cell viability was measured. Results are representative of two
independent experiments.
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Discussion
In this study, we show that LMTK2 represents a novel deter-
minant of sensitivity to TRAIL both in cancer cells and in prema-
lignant models, and its silencing results in enhanced cytotoxic
activity of different compounds. This effect is paralleled by the
modulation of the BCL2 family proteins, especially BCL2 and BIM.
Mechanistically, the down-regulation of LMTK2 causes the reduc-
tion of AKT and ERK1/2 activation, a decrease in the inhibitory
phosphorylation of GSK3b on Ser9 and consequently an increase of
its activity. Moreover, it causes the reduction of PP1A (inhibitory)
phosphorylation and this event further contributes to GSK3b acti-
vation [15], allowing the phosphatase to reduce the phosphoryla-
tion state of GSK3b. Nonetheless, as PP1A is a negative regulator of
BIM, its activation counterbalances the GSK3b-dependent accu-
mulation of BIM (Reviewed in the schematic Fig. 7d). Interestingly,
BIM up-regulation is observed only in premalignant models, while
LMTK2 silencing does not trigger BIM accumulation in cancer cell
lines, where however BCL2 is still down-regulated. This observation
supports the notion that the outcome of LMTK2 targeting on BIM
and BCL2 levels is the result of different effects arising from more
than one pathway. This is not surprising as the BIM level, for
example, strictly relies not only on its gene transcription, but also
on protein stability, which is caused by both phosphorylation and
de-phosphorylation events [35]. Therefore, all these mechanisms
could be differently regulated in normal, premalignant and fully
transformed cells. Nonetheless, the anti-apoptotic effect of LMTK2
is valid for all the cell lines tested and its silencing results in
increased sensitivity to TRAIL.
Thus far, the precise physiological function of LMTK2 is un-
known. Knock-out mice are viable even if infertile due to defective
germ cell maturation [11]. LMTK2 is highly expressed in other tis-
sues, such as skeletal muscle [9,11] and brain [36,37]. Notably, two
LMTK2 validated interactors, CDK5 [14,37], and PP1A [9], control
neuronal differentiation, synaptic plasticity and axonal transport.
The interaction between LMTK2 and the catalytic and regulatory
subunits of PP1 has been demonstrated by independent groups [9]
and shown to result in GSK3b regulation [15]. Accordingly, we
observe that PP1A de-phosphorylates and therefore activates
GSK3b [15,38]. Interestingly, both PP1A and LMTK2 were shown to
Fig. 6. The increased sensitivity to TRAIL stemming from LMTK2 silencing is mediated by BIM, BCL2 and BCL-xL. (a) HME EGFR cells were transfected with two different siRNAs targeting
BIM and LMTK2 for 48 h and then treated with 500 ng/ml izTRAIL to test cell viability after a further 24 h. Both viability graphs represent the average of 3 independent experiments
performed in technical triplicates. The mean of differences between siLMTK2 vs siLMTK2/siBIM #5 and si LMTK2 vs siLMTK2/siBIM #15, treated with izTRAIL, was 12.7% (P ¼ 0.0169)
and 10.3% (P ¼ 0.0072), respectively. P values were obtained by paired two-tailed t-test. (b) HME EGFR cells were transfected with siRNAs targeting BIM and LMTK2 alone or in
combination; after 72 h, cells were treated with 500 ng/ml izTRAIL for 4 h and subjected to western blot to detect the activation of pro-apoptotic factors. NT: non-transfected
control. (c) Caspase-3/-7 activity was measured with a ﬂuorescent substrate of Caspase-3/7 upon treatment with 500 ng/ml izTRAIL administered 48 h after the transfection
with the indicated siRNAs. (d) HME EGFR cells were silenced for LMTK2 and simultaneously transfected to ectopically express BCL2 and BCL-xL, both fused to a Myc-Tag. Control
cells were transfected with a GFP-expressing vector. After 48 h, cells were treated with 500 ng/ml izTRAIL and viability assessed after 24 h. Left panel: control of silencing and over-
expression showing the levels of LMTK2 and Myc-tagged BCL2 and BCL-xL 72 h after the transfection. Right panel: viability determined in 6 independent experiments: the mean of
differences between GFP- vs BCL2-transfected cells and GFP- vs BCL-xL-transfected cells, silenced for LMTK2 and treated with izTRAIL, was 13.2% (P ¼ 0.0081) and 15.5%
(P ¼ 0.0039), respectively. (e) Phase contrast and ﬂuorescent microscopy image taken in a representative ﬁeld to evaluate the transfection efﬁciency.
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be phosphorylated by CDK5 [37,38]. Also this kinase (CDK5) was
found by us among the 16 hits conﬁrmed in validation experiments
and therefore represents, together with other CDKs [6,39,40], a
potential target for combination therapy with TRAIL, even if the
precise mechanism by which CDK5 affects TRAIL sensitivity still
needs to be established.
Besides the role of LMTK2 in the neural system, recent ﬁndings
have suggested a function also in cancer cells. In fact, several mu-
tations have been identiﬁed in patients bearing pulmonary sarco-
matoid carcinomas [19], lung adenocarcinomas [20] and prostate
cancer [21,22], but their biological effect is still unknown. Our
ﬁndings suggest that LMTK2 could promote cancer survival by
hindering the apoptotic cascade. In fact, we show that LMTK2 tar-
geting promotes the expression of the pro-apoptotic factor BIM and
the down-regulation of the anti-apoptosis BCL2 family members,
BCL-xL and BCL2. As these proteins are universal regulators of the
apoptotic pathway, not tightly related toTRAIL-mediated apoptosis,
it is conceivable that LMTK2 is a broad regulator of cell death, rather
than that selectively triggered by TRAIL or other death ligands. In
agreement to this idea, the silencing of LMTK2 resulted in an
increased cytotoxic effect of staurosporine, etoposide, cisplatin and
especially ABT737, a well characterized inhibitor of BCL2 and BCL-
xL. Nonetheless, LMTK2 does not regulate the cell sensitivity to
every compound, as the treatment with gemcitabine, for example,
was not affected by LMTK2 silencing (data not shown). We have
found that different members of the BCL2 family are controlled by
LMTK2 in a cell-type dependent manner and all of them contribute
to the ﬁnal sensitivity. Accordingly, the up-regulation of BIM
following LMTK2 knock-down is indeed responsible for the
increased sensitivity to TRAIL, even if not sufﬁcient to trigger cell
death without an apoptotic stimulus, in agreement with other
works [35,41]. Moreover, BIM is not the only determinant and the
Fig. 7. LMTK2 silencing enhances the cytotoxic activity of BCL2-directed compounds. HME EGFR (a), MDA-MB231 (b) and BT549 (c) were silenced for LMTK2 and then treated with
10 mM ABT737. Viability was evaluated by Cell-TiterGlo. (d) According to our model, the silencing of LMTK2 causes the reduction of AKT activity, a kinase known to phosphorylate,
and therefore inhibit GSK3b. Simultaneously, LMTK2 silencing reduces the inhibitory phosphorylation of PP1A, and this in turn contributes to GSK3b activation. Accordingly, LMTK2
down-regulation correlates to an increased activation of GSK3b observable by the reduction of the inhibitory phosphorylation of Ser9. Then, GSK3b favors the accumulation of BIM
and likely promotes the inhibitory phosphorylation of PP1A on Thr320. As PP1A is a negative regulator of BIM, it counterbalances the GSK3b-dependent accumulation of BIM.
Table 2
Effect of LMTK2 silencing on the cytotoxic activity of different compounds. HME EGFR, MDA-MB231 and BT549 cells were transfected with control siRNAs and siRNAs targeting
LMTK2 and treated with serial dilutions of the indicated compounds. Viability was evaluated 24 h after the treatment and IC50 calculated by Graphpad Prism on the basis of at
least of 3 independent experiments.
Cell line Cisplatin IC50 mM Etoposide IC50 mM Staurosporine IC50 mM ABT737 IC50 mM
siCtr siLMTK2 siCtr siLMTK2 siCtr siLMTK2 siCtr siLMTK2
HME EGFR 24,4 9,10 218 129 0,840 0336 19,8 4,33
MDA-MB231 586 186 228 240 4,92 0,975 2,64 1,30
BT549 154 17,6 151 69,9 1,47 0,120 165 7,94
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silencing of BIM only partially rescues the viability of cells depleted
for LMTK2 and treated with izTRAIL. Our evidences support the
notion that also the down-regulation of BCL2 and BCL2-xL triggered
by LMTK2 silencing, contributes to the overall increased sensitivity
to treatment. Of note, also the rescue effect of ectopic BCL2 and BCL-
xL expression is only partial, as in the case of BIM, suggesting that
the overall sensitizing effect of LMTK2 silencing is ascribable to the
sum of the effects of BIM up-regulation and BCL2 and BCL-xL down-
regulation. Nonetheless, the role of BCL2 and BCL-xL could be more
substantial than shown by our results as the transfection efﬁciency
was less than 50% and therefore, their effect could be under-
estimated as many cells did not express the ectopic proteins.
Notably, LMTK2 silencing sensitizes not only premalignant cells
but also cancer cells to TRAIL cytotoxicity, as in the case of breast
and colorectal cancers. Interestingly, in these cancer cells BIM ap-
pears not involved in the increased sensitivity as its levels do not
change, but rather decline, upon LMTK2 silencing. Therefore, other
mechanisms are responsible for the increased sensitivity, and BCL2
reduction could play a role in this. Morework is indeed necessary to
understand the different mechanisms of regulation of BIM and
BCL2 in different models, but, in our work, we show that both
proteins are regulated in an opposite manner by GSK3b. This
observation, together with the ﬁnding that LMTK2 silencing re-
duces the phosphorylation, and therefore, the activation of AKT,
supports the existence of a still uncharacterized survival pathway
involving LMTK2, AKT and GSK3b, which affect cell viability by
regulating the levels of the BCL2 family members.
In conclusion, our work supports the notion that LMTK2 could
represent a new potential target for therapy and lay the basis for
the development of a new class of small molecules targeting this
kinase. These compounds could be exploitable both in clinic and as
tool for the comprehension of the physiological role of LMTK2.
Nonetheless, the observation that LMTK2 targeting sensitizes both
non-cancer, even if immortalized, and cancer cells to death high-
lights the need of further investigation to evaluate the toxicity of a
LMTK2-directed therapy in primary cells and normal tissues.
Therefore, more work is necessary to understand the biological role
of LMTK2 and to determine whether its inhibition could be
exploited as a new approach in anti-cancer therapy.
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AbstrAct
KRAS is mutated in about 20-25% of all human cancers and especially in 
pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-
survival pathways, but it also triggers the trans-activation of pro-apoptotic genes. 
In our work, we show that G13D mutations of KRAS activate the MAPK pathway, 
and ERK2, but not ERK1, up-regulates Noxa basal levels. Accordingly, premalignant 
epithelial cells are sensitized to various cytotoxic compounds in a Noxa-dependent 
manner. In contrast to these findings, colorectal cancer cell sensitivity to treatment 
is independent of KRAS status and Noxa levels are not up-regulated in the presence 
of mutated KRAS despite the fact that ERK2 still promotes Noxa expression. We 
therefore speculated that other survival pathways are counteracting the pro-apoptotic 
effect of mutated KRAS and found that the inhibition of AKT restores sensitivity to 
treatment, especially in presence of oncogenic KRAS. In conclusion, our work suggests 
that the pharmacological inhibition of the pathways triggered by mutated KRAS could 
also switch off its oncogene-activated pro-apoptotic stimulation. On the contrary, the 
combination of chemotherapy to inhibitors of specific pro-survival pathways, such as 
the one controlled by AKT, could enhance treatment efficacy by exploiting the pro-
death stimulation derived by oncogene activation.
IntroductIon
KRAS is a 21 KDa protein involved in cell signal 
transduction belonging to the RAS subfamily, which 
comprises several other small GTPases endowed with 
GTP-hydrolyzing activity. In unstimulated conditions, 
GTPases are bound to GDP and display low activity, 
unable to trigger the down-stream signaling processes. 
RAS proteins require GTP to be activated and undergo 
rapid cycles of activation and inactivation crucial for 
physiological signaling [1]. Because these cascades 
stimulate cell growth and division, aberrant RAS signaling 
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can also lead to cancer. The 3 human RAS genes (HRAS, 
KRAS, and NRAS) are among the most prevalent drivers 
of human cancer, with KRAS being mutated in 20-25% 
of all human tumors and up to 90% in certain cancer 
types, e.g. pancreatic cancer [2]. In these settings, KRAS 
activates several down-stream effectors leading to the 
stimulation of the RAF/mitogen-activated protein kinase 
kinase/extracellular signal-regulated kinase (RAF/MEK/
ERK) and phosphatidylinositol-3-kinase (PI3K) pathways.
Colorectal cancer (CRC), one of the most 
widespread cancer types, displays in 40% of cases 
KRAS activating mutations, primarily involving codon 
12 or 13. Several drug combinations are currently used 
for CRC treatment, including oxaliplatin, 5-FU and the 
camptothecin (CPT) analogue irinotecan [3]. Moreover, 
the epidermal growth factor receptor (EGFR)-blocking 
antibodies cetuximab and panitumumab are approved 
for treatment of metastatic CRC in combination 
with chemotherapy and as maintenance therapy in 
chemorefractory tumors. Receptor tyrosine kinases such as 
EGFR, through the activation of the downstream GTPases, 
regulate MAPK and PI3K pathways. Importantly, 
mutations or amplification of KRAS is often associated 
to unresponsiveness and acquired resistance to cetuximab 
[4]. 
Even though oncogenic KRAS is often associated 
with poorer prognosis, its mutations have also been 
considered for targeted therapy taking advantage of 
combinations that produce a synthetic lethal effect [5, 
6]. In fact, the presence of constitutively active KRAS 
sensitizes cancer cells to MEK and BCL-XL [7] or RAF 
[8] inhibition, TRAIL [9], 5-FU and oxaliplatin [10]. 
Nonetheless, KRAS activation is usually associated with 
reduced proneness to apoptosis and increased resistance 
to chemotherapy owing to the activation of pro-survival 
pathways [11-13] and resulting in the up-regulation of 
anti-apoptotic factors such as the members of the inhibitor 
of apoptosis proteins (IAP) family [14, 15].
IAPs are characterized by the presence of a 
conserved baculoviral IAP repeat (BIR) domain [16] 
important for protein-protein interactions. Despite the 8 
members of the IAP family had initially been considered 
essentially apoptosis negative regulators, only X-linked 
IAP (XIAP) is known to physically interact with caspases 
and prevent their activity [17]. Later studies have shown 
that IAPs regulate cell life aspects other than apoptosis. 
Cellular IAP1 (cIAP1) and cIAP2, for example, modulate 
the signaling of pro-survival pathways, such as the ones 
regulated by NF-kB transcription factors and MAPKs 
[16]. Interestingly, IAPs are often deregulated in cancer 
cells and associated to unfavorable prognosis [18]. An 
opportunity to target IAPs, and especially cIAP1, cIAP2 
and XIAP, both for therapeutic purposes and as tools in 
pre-clinic research is represented by second mitochondria-
derived activator of caspases (SMAC) mimetic (SM) small 
compounds [19]. SMs were designed to mimic the activity 
of SMAC [20], a natural antagonist of XIAP, which, by 
interacting with its BIR domains, displaces caspases 
and promotes their activity with consequent apoptosis 
induction. SMs also target cIAP1 and cIAP2, causing 
their degradation [21, 22], modulating several pathways 
and overcoming cancer cell resistance to therapy [23] 
and especially to tumor necrosis factor-related apoptosis 
inducing ligand (TRAIL) [20, 24].
Here we report that SM83, a SM recently described 
by us [25, 26], greatly enhances the cytotoxic activity of 
the topoisomerase I inhibitor CPT in premalignant models 
in which KRAS G13D is endogenously or ectopically 
expressed in human epithelial cells. The increased 
sensitivity of oncogenic KRAS-expressing cells stems 
at least in part from the basal up-regulation of the pro-
apoptotic protein Noxa, which is stimulated in an ERK2-
dependent manner. In clear contrast to the premalignant 
models, a panel of CRC lines with knock-in (KI) and 
knock-out (KO) mutations of KRAS G13D showed that 
the sensitivity to treatment is independent of KRAS status. 
Accordingly, Noxa levels are unaffected by oncogenic 
KRAS expression and other pathways, such as the ones 
controlled by PI3K/AKT, protect cancer cells from the 
potentially pro-apoptotic stimulus of mutated KRAS.
results
the combination of sMs and cPt selectively kills 
premalignant epithelial cells bearing oncogenic 
KRAS
As SMs are rarely effective in monotherapy, but 
sensitize cancer cells to other compounds, we searched 
for drugs whose cytotoxicity can be efficiently enhanced 
by SM83 using a high-throughput cell based screening 
approach. HeLa cells were exposed in vitro to SM83 
and izTRAIL in addition to a combined library of about 
3000 FDA-approved small molecule inhibitors and 
cell viability assessed (see Materials and Methods). Of 
the 3000 small molecule inhibitors assessed, we found 
that the topoisomerase I inhibitor camptothecin (CPT) 
most profoundly enhanced the cytotoxic effect of SM83 
(Table 1). In addition to the enhancing effect of CPT, 
we also found that different formulations of CPT such 
as 10-hydroxycamptothecin also enhanced the effects of 
SM83, further confirming that CPT can be effectively 
combined with SMs and TRAIL. We then asked whether 
this combination is more cytotoxic in a specific genetic 
background and treated a panel of premalignant and 
cancer cell lines with izTRAIL, SM83 and CPT alone or in 
combination (data not shown). Viability tests showed that 
the immortalized human epithelial (HME) cell line bearing 
a KI G13D mutation in the KRAS gene (D13/+) is far 
more sensitive to SM83 plus CPT treatment compared to 
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Figure 1: oncogenic KRAS increases sensitivity of HMe cells to dnA-damaging agents and trAIl. (A) The parental 
human epithelial (HME) cell line and the isogenic cell lines with knock-in mutations in KRAS (G13D), PI3K (H1047R) and EGFR 
(delE746A750) were treated with varying doses of CPT alone (left panel) or in combination with 100 nM SM83 (right panel). Viabilities 
are shown after 24 h of treatment. (B) HME D13/+ cells were pre-incubated with DMSO, 50 μM z-VAD, 20 μM Nec-1 (left panel), 10 µg/
ml Infliximab (IFX, middle panel) and 10 µg/ml Enbrel (right panel) for 1 h and subsequently treated with 100 nM SM83 and 1 μM CPT. 
Cell viability was determined after 24 h. (C, D) HME +/+ and HME D13/+ cells were mock treated and treated with 100 nM SM83, 1 μM 
CPT and with their combination for 6 h. Cells were lysed and subjected to western blot to detect the apoptosis markers cleaved PARP, 
caspase-3 and caspase-8 (C) and the SM targets cIAP1, cIAP2 and XIAP (D). Actin is the loading control, asterisks show the cleaved forms 
p17/p19 of caspase-3 and the pro-caspase p55/p57 forms of caspase-8, together with its cleaved forms p41/p43. One representative of two 
independent experiments is shown. 
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the parental HME or to HME carrying mutations activating 
PI3K and EGFR (Figure 1A). Moreover, HME D13/+ cells 
were more sensitive to izTRAIL alone or in combination 
with SM83 (Figure S1 upper panels), to the topoisomerase 
II inhibitor etoposide (ETO) and to neocarzinostatin 
(NCS), a DNA double strand break inducer (Figure S1 
lower panel), suggesting a general enhanced sensitivity 
to cell death more than a specific mechanism favoring 
CPT-mediated death. Pre-treatment with pan-caspase 
inhibitor z-VAD strongly supports the idea that SM83/CPT 
treatment kills HME D13/+ cells through an apoptotic 
mechanism (Figure 1B left panel). In fact, the blocking 
of caspases resulted in almost complete protection from 
the treatment, while necroptosis inhibitor Necrostatin-1 
(Nec-1) showed only a negligible effect. Importantly, 
as TNF is known to be a pivotal player in SM-mediated 
cell death, HME D13/+ were also pre-treated with the 
TNF-specific blockers Infliximab (Figure 1B middle 
panel) and Enbrel (Figure 1B right panel) which both 
remarkably rescued cells from the treatment, confirming 
the involvement of TNF in the SM83/CPT cell killing. 
Finally, by biochemical analysis we further confirmed 
that SM83 strongly increases the pro-apoptotic effect of 
CPT, as is evident from the substantial accumulation of 
cleaved PARP, caspase-8 and -3 (Figure 1C). Importantly, 
the altered sensitivity to treatment in cells with wild type 
or mutated KRAS did not stem from a diverse expression 
of the SM known targets cIAP1, cIAP2 and XIAP (Figure 
1D), which are also depleted at the same level by SM83.
endogenous and ectopic oncogenic KRAS 
sensitizes human epithelial cells to sM83 and cPt 
treatment
To further investigate the role of mutated KRAS in 
the increased sensitivity of HME, the cytotoxic response 
to CPT and SM83 was assessed following total KRAS 
knockdown. The results showed that reduced KRAS 
decreased the toxicity by about 50% (Figure 2A), thus 
confirming the involvement of KRAS in the enhanced 
sensitivity. Unfortunately, the lack of an antibody 
specific for mutant KRAS did not allow us to determine 
the efficiency of G13D down-regulation (Figure S2). 
Furthermore, the silencing also affected wild type KRAS, 
which might also have a protective role to the treatment. To 
overcome this limit, KRAS G13D was inducibly expressed 
in HME cells using doxycycline. Augmented levels of 
phosphorylated ERK1/2 (Figure 2B), a down-stream 
effector of KRAS, and GST-RBD pull-down experiments 
confirmed the increased expression of activated KRAS 
(Figure 2C) paralleled by an hypersensitivity to SM83/
CPT co-treatment (Figure 2D). We then repeated the 
experiments with another human epithelial cell line to 
exclude a possible cell line-specificity of our observation. 
MCF10A transduced with the KRAS G13D inducible 
vector confirmed that expression of mutant KRAS 
causes the phosphorylation of ERK1/2 (Figure 2E) and 
hypersensitivity to cell death (Figure 2F).
oncogenic KrAs-mediated up-regulation of noxa 
sensitizes cells to sM83/cPt co-treatment
To determine the mechanisms by which oncogenic 
KRAS sensitizes non-tumoral cells to treatment, several 
cell lines expressing endogenous and ectopic KRAS 
G13D were analyzed by western blot for the levels of 
pro- and anti-apoptotic proteins of the Bcl-2 family (data 
not shown). In accordance to other works, we found that 
the presence of oncogenic KRAS considerably increases 
the basal levels of Noxa in untreated cells. Accordingly, 
HME bearing the KI G13D mutation displayed higher 
levels of Noxa compared to the parental cell line (Figure 
3A left panel), while the basal levels of the Noxa natural 
antagonist Mcl-1 were not affected by oncogenic KRAS 
expression, but markedly dropped after CPT treatment 
in a SM83-independent manner. Moreover, transient 
induction of ectopic KRAS G13D in HME and MCF10A 
parental cell lines concurred to a marked increase of Noxa 
levels in both cell lines (Figure 3A right panels, upper and 
lower panel respectively). In line with these data, KRAS 
silencing reduced the levels of Noxa in HME KRAS G13D 
cells (Figure S2). Furthermore, since Mcl1 levels were 
reduced concurrently to Noxa up-regulation in HME cells 
(Figure 3A left panel), we checked whether Noxa increase 
was responsible for Mcl1 down-regulation. Mcl1 levels 
were therefore detected in KRAS G13D-induced HME 
cells which showed that the sole Noxa up-regulation in not 
sufficient to affect Mcl1 levels in untreated cells. We then 
analyzed by western blot HME KI D13/+ cells silenced 
with control or Noxa-specific siRNAs and treated with 
increasing concentrations of CPT (Figure 3B). Also in this 
case Mcl-1 stability was independent of Noxa presence, 
suggesting that Mcl-1 down-regulation stems from the 
treatment and not from Noxa up-regulation. To determine 
table 1: best hits from the high-throughput screening. 
HeLa cells were treated with FDA-approved drugs in 
combination with SM83 and izTRAIL. The most effective 
10 compounds enhancers of the cytotoxic effect are listed.
compound P-value
10-hydroxycamptothecin 0,000103319
Camptothecin 0,000040974
Camptothecine (S,+) 0,001697753
AMSACRINE 0,000274229
FLUOROURACIL 0,000537959
Aminacrine hydrochloride 0,015471379
Decitabine 0,000022640
MEFLOQUINE 0,000168791
Sutent 0,000444038
NETILMICIN SULFATE 0,005887782
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whether the oncogenic KRAS-dependent accumulation of 
Noxa is responsible for the hypersensitivity to SM83/CPT, 
viability tests were performed after Noxa depletion (Figure 
S2). The results showed that Noxa silencing confers 
resistance to treatment in HME D13/+ cells (Figure 3C).
KrAs-induced up-regulation of noxa is mediated 
by erK2
We next investigated the mechanisms responsible 
for the acquired sensitivity of KRAS-mutated HME to 
treatment. Both parental and D13/+ HME cell lines were 
treated with CPT and SM83 in the presence of various 
inhibitors of the MAPK, AKT and PI3K pathways which 
can be stimulated by activated RAS. In parental cells, 
the administration of MEK1/2 inhibitors PD98059 and 
UO126, AKT inhibitor Triciribine or PI3K inhibitor 
LY294002 did not affect significantly the toxicity of 
SM83/CPT treatment (Figure 4A). In contrast, both 
MEK1/2 inhibitors partially protected D13/+ HME cells 
from SM83/CPT treatment and conferred resistance at the 
same degree as parental cells (Figure 4A). Having found 
that Noxa is a pivotal mediator of KRAS-dependent 
increased sensitivity to the combination (Figure 3C), we 
evaluated whether the MAPK pathway was responsible 
for the increased levels of Noxa. We found that both 
MEK inhibitors reduced, as expected, the levels of 
phosphorylated ERK1 and ERK2, and concurrently 
reduced the levels of Noxa (Figure 4B). Interestingly, 
also Mcl1 levels were slightly reduced by the MEK 
inhibitors, suggesting that both Noxa and Mcl1 expression 
is regulated by the MEK/ERK pathway. Importantly, 
MEK inhibition slightly reduced Noxa basal levels also 
in parental HME (left panel) suggesting that the MAPK 
Figure 2: endogenous and ectopic mutated KRAS confers sensitivity to sM83 and cPt co-treatment. (A) HME +/+ and 
HME D13/+ were transfected with siRNA targeting KRAS for 48 h and subsequently treated with 100 nM SM83 and 1 μM CPT. Cell 
viability was determined after 24 h of treatment. (B) HME pINDUCER20-Mock (Mock) and HME pINDUCER20-KRAS G13D (G13D) 
were incubated with doxycycline (Dox, 250 ng/ml) for 48 h, lysed and a western blot was performed. The presence of activated KRAS was 
determined by detection of phosphorylated ERK1/2. (C) Active GTP-RAS was purified in cells stimulated as in (B) by pull-down assay 
using the recombinant RBD domain of RAF1; HME D13/+ are shown as positive control for activated KRAS. (D) HME Mock and KRAS 
G13D were incubated with Dox (250 ng/ml) for 48 h and treated with 100 nM SM83 and 1 μM CPT. Cell viability was determined after 24 
h. (E) MCF10A Mock and KRAS G13D were incubated with Dox (250 ng/ml) for the indicated time, lysed and analyzed by western blot 
for the detection of ERK1/2 and phosphorylated ERK1/2. Actin is shown as a loading control. (F) MCF10A Mock and KRAS G13D were 
incubated with Dox (250 ng/ml) for 48 h and treated with 100 nM SM83 and 0.1 μM CPT. Cell viability was determined after 24 h. One 
representative of two independent experiments is shown.
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pathway stimulates Noxa also in physiological conditions. 
To understand whether MEK targets ERK1 and ERK2 both 
contribute to Noxa regulation, we silenced each of them 
in D13/+ HME cells and found that only ERK2 down-
regulation reduced Noxa levels, while ERK1 silencing 
marginally increased accumulation of Noxa (Figure 4C 
right panel). Again, Mcl1 was not down-regulated by 
Noxa accumulation, further confirming that the treatment 
with CPT, and not Noxa up-regulation, was responsible for 
Mcl1 reduction in HME cells (Figure 3A). In line with the 
regulation of Noxa observed in figure 4C, ERK1 silencing 
slightly, but significantly, enhanced the sensitivity of 
D13/+ HME cells to SM83/CPT treatment, while ERK2 
silencing resulted in the opposite effect (Figure 4D).
sensitivity to sM83/cPt is independent of KrAs 
status in a panel of colorectal cancer cell lines
Our findings support the notion that oncogenic 
KRAS can sensitize premalignant cells to SM83/CPT 
treatment. We then considered whether this also occurs 
in malignant cells, and for this reason we employed a 
panel of isogenic CRC cell lines where mutated KRAS 
is either KI (+/+ and D13/+, SW48 and Lim1215) or KO 
(D13/- and +/-, HCT-116 and DLD1). Surprisingly and in 
Figure 3: Increased noxa expression in KRAS-mutated HMe favours sM83/cPt-induced cell death. (A, left panel) HME 
+/+ and HME D13/+ cells were treated with 100 nM SM83 and 1 μM CPT for 6 h, lysed and subjected to western blot to detect Noxa and 
Mcl1 levels. (A, right panel) HME/MCF10A Mock and KRAS G13D were incubated with Dox (250 ng/ml) for the indicated time and 
subjected to western blot to detect Noxa and Mcl1 levels. Actin is shown as the loading control. (B) HME D13/+ cells were trasfected with 
control and Noxa-targeting siRNAs and, after 48 h, were treated with the indicated concentration of CPT (µM) for 6 h. Cells were then lysed 
and analyzed by western blot to evaluate Mcl1 levels. Noxa is shown to check the silencing efficiency and actin as the loading control. (C) 
HME +/+ and HME D13/+ were transiently transfected with siRNA targeting Noxa for 48 h and subsequently treated with 100 nM SM83 
and 1 μM CPT. Cell viability was determined after 24 h. One representative of two independent experiments is shown.
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Figure 4: erK2, but not erK1 is responsible for KrAs-dependent noxa-induction. (A) HME +/+ and HME D13/+ cell 
lines were pre-incubated with 50 μM PD98059, 25 µM UO126, 20 μM Triciribine and 20 μM LY294002 for 2 h, and then treated with 100 
nM SM83 and 1 µM CPT. Cell viability was quantified after 24 h. One representative of three independent experiments is shown. (B) HME 
+/+ (left panel) and HME D13/+ (right panel) cell lines were treated with 50 μM PD98059, 25 nM UO126, 20 μM Triciribine and 20 μM 
LY294002 for 2 h, and subsequently analyzed by western blot to detect the phosphorylated forms of AKT, ERK1 and ERK2, their total 
levels (upper panels) or Noxa and Mcl1 (lower panels). Actin is shown as loading control. (C) HME +/+ and HME D13/+ were transiently 
transfected with the indicated siRNAs for 72 hours and subsequently analyzed by western blot to detect total and phosphorylated ERK1 and 
ERK2, and their total levels (left panel), Noxa and Mcl1 (right panel). Actin is shown as loading control. (D) Parental HME +/+ and HME 
D13/+ cells were silenced for 48 h and then treated with DMSO and 100 nM SM83 plus 1 µM CPT for further 24 h. One representative of 
three independent experiments is shown. * P < 0.05 vs siCtr.
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contrast to the premalignant settings, the sensitivity of the 
CRC cell lines to SM83/CPT treatment was independent 
of the KRAS status (Figure 5A-D). We then investigated 
the Noxa status, which was responsible for the increased 
sensitivity of normal epithelial cells bearing oncogenic 
KRAS, and found that its levels were unaffected by the 
presence of mutated KRAS (Figure 5E-H). Likewise, the 
levels of Noxa-antagonist Mcl1 were not repressed by the 
treatment with CPT and/or SM83, and further experiments 
confirmed an increased stability of Mcl1 in colorectal 
cancer compared to HME cells (Figure S3). Noxa basal 
levels were however higher in CRC than in HME cell lines 
(data not shown), suggesting that pro-apoptotic mediators 
can even be up-regulated in tumor cells, but there are 
likely other activated pathways that counterbalance the 
potential pro-apoptotic stimuli.
Aberrant activation of AKt counterbalances 
KrAs-mediated pro-apoptotic scenario in 
colorectal cancer cells
Despite the presence of mutant KRAS, our findings 
suggest that cancer cells are not sensitized to SM83/CPT 
treatment. Therefore, we hypothesized that malignant 
progression might have caused the deregulation of other 
pathways that can counterbalance the potential apoptotic 
effect of oncogenic KRAS. Interestingly, HCT116 and 
DLD1 cells bear mutated PI3K, which results in hyper-
activation of the PI3K/AKT pathway, a signaling cascade 
known to promote cell survival. For this reason, we treated 
HCT116 and DLD1 cells bearing mutated and wild type 
KRAS with SM83/CPT after pre-treatment with inhibitors 
of MEK1/2, AKT and PI3K. Interestingly, and concordant 
to our hypothesis, AKT inhibition restored sensitivity 
to the treatment only in the presence of mutant KRAS 
(Figure 6A and 6B). Noxa levels were lowered by MAPK 
blocking (Figure 6C and 6D) as already observed in HME 
cells (Figure 4B), but were not affected by AKT inhibition, 
suggesting that the AKT pathway blocks the pro-death 
effect triggered by oncogenic KRAS in an independent 
fashion. Importantly, AKT inhibition sensitized to 
SM83/CPT treatment also CRC cell lines bearing wild 
type PI3K (Figure S4), further supporting the idea that 
AKT counteracts the pro-death stimulus deriving from 
oncogenic KRAS. Surprisingly, LY294002 treatment, 
which reduced AKT activation, did not sensitize to SM83/
CPT treatment (Figure 6C and 6D). We speculate that this 
stems from the fact that the LY294002 inhibitor did not 
completely abolish AKT phosphorylation and therefore 
we tested the GDC-0941 PI3K inhibitor. This compound 
reduced the AKT activation more efficiently (Figure 6E 
left panel) and sensitized the HCT116 D13/- in the same 
way as Triciribine (Figure 6E right panel). Finally, we 
investigated the mechanisms by which Noxa levels are 
controlled in HCT116 cells and demonstrated that the 
findings described for HME are true also in this cancer cell 
line. In fact, the targeting of ERK1 by silencing enhanced 
the levels of Noxa, while a specific siRNA targeting ERK2 
slightly reduced its expression (Figure 6F).
dIscussIon
In our work, we searched for FDA-approved drugs 
that increase the cytotoxic activity of IAP-antagonizing 
compounds and death ligands. For this purpose, using a 
high-throughput approach, we combined SM83 [25] and 
izTRAIL [29] to a library of about 3000 compounds. 
CPT was identified several times among the best hits 
and validated, alone or in combination with SM83 and/
or izTRAIL, in a panel of normal and cancer cell lines 
bearing KI and KO mutations in genes frequently mutated 
in cancer. The employment of isogenic cell lines with 
distinct point mutations is a powerful tool to comprehend 
the effect of oncogene activation [31] and addiction [32], 
and synthetic lethal interactions [27, 33] in cancer cells. 
With this approach, we found that the endogenous and 
ectopic expression of KRAS bearing the G13D mutation 
sensitizes normal, but not cancer cells, to CPT plus SM83 
or TRAIL treatment, and to other DNA-damaging agents.
Since oncogenic KRAS stimulates the up-regulation 
of the pro-apoptotic protein Noxa [10, 34], we checked 
the occurrence of this event in premalignant cells and 
whether it was associated with the increased sensitivity 
to treatment. In both human epithelial cells HME and 
MCF10A, the expression of oncogenic KRAS was 
indeed responsible for the up-regulation of Noxa in a 
MEK/ERK-dependent manner and for the augmented 
death upon SM83/CPT treatment. Accordingly, chemical 
inhibition of the MEK1/2 kinases that results in prevention 
of ERK1/2 phosphorylation and silencing of ERK2, but 
not ERK1, down-regulated Noxa in HME D13/+ to levels 
comparable to parental HME (+/+) cells. Of note, ERK2 
silencing slightly, but reproducibly, protected HME D13/+ 
cells, while ERK1 silencing even sensitized to SM83/CPT 
treatment and simultaneously increased Noxa basal levels 
especially in CRC cell lines. The observation that ERK1 
and ERK2 display opposite effects in regulating Noxa 
levels and mediating chemotherapy responsiveness was 
also described in hepatocellular carcinoma cells [35]. In 
this case, ERK2 knockdown was responsible for increased 
Noxa levels after cisplatin treatment. Although we 
investigated Noxa basal levels in our experiments, these 
contrasting results strongly support that ERK1 and ERK2 
mutually regulate each other [36] in a cell type-dependent 
manner. Surprisingly, MEK inhibitors strongly prevented 
treatment cytotoxicity, while siRNA targeting ERK1 
and ERK2 only have a modest effect, despite siERK2 
efficiently down-regulated Noxa levels. This suggests that 
other unknown regulatory mechanisms between the two 
ERK proteins eventually impact on the treatment outcome.
We then asked whether our findings are true not only 
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Figure 5: oncogenic mutation of KRAS does not confer sensitivity to combined sM83/cPt nor stimulates noxa levels. 
SW48 +/+ and SW48 D13/+ (A), HCT116 +/- and HCT116 D13/- (B), Lim1215 +/+ and Lim1215 D13/+ (C), DLD1 D13/- and DLD1 +/- 
(D) cell lines were treated with DMSO and the combination of SM83 and CPT at varying concentrations. Cell viability was evaluated after 
24 h. One representative of three independent experiments is shown. SW48 +/+ and SW48 D13/+ (E), HCT116 +/- and HCT116 D13/- (F), 
Lim1215 +/+ and Lim1215 D13/+ (G), DLD1 D13/- and DLD1 +/- (H) cell lines were treated with DMSO and 100 nM SM83, 0.1 µM 
CPT either alone or in combination for 6 h. Cells were lysed and analyzed by western blotting to determine Noxa and Mcl1 levels. One 
representative of two independent experiments is shown. Asterisk indicates the specific band of Actin shown as loading control.
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Figure 6: Aberrant AKt activation protects Hct116 and dld1 cells from the pro-death effect of oncogenic KRAS. 
(A) HCT116 and (B) DLD1 cells were pre-incubated with 50 μM PD98059, 25 μM UO126, 20 μM Triciribine and 20 μM LY294002 for 
2 h, and then mock-treated or treated with 100 nM SM83 and 1 µM CPT. Cell viability was quantified after 24 h. (C) HCT116 and (D) 
DLD1 cells were treated for 2 h with the indicated inhibitors as in (A) and then analyzed by western blot to detect Noxa levels and total 
and phosphorylated AKT and ERK levels. Actin is shown as loading control. (E, left panel) HCT116 D13/- cells were treated with 1 μM 
GDC-0941 for 2 h and analyzed by western blot to detect total and phosphorylated levels of AKT. Actin is shown as the loading control. 
(Right panel) Viability of HCT116 D13/- pre-treated with 1 μM GDC-0941 for 2 h and then treated with 100 nM SM83 and 1 µM CPT. Cell 
viability was quantified after 24 h and expressed as viability percentage to inhibitor alone. (F) HCT116 cells were transfected with siRNAs 
targeting ERK1 and ERK2, cells were collected after 72 h and analyzed by western blot to detect Noxa and total and phosphorylated levels 
of AKT and ERK. Actin is shown as loading control.
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in premalignant cells, but also in cancer cells. To this end, 
a panel of isogenic colon cancer cell lines with KI and KO 
mutations of KRAS was tested. In clear contrast to HME 
and MCF10A cells, Noxa levels did not depend on KRAS 
status in cancer cells and in line with this observation cell 
sensitivity was almost identical in each pair of isogenic 
cells. Basal levels of Noxa in cancer cells were higher 
than in epithelial cells (data not shown), suggesting that 
tumor cells constitutively express some pro-apoptotic 
proteins at high level, but could also activate parallel 
pro-survival pathways to counteract the pro-death signals 
supported by the MEK/ERK axis. Considerable evidence 
shows that mutations in the RAS/MEK/ERK cascade are 
associated to aberrant activation of PI3K/AKT signaling 
[37] and therefore both pathways should be targeted 
simultaneously for effective responsiveness to treatment 
[11, 38]. In accordance to this hypothesis, HCT116 cells 
and DLD1, which bear PI3K activating mutations, are 
sensitized to SM83/CPT treatment when pre-treated 
with AKT inhibitors only in the presence of oncogenic 
KRAS, supporting the notion that AKT is protecting from 
oncogenic KRAS-dependent cancer cell sensitization 
(Figure 7). It is important to note that this protective role 
was demonstrated also in cells bearing wild type PI3K 
(Figure S4), confirming the general pivotal role of AKT in 
counterbalancing the pro-death effect of oncogenic KRAS.
In conclusion, our work has two main implications. 
First, targeting down-stream effectors of oncogenes might 
result in an immediate and transient anti-proliferative 
effect often achieved by conventional therapies, but, 
more importantly, could also shut-down the pro-death 
signals derived from oncogene activation. Secondly, for 
a successful treatment, targeting of the EGFR/MAPK 
pathway alone is not sufficient [39], as it results in 
emerging protecting mutations [4, 40], feedbacks [41] 
and incomplete responses. It is therefore imperative to 
characterize and inhibit also the aberrantly activated 
survival pathways in a combination treatment, in order 
to overcome the anti-apoptotic effect of PI3K/AKT 
activation and simultaneously to exploit the pro-death 
signal stemming from oncogenic activation.
Figure 7: Proposed mechanism for oncogenic KrAs-mediated sensitization to cell death. In premalignant models, normal 
epithelial cells expressing endogenous or ectopic mutated KRAS express high levels of Noxa due to the hyper-activation of MAPK kinases 
and in particular of ERK2. In these settings, the basal activation of the PI3K/AKT pathway is not sufficient to protect from this pro-death 
stimulus and treatment with several cytotoxic agents results in Noxa-dependent cell killing. In contrast, in CRC cells, Noxa levels are 
independent of KRAS status and oncogenic KRAS-bearing cells respond to treatment to the same extent as in the presence of wild-type 
KRAS. In fact, mutated PI3K and up-stream stimuli likely deriving from the tyrosine kinase receptors activate AKT, which counterbalances 
the potential pro-death stimulus deriving from oncogenic KRAS.
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MetHods
cell lines
The human isogenic hTERT-immortalized mammary 
epithelial cell lines HME +/+ and HME D13/+, and the 
human epithelial mammary MCF10A together with the 
isogenic pairs of colorectal cancer cell lines SW48 +/+ and 
SW48 D13/+, HCT116 +/- and HCT116 D13/-, Lim1215 
+/+ and Lim1215 D13/+, DLD1 D13/- and DLD1 +/- have 
already been described [4, 27]. HME isogenic pairs and 
MCF10A cell lines were cultured in DMEM-F12 (Gibco), 
supplemented with 10% FBS (LONZA), 2 mM glutamine 
(LONZA), 20 ng/ml EGF (Immunological Science), 10 
µg/ml insulin (Sigma), 500 µg/ml hydrocortisone (Sigma-
Aldrich). SW48 and DLD1 isogenic pairs were cultured 
with DMEM (Gibco) supplemented with 10% FBS and 
2 mM glutamine. Lim1215 isogenic pairs were cultured 
with RPMI (LONZA) supplemented with 10% FBS, 
2 mM glutamine and 1 µg/ml insulin. HCT116 were 
cultured in RPMI, supplemented with 2 mM glutamine, 
sodium pyruvate (LONZA), and non-essential amino acids 
(LONZA). HeLa cells for the high-throughput screening 
and packaging HEK293FT (Life Technologies) for 
lentiviral production were cultured in DMEM with 10% 
FBS. All cell lines were mycoplasma-free as determined 
by Takara Mycoplasma Detection Kit (Clontech).
reagents
Antibodies targeting pan-RAS, Noxa (CalBiochem), 
Actin and ERK1/2 (Sigma), cleaved-PARP, cleaved 
caspase-3, phosphoERK1/2 (Thr202/Tyr204), pAKT and 
AKT (Cell Signaling), cIAP1 (R&D Systems), cIAP2 and 
XIAP (BD Biosciences), caspase-8 (Enzo Life Sciences) 
and Mcl-1 (Santa Cruz Biotechnology) were employed 
in western blot experiments. z-VAD(OMe)-FMK was 
purchased by BIOMOL, Necrostatin-1 from Enzo Life 
Sciences. PD98059 and UO126 were purchased from 
CalBiochem, LY294002 from Sigma, GDC-0941 and 
Triciribine from Selleckem. Infliximab (Schering-Plough) 
and Enbrel (Wyeth Pharmaceuticals) were used as TNF 
blockers. CPT and neocarzinostatin were purchased from 
Sigma-Aldrich, etoposide by Teva. SM83 synthesis has 
been described elsewhere [25, 28], while izTRAIL was 
purified as already shown [29]. Mutant KRAS (G13D) 
was cloned in the pINDUCER20 and lentiviral particles 
prepared modifying an already described protocol [30] 
and using Lipofectamine 2000 as transfection reagent. 
Expression of the transgene was induced by doxycycline 
(Sigma-Aldrich) at the indicated concentrations.
High-throughput screening
On day 1, 350 HeLa cells/well were seeded in 
384-well white plates in 20 µl medium. At day 2, media 
was changed with cells being exposed to 100 nM SM83 
in addition to FDA-approved drug libraries (ENZO 
Life Sciences, MicroSource Discovery Systems Inc. 
and Prestwick Chemical, France) with the drug library 
compounds present at a final concentration of 1 µM. At 
day 3, cells exposed to SM83 were also exposed to 20 
pg/ml izTRAIL. Cell viability was estimated on day 5 by 
CellTiter-Glo (Promega). Hits were selected due to their 
capability to enhance the cytotoxic activity of SM83/
izTRAIL and then validated using the same HeLa cells 
employed in the screening. In validation experiments, 
SM83 and izTRAIL were administered alone and in 
combination, also changing the schedule and pre-treating 
cells with SM83 24 h before izTRAIL or administrating 
these compounds simultaneously. On the basis of 
these results, validated hits were tested in a panel of 
premalignant and cancer cell lines.
Western blot
Cells were harvested by centrifugation at 4500 
rpm for 5 min at 4°C. After washing once with PBS, 
lysates were prepared by resuspending cell pellets in 
60-100 µl lysis buffer (125 mM Tris HCl pH 6.8, 5 % 
SDS) supplemented with 1x complete protease (Roche 
Diagnostics) and phosphatase inhibitors (Sigma-Aldrich). 
Lysates were boiled at 99°C, sonicated for 20 seconds at 
RT. Then lysates were centrifuged at 13000 rpm for 20 
min at RT and cleared supernatants were transferred into 
a new tube and frozen at -20°C. Cell lysates were mixed 
with 4x reducing SDS-Sample buffer containing 10% 
β-mercaptoethanol (Sigma-Aldrich) and heated for 10 
min at 99°C. Proteins (50 µg) were separated by SDS-
PAGE using pre-cast 4-12% BisTris NuPAGE gels (Life 
Technologies), blotted to PVDF membranes (Millipore), 
which were washed with PBS-tween for 5 min, blocking 
buffer made of 4% non-fat milk in PBS-tween for 30 min 
and then incubated overnight with the indicated primary 
antibodies. Proteins were detected after hybridization 
with appropriate horseradish peroxidase (hrp)-conjugated 
secondary antibodies by adding a chemiluminescent 
substrate (EuroClone). 
cell viability assays
96-well optical bottom, polymer base white plates 
(Thermo Scientific) were used for viability tests. At day 
1, 10000 cells per well were seeded in 100 µl medium. 
At day 2, cells were treated adding the indicated drug(s) 
in 10 µl volume per well. At day 3, cell viability was 
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determined using the CellTiter-Glo assay according to 
the manufacturer’s instructions. Statistical analysis was 
performed with GraphPad Prism 5.02 using the two-tailed 
unpaired t-test.
transfection and lentiviral transduction
To achieve transient knock-down of target proteins 
in HME cells, a reverse transfection protocol employing 
siRNAs (Qiagen) and RNAiMAX (Life technologies) was 
used. Briefly, 3.25 µl RNAiMAX and 200 µl Optimem 
(GIBCO) were mixed and incubated for 5 min at RT. 
Subsequently, 3.25 µl siRNA of a 20 µM stock were 
added, mixed and incubated for further 30 min at RT. The 
transfection mix was placed in a 6-well plate and 0.15 x 
106 cells seeded in 800 µl on top. 
Tumor cells were seeded the day before transfection 
and the same transfection mix as for reverse transfection 
was added on top of cells 24 h later. The cells were then 
incubated for 48 h before being drug-treated for further 24 
h or cultured for 72 h before stopping the experiment. In 
each experiment, scramble siRNAs (siCtr) were used as 
a control.
Cells transduced with lentiviral particles 
were cultured in the presence of medium collected 
from HEK293FT packaging cells transfected with 
pINDUCER20-KRAS G13D (referred to as G13D) or 
empty vector (Mock). After 48 h, medium was replaced 
and fresh medium added in the presence of 500 µg/ml 
G418 (Life Technologies).
ras-GtP pull-down assay
2.5 x 106 cells were seeded into 10 cm dishes. The 
next day, cells were incubated with and without 250 
ng/ml of Dox. Cell lysis and RAS-GTP pulldown was 
performed. Cells were lysed in 500 μl of IP-lysis buffer 
supplemented with a cocktail of protease inhibitors. To 
fully detach lysed cells, they were scratched using a cell 
scraper and transferred into tubes for a 30-minute lysis 
at 4 °C on a rotator. Lysates were centrifuged at 13000 
rpm for 30 min and cleared supernatants were transferred 
to a new tube. RAS-GTP was precipitated using beads 
coated with the RAF1-binding domain RBD recombinant 
protein. The following day, beads were washed 5 times 
with IP-lysis buffer and precipitated protein complexes 
were eluted from the beads via boiling in SDS-Sample 
buffer for 10 minutes at 80°C. Proteins were separated by 
SDS-PAGE and analyzed by western blot. As a loading 
control, proteins were stained by blue coomassie (Thermo 
Scientific Pierce). 
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